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  iAbstract 
Jembrana disease virus (JDV) is a lentivirus associated with an acute disease 
syndrome of Bali cattle (Bos javanicus) in Indonesia. Control of Jembrana disease 
currently involves serological monitoring of infection in endemic areas, restriction of 
movement of cattle from these areas and ring-vaccination around outbreaks of the 
disease with a tissue-derived inactivated-virus vaccine.  
Earlier investigations at Murdoch University resulted in a vaccine combining a mix of 
recombinant capsid (CA) and Tat proteins that ameliorated the clinical signs of JDV 
infection in vaccinated cattle. This thesis reports the development of an alternative 
novel fused CA and Tat polyprotein antigen emulsified in incomplete Freund’s 
adjuvant (IFA) as a vaccine. This polyprotein could be produced in a single operation 
at a lower cost than the mix of the 2 individually produced recombinant proteins. The 
effect of vaccination with this CA and Tat polyprotein vaccine was compared to 
vaccination with a mixture of individual CA and Tat proteins in small groups of cattle 
that were subsequently challenged with virulent JDV. It was found that the fused 
polyprotein vaccine elicited a greater antibody response against both the CA and Tat 
antigens than a vaccine containing the mix of individual recombinant proteins. In 
cattle vaccinated with the fused recombinant polyprotein the viral load and 
lymphocyte response to infection was similar to that in cattle vaccinated with the mix 
of individual proteins.  When the CA and Tat polyprotein vaccine was administered to 
cattle under field conditions, the vaccine induced minimal side effects and an 
antibody response to both CA and Tat proteins that persisted for 12 months.  
A recombinant protein antigen was produced for ELISA and Western immunoblotting 
assays that enabled serological detection.  This antigen provided an alternative to the 
whole virus antigen that is currently used in Indonesia for these serological assays. 
The whole virus antigen is prepared from plasma of JDV-infected cattle using a 
differential centrifugation technique and is difficult to produce in Indonesia. It was 
found that a recombinant full length CA (p26) protein antigen used in an ELISA 
provided sensitivity and specificity equivalent to that obtained by Western 
immunoblotting with the whole virus antigen. This recombinant CA protein antigen is 
now used in routine serological assays for detection of JDV in Indonesia. 
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  8Chapter 1.  Introduction 
 
Jembrana disease in Bali cattle (Bos javanicus) was first detected on the island of Bali 
in Indonesia in 1964. The initial outbreak occurred in the Jembrana district and soon 
spread to surrounding districts (Adiwinata, 1968; Budiarso and Hardjosworo, 1976). 
Within a year the disease had spread throughout Bali and had killed an estimated 
26,000 cattle out of the 300,000 Bali cattle on the Island. The disease has since spread 
to and is now endemic in the Bali cattle population of the islands of Java, Sumatra and 
the Indonesian provinces of Kalimantan in Borneo island (Hartaningsih et al., 1993; 
Soeharsono, 1995; Soeharsono and Temadja, 1995). The aetiological agent was 
identified as a virus and designated Jembrana disease virus (JDV) and then 
subsequently identified as a lentivirus genetically and antigenically similar to Bovine 
immunodeficiency virus (BIV) in 1993 (Chadwick et al., 1995a; Kertayadnya, 1995; 
Kertayadnya et al., 1993; Wilcox et al., 1995).  The genetic characterization of the 
virus has provided the opportunity for the utilization of molecular biological 
techniques for the development of improved diagnostic and control procedures. 
The control of Jembrana disease in Indonesia has been based primarily on restrictions 
on the movement of cattle out of endemic regions to disease-free areas. This has been 
supplemented by the development of a whole virus immunoassay to monitor the 
distribution of the disease in Indonesia and subsequently by the use of a tissue-derived 
inactivated virus vaccine prepared from the spleen of experimentally infected animals 
(Hartaningsih et al., 1995b). This vaccine has been shown to ameliorate the disease 
and prevent mortalities in vaccinated cattle but due to production issues and cost is 
only produced in small amounts and used only to ring-vaccinate around outbreaks to 
slow the spread of the disease to adjacent areas (Hartaningsih et al., 2001). A second 
generation vaccine using the bacterially expressed JDV Capsid and Transactivator of 
Transcription glutathione-S-transferase (GST) tagged proteins was also reported to 
ameliorate Jembrana disease  and prevent mortalities in experimentally infected cattle 
(Ditcham, 2007). 
The major objectives of the studies reported in this thesis were the development and 
use of recombinant proteins expressed with a bacterial expression system, to replace 
the whole virus immunoassays currently used in Indonesia and the development and 
  9testing of an alternate recombinant protein vaccine that could be produced from a 
single construct. 
To provide a background for the research reported in this thesis, a review of the 
literature relating to lentiviruses and Jembrana disease was undertaken and is 
presented in Chapter 2. This review includes background information on lentiviruses, 
other animal lentiviruses with emphasis on their diagnosis and control by vaccination, 
historical aspects of Jembrana disease and BIV, and on potential systems for 
recombinant protein production and their use for the production of diagnostic reagents 
and vaccines. 
In Chapter 3, the development of recombinant proteins expressed in Escherichia coli 
and used as antigens to replace the current whole virus antigen used in immunoassays 
is described.  This Chapter also includes a description of the Western immunoblot 
assay and ELISA utilising the recombinant protein as antigen for the detection of CA 
and Tat antibody in cattle, and a comparison of the sensitivity and specificity of the 
assays utilizing these recombinant proteins to those utilizing the whole virus antigen. 
To improve on previous methods used to produce individual recombinant CA and Tat 
proteins of JDV, that were combined and used as a vaccine for Jembrana disease 
(Ditcham, 2007), a system for the expression in E. coli of both these proteins as a 
GST-tagged polyprotein (CA/Tat-GST) from a single construct was developed and is 
reported in Chapter 4. This chapter also includes a description of methods used for the 
optimization of induction and purification of the protein, in vitro cytotoxicity of the 
recombinant products, and methods used for determining purity and contamination of 
the polyprotein with nucleic acid and endotoxins. 
Chapter 5 reports the use of the CA/Tat-GST polyprotein as a vaccine for inhibition of 
the effects of JDV infection in small groups of cattle.  The efficacy of the polyprotein 
as a vaccine was compared to the use of a vaccine containing a mixture of 
individually prepared CA-GST and Tat-GST proteins.  
Chapter 6 describes the use of the CA/Tat-GST polyprotein in a large scale trial 
involving 100 vaccinated cattle and 100 control cattle over a 12 month period. This 
included an examination of possible adverse clinical effects of vaccination and the 
subsequent antibody response to vaccination. 
  10A general discussion of the positive outcomes of the research reported in the thesis, of 
the limitations of the research and potential methods for improvement of the outcomes 
is presented in Chapter 7. 
 
  11Chapter 2.  Review of literature 
 
This chapter reviews the current literature relevant to the objectives of the research 
undertaken and reported in this thesis on Jembrana disease and Jembrana disease virus 
(JDV).  JDV is a member of the bovine lentiviruses within the family Retroviridae, so 
an overview of the characteristics of retroviruses, and lentiviruses in particular is 
given to provide background information on the structure, genome, antigenicity and 
replication of this group of viruses. An understanding of the comparative 
pathogenesis, viral structure, genomics and antibody response to the lentiviruses was 
considered crucial to an understanding of the significance of the investigations 
reported in this thesis.  
The nomenclature used in this thesis for viral genes and proteins is that suggested by 
(Fauquet and Mayo, 2001; Pringle, 1999) where gene names are in lower case and 
italics e.g. env. The abbreviations for the encoded proteins have at least the initial 
letter in uppercase, e.g. Tat, Env and TM, and are not italicized.   
Retroviruses 
The family Retroviridae is comprised of a diverse group of viruses divided into 7 
genera: Alpharetrovirus, Betaretrovirus, Deltaretrovirus, Gammaretrovirus, 
Epsilonretrovirus, Spumavirus and Lentivirus. These are all animal viruses that use 
RNA as their genetic material within the virion and DNA as the genetic information 
within the infected host cell. Due to their dual genetic information systems, 
retroviruses have acquired characteristics of both DNA and RNA viruses (Flint et al., 
2000). An important feature of retroviruses is therefore their ability to use the enzyme 
reverse transcriptase to produce a proviral DNA (proviral) copy of the RNA genome, 
which is subsequently integrated into the host genome. Integration of the virus 
genome into the cellular genome makes retroviruses highly efficient molecular 
parasites. They can be subdivided into oncogenic or non-oncogenic types based on 
their ability to cause any form of neoplasia in the infected host species, and all but the 
Spumavirus and Lentivirus genera have oncogenic potential  (Levy, 1993a). Large-
scale research into animal and human retroviruses has intensified in the last 2 decades, 
prompted by the discovery of Human immunodeficiency virus (HIV).     
  12Lentiviruses 
Lentiviruses are exogenous viruses that are biologically and genetically distinct from 
other retroviruses (Pantaleo and Walker, 2000). There are at least 8 known species in 
humans and animals, with HIV being the best (Foley, 1998). Other known species are 
Maedi visna virus (MVV) in sheep, Caprine arthritis encephalitis virus (CAEV) in 
goats, Simian immunodeficiency virus (SIV) in non-human primates, Feline 
immunodeficiency virus (FIV) in wild and domestic cats, Equine infectious anaemia 
virus (EIAV) in various species of Equidae, and the related bovine species Bovine 
immunodeficiency virus (BIV) and JDV.  
Lentiviruses typically produce an initial mild acute disease syndrome soon after 
infection, followed by apparent recovery and a prolonged asymptomatic phase, 
followed by a progressive chronic symptomatic phase often leading to death. The 
exceptions to this include BIV, that seems to be associated with sub-clinical infection 
only (Gonda, 1992), and JDV and the SIVsmmPBj14 that cause severe and sometimes 
fatal acute disease syndromes after short incubation periods (Campbell, 1995; 
Soeharsono et al., 1995a; Wilcox et al., 1995). Lentiviruses principally infect cells of 
the immune system including macrophages, B-cells and T-cells, which leads to a 
compromised immune system and subsequent secondary infections.  
The lentivirus genome encodes 3 large polyproteins from the 3 major open reading 
frames (ORF): gag (derived from group antigen) encoding structural proteins), pol 
(derived from polymerase) encoding viral enzymes, and env (derived from envelope) 
encoding envelope glycoprotein involved with virus-host cell interactions as shown in 
Figures  2.1 and 2.2. Lentiviruses also encode a number of accessory proteins from 
genes located between the pol ORF and the 3’ LTR that have important regulatory 
functions during viral replication; these genes are characteristic of and unique to 
lentiviruses, and some of these are unique to the individual lentiviruses (Flint et al., 
2000; Levy, 1993a). The common lentivirus accessory genes are vif encoding Vif 
(viral infectivity factor), tat encoding Tat (trans-activator of transcription), rev 
encoding Rev (regulator of expression of virus) and nef (negative factor) which is 
unique to primate lentiviruses (Miller et al., 2000b). 
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Figure 2.1. Schematic illustration of the morphology and genome structure of lentiviruses 
showing the 3 main open reading frames (ORF). The genes encoding the accessory proteins 
are not shown. The diagram is an adaptation of that used by Gonda (1992) to describe the 
structure of BIV. 
 
Pathogenesis of lentivirus diseases 
Knowledge of the replication of lentiviruses is crucial for an understanding of the 
progression of the diseases they induce and the host response to infection. The first 
step in the infection process is the entry of the virion into the host cell, facilitated by 
high affinity binding of the surface envelope (SU) glycoprotein to specific viral cell 
receptors on the surface of the susceptible host cell (Gonda et al., 1994; Pantaleo and 
Walker, 2000). Once attached to the host cell, viral entry proceeds by fusion of the 
viral envelope with the membrane of the cell, enabling the virus core comprising of 
NC and CA (residual structure formed by loss of the matrix protein and envelope 
glycoprotein) to enter the cytoplasm of the host cell, wherein the single-stranded viral 
RNA is reverse transcribed into a double-stranded viral DNA utilising the intravirion 
virus-encoded reverse transcriptase. This double-stranded DNA is transported to the 
nucleus and integrated into the host cell’s chromosomes via an intravirion virus-
encoded integrase (Flint et al., 2000). The integrated virus double-stranded DNA 
(provirus DNA) is duplicated each time the cell divides, thus maintaining the virus 
  14genome through generations of cell division.  Upon activation of key cellular and 
exogenous signals (yet to be elucidated) viral expression can be initiated (Gonda, 
1992). Once the host cellular enzymes transcribe the viral DNA into mRNA, using 
splicing mechanisms, the RNA transcripts are transported to the cytoplasm where they 
are translated to non-glycosylated proteins by free ribosomes or to glycosylated 
proteins by endoplasmic reticulum bound ribosomes and the Golgi apparatus. The 
virus components are then assembled in the cytoplasm and are released from the cell 
by a budding process when the virus acquires the envelope and further maturation can 
occur after release of the virus from the cell (Hovden, 2001) (Figure 2.2). 
 
Figure 2.2. Schematic diagram illustrating the series of events that occur during lentivirus 
o 
urs, 
 cells 
replication cycle within the host cell. Once the virus binds and enters the host cell leading t
the loss of the envelope and capsid surrounding the ssRNA. The ssRNA is then reverse 
transcribed into dsDNA and integrated into the host chromosome. Once cell division occ
viral mRNA is transcribed and then translation of the viral products follows. Unlike AIDS 
inducing lentiviruses which do not form intracytoplasmic particles before JDV viral 
components are then assembled and bud from the host cell to infect other susceptible
(adapted from Stewart 2005). 
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An immune response to viruses occurs when the physical and chemical barriers such 
as skin, mucous secretion, acidity and tears are overcome or bypassed by the virus 
(Cotran et al., 1999). Once these defences are breached, there are 3 main processes 
involved in the immune response: recognition of the virus, activation of the immune 
response, and control of the immune response once the viral infection is cleared. The 
immune response that occurs can be divided into 2 main types: one associated with 
the innate immune system and one associated with the adaptive immune system (Flint 
et al., 2000).  
The innate immune system is a non-specific system that is being continuously 
activated in response to infection by viruses (Cotran et al., 1999). Once triggered, the 
innate immune system controls interferon production, complement and inflammatory 
responses. Interferons can induce an anti-viral state in neighbouring cells that will 
inhibit virus replication, and play a role in the clearance of infected cells by activating 
the complement cascade, natural killer cells (NK), macrophages or neutrophils 
(Narayan et al., 1982). The inflammatory response is usually only strongly activated 
by cytopathic viruses that cause significant cell damage. The innate immune response 
is vital as it is the body’s first response to the virus, can be activated within hours of 
infection and is often a precursor to the adaptive immune response (Cotran et al., 
1999).   
In contrast to the innate immune system, the adaptive immune response is specific and 
tends to be much slower, taking days to weeks to reach peak activity (Roitt and 
Delves, 2002). The increased response time is the requirement for activation of 
antigen-presenting cells (APC) before the process of differentiation and maturation of 
the response can occur. The adaptive immune response is categorized into 2 main 
classes: humoral and cell-mediated.    
The humoral response is the presentation of antigens to immature B-lymphocytes that 
then differentiate into plasma/antibody-secreting cells. The 5 classes of antibodies 
produced are IgA, IgM, IgD, IgE and IgG, all of which have different antigen binding 
properties and biological roles (Roitt and Delves, 2002). The classes that appear to be 
important in viral infections are IgA (involved in mucosal viral defence), IgM 
(important in early viral agglutination and activation of the complement cascade) and 
  16IgG (the prime effector antibody class in viral clearance) (Cavacini et al., 2003). IgG 
is the major class of antibody produced in response to infection: 75% of all antibodies 
present in plasma are of this subtype. IgG has a half-life of 1-3 weeks (depending on 
the subclass) and is produced predominantly after a second exposure to an antigen. 
There are 4 subclasses of IgG (IgG1, IgG2, IgG3 and IgG4), with IgG1 being the 
most abundant subclass (Flint et al., 2000). In HIV-1 infections, IgG1 and IgG3 are 
involved in binding and neutralization of virus (Cavacini et al., 2003). Some classes 
and subclasses of antibody are important regulators of cell-mediated immunity and 
inflammation (Casadevall and Pirofski, 2003) whilst others such as IgM, IgG and IgA 
can activate the complement cascade leading to clearance of virally infected cells 
(Casadevall and Pirofski, 2004).  
The cell-mediated immune response is brought about by the actions of the helper or 
cytotoxic T lymphocytes. These cytotoxic T lymphocytes are activated by APC that 
either destroy infected host cells directly or do so by antibody-dependant cell-
mediated cytotoxicity. The helper T lymphocytes release factors which activate and 
enhance the activity of other T and B lymphocytes and also limit cell division in 
infected tissues, thus preventing viral spread (Roitt and Delves, 2002).   
Small ruminant lentiviruses 
Although the primate lentiviruses are the best characterized of all the lentiviruses, 
they were not the first lentiviruses identified. The small ruminant lentivirus OMVV 
was discovered first and is described below.  
Ovine maedi-visna virus (OMVV) 
OMVV infects sheep causing the 2 diseases “maedi” and “visna,” affecting the central 
nervous system (CNS) and respiratory system, respectively (Dawson, 1987). These 
diseases appear to be confined to sheep in the northern hemisphere (Campbell, 1995) 
and have not been identified in Australia.   
OMVV is a spherical enveloped virion 80-100 nm in diameter which is 
morphologically similar to other lentiviruses (Levy, 1993b)  The virus replicates 
primarily in circulating monocytes and tissue macrophages. After infection of sheep, 
typically by transfer of infected blood, or in lambs by ingestion of virus-infected milk 
from infected dams during suckling, viraemia can be detected 2-6 weeks post-
  17infection and continues until death of the animal. Clinical signs do not develop for a 
prolonged period (months to years) post-infection.  Maedi is characterized by chronic 
respiratory disease and mastitis in older ewes, and visna by meningoencephalitis and 
arthritis (Dawson, 1987).  
Within 6-10 days of infection, there is a detectable antibody response to the CA and 
predicted MA (p16) proteins of OMVV. Not all infected animals develop a humoral 
immune response to the Env proteins, and sheep with chronic lesions may not have a 
detectable antibody response to virus proteins including p14, the predicted MA, and in 
some cases even CA. This total lack of antibody response to virus antigens in 
chronically infected animals makes diagnosis difficult (Houwers and Nauta, 1989).  
Currently, there are no commercial vaccines available for OMVV. 
Caprine arthritis-encephalitis virus (CAEV) 
CAEV is genetically and antigenically related to OMVV, producing disease 
syndromes in goats that are similar to those induced by OMVV in sheep (Foley, 
1998). CAEV infection is most common in high-density dairy goat production areas 
in America and Europe but it has also been diagnosed in Africa, Australia and New 
Zealand (Levy, 1993a). The infectious virus is an enveloped spherical virion 110 nm 
in diameter (Levy, 1993b).  
Transmission of the CAEV between animals occurs via milk, blood, saliva or 
urogenital secretions (Logan et al., 2004). Upon entry into a susceptible animal by 
ingestion, the virus is absorbed into the small intestine wall and then infects 
mononuclear cells in the region; when these mononuclear cells mature into 
macrophages, the virus is activated and replication occurs (Narayan et al., 1982). The 
clinical manifestations of infection are similar to those of OMVV infection in sheep, 
and principal lesions occur in the CNS resulting in encephalitis (observed mainly in 
kids) or chronic arthritis (observed mainly in adults). Other manifestations of 
infection can also occur, including pneumonia, mastitis, secondary infections and 
progressive weight loss; death is inevitable once clinical signs develop (Cheevers et 
al., 1988).   
Although virus infection results in a strong humoral and cell-mediated response, 
typical of the response in other lentivirus infections, this fails to eliminate the virus 
from the infected animal (Narayan et al., 1982). Serologically, in CAEV infections the 
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proteins are also detectable in infected animals (Bertoni et al., 2000).  
Equine infectious anaemia virus (EIAV) 
Equine infectious anaemia was the first lentivirus-induced disease reported, described 
initially in horses in France in 1904. The virus, a circular virion approximately 100 
nm in diameter with many envelope projections was, however, only characterized 
recently (Levy, 1993b). Infections of Equidae with EIAV have been reported 
throughout the world but infection appears more prevalent in warmer climates, 
possibly because EIAV is a blood-borne virus mechanically transmitted by parasitic 
vectors such as biting flies (family Tabanidae) although it can also be transmitted 
iatrogenically via surgical equipment or syringes used on multiple animals (Foil et al., 
1983).  
Like CAEV, the virus replicates in monocytes and macrophages (Oaks et al., 1998) 
and endothelial cells (Oaks et al., 1999). The anaemia is immunologically-mediated: 
virions are released from infected cells and bind to red blood cells (RBCs) causing 
them to be targeted by the immune system, resulting in lysis of the RBCs and 
subsequent anaemia (Levy, 1993b). Following the initial infection, neutralizing 
antibody is produced and virus replication declines. This state continues until another 
variant of the virus is produced that can evade the pre-existing neutralizing antibody, 
initiating a new cycle of virus replication and disease (Sellon et al., 1996). Each EIAV 
creates 10-20 copies of proviral DNA which are integrated into the host 
chromosomes, enabling persistence of the virus in infected animals (Levy, 1993b).  
There are 2 recognized clinical phases of equine infectious anaemia, a highly 
pathogenic acute phase with varying degrees of fever and anaemia, which leads to 
death in less than 5% of infected animals. Recovery from this initial acute phase is 
followed by recurrent cycles of viraemia and anaemia, but this is not seen in all 
infected horses. In this recurrent phase, infected animals have periodic occurrences of 
disease characterized by clinical signs of fever, decreased fertility, petechial 
haemorrhages, leucopenia, oedema, loss of weight and condition, and depression. 
Between each febrile disease period there is a sub-clinical infection where horses have 
low level circulating virus and antibody (Levy, 1993b).  
  19Serologically, EIAV-infected animals develop a  response against the p26 CA (Ball et 
al., 1992), the gp45 TM and gp90 SU antigens (Chong et al., 1991). 
Feline immunodeficiency virus (FIV) 
FIV is a spherical 105-125 nm virion with poorly defined envelope projections (Levy, 
1993c) first identified in California in 1986 (Pedersen et al., 1987).  
The main route of transmission of FIV is the inoculation of saliva from the bite of 
infected cats, but other routes of infection including in utero and perinatal 
transmission via milk are also possible (Torten et al., 1991). FIV infects not only 
domestic but also large wild cats in game parks in eastern Africa and in captivity 
throughout the world, and can cause a disease that is very closely related to that 
caused by HIV-1 (Brown et al., 1994; Burkhard and Dean, 2003; Langley et al., 1994; 
Olmsted et al., 1992). The progression of disease associated with FIV infection is said 
to be an important model for HIV infection studies (Campbell, 1995).  
Similar to HIV and SIV, and unlike the macrophage-tropic OMVV, CAEV and EIAV, 
FIV primarily infects macrophages and lymphocytes. Following infection, animals 
develops a chronic infection that is generally associated with 3 clinical stages that are 
very similar to those seen in HIV infections: an initial acute phase associated with 
fever and lymphadenopathy (enlarged lymph nodes); a subsequent second sub-clinical 
phase lasting months to years with varying viral plasma load; a third active phase in 
which there is a progressive destruction of the lymphocytes and subsequent 
immunodeficiency. Cats progressing to the final chronic stage develop many 
secondary or opportunistic infections that eventually result in death (Torten et al., 
1991).  
Serologically, a detectable antibody response against the Gag and Env proteins occurs 
but some confusion exists as to which antibodies appear first (Burkhard and Dean, 
2003; Torten et al., 1991).  
Primate lentiviruses  
These lentiviruses are the most intensively studied of all the lentiviruses.  The simian 
viruses provide a valuable model for comparative research purposes of HIV infection, 
and both the simian and human viruses provide a valuable insight into the pathogenic 
mechanisms involved in non-primate lentivirus infections. 
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Several retroviruses have been detected in numerous monkey species throughout 
Africa, some of which have been associated with disease including an AIDS-like 
syndrome called Simian AIDS (SAIDS) (Levy, 1993c).  These lentiviruses are most 
closely related to the human lentiviruses, and there is strong evidence that the human 
lentiviruses were derived from SIV infections of non-human primates (Foley, 1998). 
The first simian retrovirus identified was a D type retrovirus (a deltaretrovirus) (Levy, 
1993c). Another retrovirus was identified subsequently, originally designated Simian 
T lymphotropic virus strain III but later redesignated SIV. Numerous strains of SIV 
exist, each with differing characteristics and  disease pathogenesis, however they are 
generally classified by the species infected e.g. SIVsmm for the SIV detected in sooty 
mangabeys (Levy, 1993c). 
Morphologically, SIV have an irregular roughly circular shape and are approximately 
125-165 nm in diameter with outer envelope projections (Levy, 1993c). The method 
of their transmission in monkey populations in the wild is arguable but there is strong 
evidence that, like HIV, the main method of transmission is sexual (Milman and 
Sharma, 1994). The cell types infected are primarilt monocyte/macrophages and T 
cells bearing the CD4+ receptor similar to HIV (Chakrabarti et al., 1994).  
In some circumstances, a disease with a remarkably similar pathogenesis to HIV 
ensues post-infection with some SIV biotypes, characterized by typical lymphoid 
depletions, immunodeficiency and fatal secondary infections (Levy, 1993c). Many 
SIV biotypes in African primates produce sub-clinical infections and the viruses 
appear adapted to their primary host, with disease occurring only when virus is 
inoculated into a heterologous host, for example when SIVsmm was inoculated into 
Asian macaques (Levy, 1993c). An acute form of SIV due to a mutant strain of 
SIVsmm, designated SIVsmmPBj14, was identified that caused an acutely lethal disease 
within 8-12 days of infection in Asian macaques.  Antibodies against the Gag and Env 
proteins have been detected in infected animals, and neutralising epitopes in the SU 
protein identified (Cole et al., 1998; Kannagi et al., 1986). 
Human immunodeficiency virus (HIV) 
HIV is the most characterized lentivirus and there are 2 types, HIV-1 and HIV-2. Both 
of these subtypes cause AIDS in affected individuals (Andersson et al., 1997; Cotran 
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covered with small surface projections on the outer envelope of the virion (Levy, 
1993d).  
Transmission of HIV involves the transmission of virus in body fluids of infected 
individuals via infected blood, sexual contact, vertical transmission and sharing of 
contaminated needles (Cotran et al., 1999). Entry of HIV into the body occurs through 
mucosal surfaces where susceptible T cells and macrophages (those bearing the CD4+ 
receptor) in the region are infected. After entry into the cell, virus replicates and 
newly formed virions are released into the lymph or circulatory system, leading to 
infection of other susceptible T cells (Flint et al., 2000). Following entry into the 
lymph and circulatory systems, 3 stages of the disease process ensue. The first stage is 
an acute infection 4-6 weeks after the initial infection, characterized by large numbers 
of infectious virus particles produced in the lymphatic system, associated with 
swollen lymph nodes and flu-like symptoms.  Recovery from this phase is followed 
by a second or asymptomatic phase characterized by a steady decline in CD4+ cells. 
This phase of infection may persist for as few as 4 months but may be as long as 
several years. The third (symptomatic) stage of disease is associated with changes in 
the phenotype of the virus and increased replication of virus, resulting in marked 
depletion of CD4+ cells and immunosuppression, leading to the clinical condition 
AIDS (Figure 2.3). Clinical manifestations of the third stage are lymph node 
enlargement, chronic immune stimulation and the production of auto-antibodies 
(Cotran et al., 1999). Immunosuppression leads to opportunistic infections by 
organisms such as Toxoplasma gondii, Cryptococcus neoformans and Pneumocystis 
carinii. Other pathologic conditions associated with HIV infection and associated with 
the immunosuppression include cancers such as Kaposi’s sarcoma, B cell lymphomas 
and anogenital carcinomas, in addition to damage occurring to the gastrointestinal 
system, visceral organs, and haematopoietic system. Neurological disorders as a 
consequence of HIV infection of neural cells are also seen (Georgsson, 1994).  The 
neurological lesions, in addition to all the other symptoms as a consequence of 
immunosuppression, cause a general deterioration of health and eventually result in 
death if antiviral therapy is not initiated and maintained (Flint et al., 2000). Antibodies 
against all the HIV viral proteins have been reported although they are rarely seen 
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et al., 1999). 
 
 
Figure 2.3. Course of a typical HIV-1 infection, the best characterized of all lentivirus 
infections. After primary infection an acute disease process occurs soon after infection that is 
associated with a transient high plasma virus load and a decrease in CD4
+ cells. This is 
followed by a prolonged sub-clinical period, with a progressive decrease in total CD4
+ cells 
an eventual increase in virus load leading to the onset of immunosuppression and 
opportunistic secondary infections (AIDS). Adapted from Weiss (1993). 
 
 
Bovine lentiviruses 
There are currently only 2 known bovine lentiviruses: BIV which produces a mild or 
sub-clinical disease syndrome, and JDV which produces an acutely pathogenic 
infection particularly of Bali cattle.  The 2 viruses share significant nucleotide and 
amino acid identity. 
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History 
BIV was initially identified in a dairy cow in Louisiana (Van Der Maaten et al., 
1972). This initial report was virtually ignored by the scientific community until HIV 
infections became a global issue and the bovine virus was identified as a lentivirus 
with a genomic organization similar to HIV (Gonda et al., 1987). This original strain 
of BIV was designated the R29 strain, and other strains have since been detected in 
America and in many other countries (Scobie et al., 2001; Suarez et al., 1993). 
Burkala et al. (1999) presented evidence that BIV is present in Australia with roughly 
3.8% of animals testing seropositive to BIV and JDV recombinant protein antigens. 
Transmission and host species 
The exact mode of transmission of BIV is yet to be confirmed, but it was suggested 
that the primary routes of infection occur via virus in blood, milk and other body 
fluids, and by vertical transmission (Gonda et al., 1994). Other suggested routes of 
infection include contaminated instruments or via virus-contaminated colostrums 
(Levy, 1993b). The range of cattle species susceptible to BIV infection is yet to be 
determined but it appears that most cattle breeds are susceptible (Gonda, 1992). Other 
species of animals used in transmission studies to test the host range of the BIV R29 
strain include New Zealand white rabbits, which develop a persistent viraemia after a 
single injection of BIV infected cells. Rabbits develop a BIV-specific humoral 
immune response and virus can be detected in the spleen, lymph and peripheral blood 
leucocytes, indicating that BIV in rabbits affects cells of the immune system (Pifat et 
al., 1992). Experimental infections of sheep and goats with the R29 strain have caused 
these animals to seroconvert within 2 weeks of the inoculation of virus. However, 
some doubt still exists as to whether these animals actually became infected or 
produce antibodies to the administered viral components (Jacobs, 1995). These 
results, indicating susceptibility of not only cattle, but also sheep, goats and rabbits to 
the same lentivirus are unusual as most lentiviruses produce infection in only a single 
or closely related host species. 
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BIV is one of 3 syncytial-inducing viruses found in cattle and is 80-100 nm in 
diameter with short surface envelope projections (Levy, 1993b). The genome is 8,482 
bases long (Florida strain 127; BIV 127) and analysis of the few strains that have been 
detected suggests the virus has been genetically stable over time (Carpenter et al., 
2000) unlike most lentiviruses which have a relatively fluid genetic and therefore 
antigenic structure (Garvey et al., 1990). The primary cell types infected with the 
virus appears to be B-lymphocytes and macrophages but proviral DNA is also present 
in CD3+, CD4+, monocytes, T cells, neurons, smooth muscle cells, endothelial cells, 
microglial cells and CD8+ cells, which indicates that the virus has broad cell tropism 
(Heaton et al., 1998; Whetstone et al., 1997; Zhang et al., 1997a).  
The BIV genome has the obligatory gag, pol and env genes that are present in all 
retroviruses but it also encodes additional accessory genes characteristic of 
lentiviruses and including vp2 (also called vpw), vp3 (also called vpy), rev, p2L, p3, 
p2, p7, tmx, tat and vif (Gonda et al., 1994). The Gag precursor polyprotein (55 kDa) 
is cleaved to produce MA (16 kDa), CA (26 kDa), p2L, p3 and NC (7 kDa) proteins, 
which are structural proteins (Battles et al., 1992). The Env precursor polyprotein 
(102 kDa) is cleaved to produce the SU (62 kDa) and TM (40 kDa) glycoprotein that 
are important in virus-host interaction and entry of virus into the host cell (Gonda, 
1992). The Pol precursor polyprotein (120 kDa) is cleaved into a viral integrase, 
reverse transcriptase and a protease, which are functional enzymes required for 
replication. The proteins encoded by the accessory genes are Tat (14 kDa), Rev (23 
kDa), Tmx (19 kDa) and Vif (predicted size 23 kDa). BIV potentially encodes 2 extra 
and unique proteins, Vpw (predicted size 7 kDa) and Vpy (predicted size 10 kDa) 
which have unknown biological function (Gonda et al., 1994). Generally, most of the 
research on BIV has utilized the original R29 strain (Straub and Levy, 1999; Van Der 
Maaten et al., 1972) or its derivatives but now more studies are focusing on other 
isolates of the virus to determine whether R29 infection is a reliable model for BIV 
infection (Baron et al., 1997).  
Pathogenesis of BIV infection 
Experimental infections with BIV suggest that in most cattle there is often a mild or 
sub-clinical response to infection (Flaming et al., 1993). Some early reports of the 
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diarrhoea virus which confounded the results obtained.  However, it seems that 
infection can result in transient leucocytosis, lymphoid hyperplasia and 
lymphadenopathy but unknown longer-term consequences have been suggested 
(Carpenter et al., 1992). Other related clinical manifestations of BIV infection that 
have been reported are increased co-infections with Bovine leukaemia virus (BLV), 
hepatic disease, mastitis, decreased immune competence (Zhang and Barkalis, 1997) 
and other secondary infections, all of which might cause significant production loss 
(Campbell, 1995).  
Jembrana disease  
History 
The initial outbreak of Jembrana disease occurred in Sankaragung, a village within the 
Jembrana district of the island of Bali in 1964 and it was originally thought to be 
haemorrhagic septicaemia due to Pasteurella.  However, attempts at vaccination 
failed to eradicate or prevent the spread of the disease suggesting a novel pathogen 
was responsible. Affected cattle were Bos javanicus (Bali cattle) a domesticated form 
of the wild banteng cattle common in Bali. Bubalus bubalis (buffalo) were also said to 
be involved, although the involvement of buffalo has never been reported again.  
Within 12 months, the disease was reported in all 8 districts of the island in 
association with a high case fatality rate (Soeharsono and Temadja, 1995).  
The first tissue and blood samples of the affected cattle were submitted in April 1965 
to the Bogor Animal Disease Research Institute (ADRI) in West Java, where analysis 
of these and other samples from field investigations led the Bogor ADRI to conclude 
that the pathological agent was either rinderpest virus or a rinderpest-like virus. A 
mass vaccination program against rinderpest was initiated on Bali and (although 
rinderpest was not the cause) the disease was not reported again for another 7 years 
when a smaller more localized outbreak was recognized in the Tabanan region of Bali 
in 1972 (Soeharsono and Temadja, 1995). A third outbreak of the disease was 
reported in 1981 in the Karangasem region of Bali (Soeharsono, 1995). The disease 
has also since been reported in Bali cattle in other areas of Indonesia including 
Lampung Province in Sumatra  island (Prabowo, 1995), South Sumatra in 1976 and 
West Sumatra in 1992 (Tembok and Erinaldi, 1995), and East Java in 1978 (Tembok 
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from regions where the disease was endemic, suggesting that the infectious agent 
originated in Bali, and was disseminated in association with the illegal transport of 
infected cattle from Bali. The disease has since been detected in Kalimantan (Wilcox, 
1995) on the island of Borneo but there is no evidence of how the virus was 
transmitted to Kalimantan.   
The aetiological agent was identified as a lentivirus closely related to BIV (Chadwick 
et al., 1995b; Kertayadnya et al., 1993). Contention exists as to the origin of JDV and 
3 main explanations for its origin have been proposed. The first was that in 1964, 
there was a foreign cattle ship in Buleleng harbour, and although this was 100 
kilometres from the site of the first infection it was possibly responsible for the initial 
outbreak of Jembrana disease in local Bali cattle. The second explanation was that at 
the time of the initial outbreak, there were mass vaccinations against foot and mouth 
disease in Indonesia using inactivated virus vaccines and the vaccines might have 
been contaminated with JDV; this is unlikely considering the instability of lentiviruses 
and JDV. The final theory, the most plausible, was that banteng, buffalo or deer from 
the West Bali National Park adjacent to the Jembrana district were the primary host 
and transmitted the virus to nearby domesticated cattle (Soeharsono et al., 1995c; 
Soeharsono et al., 1995d). 
Host species 
The major host cattle species for JDV is now domesticated Banteng (Bos javanicus) 
(Figure 2.4). Studies with other species of cattle such as Friesians (Bos taurus), 
Ongole (Bos indicus), buffalo (Bubalus bubalis) and cross-bred Rambon and Madura 
breeds (Bos javanicus x Bos indicus) have shown that they can be experimentally 
infected with JDV (Soeharsono et al., 1995d) but the clinical disease and pathological 
lesions resulting from infection are less severe and the infection in these species could 
be easily missed under field conditions (Soeharsono et al., 1995b). Sheep, goats and 
pigs can be infected with JDV and while some pigs developed a fluctuating febrile 
reaction the only species to develop a detectable viraemia was sheep (Soeharsono et 
al., 1995a). This suggests that like BIV, the virus associated with Jembrana disease 
has a larger host range than other lentiviruses, and supports the theory that the original 
outbreak could have originated from another ruminant species in the nearby national 
park (Soeharsono et al., 1995a). 
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Figure 2.4. Female Bos javanicus cattle on Bali Island.  The coat colour of the cattle is sex-
linked: females are light brown as shown and mature males are dark, almost black.  Note the 
distinctive white markings on the rump. Photograph courtesy of Professor Joe Brownlie, 
Royal Veterinary College. 
 
 
Jembrana disease virus 
The virion is a roughly circular to ovoid enveloped virus of 90-130 nm diameter 
which uses C-type budding to release from infected host cells (Kertayadnya et al., 
1993). The JDV genome is 7,732 bases in length, 750 bases shorter than the BIV 127 
genome, an infectious BIV clone derived from the R29 strain by Garvey et al. (1990); 
however, the 2 genomes share 72% nucleotide identity. The major differences 
between BIV and the JDV genome are deletions of up to 431 bases in length in the SU 
region of the genome and numerous insertions of up to 33 bases throughout the 
genome (Figure 2.5). Other differences between the JDV and BIV genomes include 
several differences in the cis-acting sequences (promoters, enhancers, TAR, splice 
sites and frame shift sequences) and nucleotide changes that could lead to amino acid 
changes in the coding regions, especially in the env regions but also in gag and pol 
genes (Chadwick, 1995; Gonda et al., 1994). The JDV genome also lacks the Vpw, 
p2L, p3 and Vpy proteins found in BIV and there are also probable differences in the 
processing of the gag gene that differ to JDV (Chadwick, 1995). 
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Figure 2.5. Comparative genomic maps of the JDV genome (top), BIV genome (middle) and 
HIV-1 genome (bottom). The major ORFs are shown in black and the location of the 
accessory genes is indicated in red and yellow.  From Stewart (2005).   
 
Transmission of Jembrana disease virus infection 
The mechanism of transmission of JDV has not been determined but probable routes 
of infection have been identified. One hypothesized method of transmission was from 
cattle during the acute phase of infection when circulating virus levels reach 10
8 virus 
particles/mL in blood, suggesting mechanical transmission either by contaminated 
syringes or by arthropod vectors would be possible (Soeharsono et al., 1995d). 
Supporting this theory was data indicating that infection seems to require close 
contact between infected and susceptible cattle, as the spread of infection to cattle on 
islands close to Bali has not occurred. This indicated that the transmission was either 
by animal-to-animal contact or mechanically by short-range arthropod vectors that 
cannot travel large distances. In experimentally infected cattle kept in close contact 
with each other, transmission from infected to in-contact cattle has been clearly 
demonstrated (Soeharsono et al., 1990). The possibility of other means of 
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have not been investigated fully, but there is evidence that during the acute phase of 
infection, JDV is shed into milk from infected cattle and that conjunctival and oral 
infection is possible (Soeharsono et al., 1995d).  
Seroprevalence and epidemiology of Jembrana disease  
The seroprevalence of JDV has been investigated in Lampung, Sumatra, Kalimantan, 
Lombok, Sulawesi and Java using sucrose-purified whole virus antigen in an ELISA 
(Hartaningsih et al., 1993) and the islands where JDV infection has been detected 
serologically and Jembrana disease has been detected clinically and pathologically are 
shown in Figure 2.6. The seroprevalence of JDV antibody-positive cattle on Lampung 
varied from 0-35% in different areas with a mean of 13% over the whole province. 
Kalimantan had the highest prevalence of seropositive cattle with a range of 15-76% 
antibody positive cattle in different areas with a mean of 43%. On Java, only one 
province was tested and there was 31% antibody positive (Figure 2.6). In Sulawesi 
and Lombok, antibody-positive cattle were not detected (Soeharsono and Temadja, 
1995).  
 
 
Figure 2.6. Areas of Indonesia where JDV infection has been detected (in red).  Antibody 
positive cattle have also been detected in Sulawesi but Jembrana disease has not been 
detected, suggesting the presence of a second non-pathogenic bovine lentivirus in cattle in 
this island.   
 
Seropositive cattle have also been identified in South Sulawesi although no clinical 
signs or other evidence of Jembrana disease have been reported in cattle in Sulawesi 
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(Soeharsono, 1995). The serological studies reported by Hartaningsih et al. (1995) did 
not take into account the possible presence of a second lentivirus in Indonesia that 
could cross-react with JDV antigens and almost certainly could have resulted in the 
inclusion of false-positives into the data.  
A seroprevalence survey was carried out in Bali over a 12-month period, testing 
different herd sizes and herd intensities using native antigen ELISA (Soeharsono, 
1995). The study found that large intensive farms had a higher seroprevalence than 
cattle owned by smallholders and as the smallholder herd size increased so did the 
prevalence of seropositive cattle. The number of seropositive cattle was found to be 
higher in the wet season which suggested there could be more exposure due to 
increased insect (tabanid or mosquito) activity (Putra and Sulistyana, 1995), again 
supporting the theory that blood-sucking insects are a likely source of new infections. 
Pathology of Jembrana disease resulting from JDV infection 
The pathogenesis of the disease was investigated in 18-month-old Bali cattle that were 
given an intravenous inoculation of JDV, which resulted in clinical signs of disease 
occurring 4-12 days post-infection (Soeharsono et al., 1995a). The main clinical 
features of infection were an elevated body temperature, loss of condition, anorexia, 
lethargy, enlargement of superficial lymph nodes, bloody diarrhoea and a discharge 
from the nose. The case fatality rate was 17% and although all infected cattle showed 
clinical signs of infection they did not necessarily exhibit all the clinical changes 
(Soeharsono et al., 1995a). Jembrana disease causes marked haematological changes 
in affected Bali cattle: leucopenia as a result of a lymphopenia, eosinopenia and 
neutropenia, thrombocytopenia, anaemia, increased blood urea concentrations and 
diminished total plasma protein concentration; these changes occur principally during 
the febrile period (Soeharsono et al., 1995a). Gross pathological changes include 
vascular damage such as mild exudates and haemorrhages, but the most striking 
changes are lymphadenopathy and splenomegaly. Lymphoid tissues of all organs, 
particularly in the enlarged lymph nodes and spleen, feature proliferating 
lymphoblastic cells predominantly throughout parafollicular (T-cell) areas, and 
atrophy of follicles (B-cell areas). A proliferative lymphoid infiltrate was also found 
in the parenchyma of most organs, particularly the liver and kidneys and an infiltrate 
containing proliferative macrophage-like cells was found in the lungs (Dharma et al., 
  311994). This acute and significant pathology was in stark contrast to the relatively mild 
pathology post-infection with BIV, even though the 2 virus types are genetically 
similar. Infection with JDV also appeared to immunosuppress cattle which would 
make them more susceptible to secondary infection and opportunistic pathogens 
(Wareing et al., 1999).  There is anecdotal evidence of an increased occurrence of 
secondary infections, including haemorrhagic septicaemia, in cattle with Jembrana 
disease (Wilcox, Personal Communication).  This might be expected from the severe 
lymphoid depletion persisting for at least 6 weeks post-infection (Dharma, 1995). 
Virus infection appears to provide protective immunity and attempts to re-infect 18 
cattle recovered from experimentally-induced disease as long as 22 months previously 
were able to induce a febrile response in only one of the re-infected cattle.  This 
indicated that the immunity is maintained over a long period of time and that a 
vaccine should be effective in giving long term immunity (Soeharsono et al., 1995a).  
Molecular genetics of JDV  
JDV theoretically could encode 14 proteins (Chadwick et al., 1995b) some of which 
are shown in the schematic diagram in Figure 2.2. The major components of the virus 
are the MA, CA and NC proteins that are cleaved from the Gag precursor polyprotein 
encoded by the gag ORF, typical of lentiviruses (Chadwick et al., 1995b). MA is a 
125 amino acid (14.3 kDa) protein located at the N-terminal end of the Gag 
polyprotein. In other lentiviruses, MA is the most abundant structural virus protein, 
essential in the late virus infection cycle that is targeted to the plasma membrane and 
involved in incorporation of viral components into budding virions (Keirnan et al., 
1998). The JDV MA has a 60% amino acid identity with the MA of the BIV 127 
(BIV127) strain and they cross-react antigenically (Desport et al., 2005). The CA 
protein is cleaved from the central region of the Gag polyprotein and is predicted to be 
226 amino acids long (25.3 kDa) and to share 75% amino acid identity with the CA 
protein of BIV127. The CA protein is the immunodominant protein in BIV and JDV 
and the CA proteins of the 2 bovine lentiviruses cross-react antigenically with each 
other (Desport et al., 2005; Kertayadnya et al., 1995) and with other lentiviruses due 
to a highly conserved major homology region (MHR) (Chadwick et al., 1995b; 
Cheevers et al., 1988; Rosati et al., 1999). The NC protein is encoded by a region at 
the carboxy-terminus of the Gag polyprotein (85 amino acids long) and is predicted to 
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RNA of the virus within the infected host cell (Zhang and Barkalis, 1997). 
The functional intravirion proteins (enzymes) of JDV are encoded by pol and are 
predicted to be expressed as a 1,027 amino acid and 118 kDa Pol precursor 
polyprotein, which is cleaved by the host cell proteases into an integrase (IN), a 
reverse transcriptase (RT) and viral protease (PR). The pol gene shows 68% 
nucleotide identity to the BIV 127 pol (Chadwick et al., 1995a) but no analysis of the 
individual enzyme similarity has been undertaken.   
The Env polyprotein of JDV encoded by env ORF is predicted to be 781 amino acids 
long (88.8 kDa) and with 31% identity to the BIV 127 Env precursor polyprotein. 
This protein undergoes further cleavage by the virus-encoded protease to produce SU 
and TM glycoproteins, and a putative Tmx protein.  
The JDV SU is predicted to be 422 amino acids long (47.8 kDa), which is smaller 
than the BIV127 SU protein, and there is only a 24% amino acid identity between the 
JDV and BIV proteins (Chadwick, 1995). The vital role of SU in the first stage of the 
replication process, combined with its ability to induce a strong neutralising and non-
neutralising antibody response, has made it a candidate for vaccines and differential 
tests due to the presence of many epitopes in variable regions (Ball et al., 1992; 
Gallaher et al., 1995).  
The JDV TM protein is predicted to be 359 amino acids  (41.1 kDa) with a 39% 
amino acid identity to BIV127 TM (Chadwick et al., 1995b; Gallaher et al., 1989). 
The HIV TM is vital to virus-host binding and interaction and consistent antibody 
responses have been observed against it, which highlights its potential as an additional 
vaccine candidate (Gallaher et al., 1989).  
There are 6 potential accessory proteins encoded by JDV that have yet to be 
characterized fully, including Tat, alternative Tat, Tmx, Vif, Rev and alternative Rev 
that could all be important in virus regulation and immune modulation. Tat is 97 
amino acids (10.7 kDa) and shares a 54% amino acid identity with BIV 127 Tat while 
the alternative Tat is 114 amino acids long (12.5  kDa) (Chen et al., 1999; Liu et al., 
1992; Setiyaningsih et al., 2008). The main functions of Tat in HIV are to activate 
transcription of proviral DNA for viral replication, recruit new viral targets (cells 
bearing CD4+ receptors), shield the virus-infected cell from the immune system and 
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antibodies in HIV-infected individuals indicates that this could be an important 
candidate protein for a vaccine (Pantaleo and Walker, 2000). The JDV Rev is 
predicted to be 213 amino acids (23.8 kDa) and shows 35% identity to BIV127.  The 
alternate JDV Rev is predicted to be 164 amino acids (22.4 kDa). Rev is theoretically 
functionally homologous with the cognate HIV proteins and shown in HIV to activate 
the export of partially spliced and unspliced viral mRNAs throughout the host cell 
(Pantaleo and Walker, 2000). Vif is a 197 amino acid (22.9 kDa) protein that shows a 
55% amino acid identity with BIV127 Vif.  The latter stages of viral assembly seems 
to be affected by this protein but its complete role in virus replication has yet to be 
elucidated (Miller et al., 2000b). The final JDV accessory protein is the unique Tmx 
seen only in bovine lentiviruses; this protein is 164 amino acids (18.5 kDa) and has an 
unknown function (Chadwick, 1995). 
Current lentivirus vaccines 
There are 4 main strategies that have been successfully used to produce successful 
vaccines to viral infections: live attenuated virus vaccines, inactivated or killed whole 
virus vaccines, viral subunit/recombinant protein vaccines, and DNA vaccines. 
Lentiviral vaccines are extremely problematic as these viruses readily infect immune 
cells of the host, so priming the immune response by vaccination would recruit cells 
for the virus to infect.  
There is only one commercially available vaccine for any lentivirus and this is for FIV 
(Uhl et al., 2002). This vaccine is an inactivated whole virus vaccine containing 2 low 
pathogenic strains of FIV; this protects approximately 2/3 of vaccinated cats 
depending upon the strain of FIV used to challenge the cats, although in control (non-
vaccinated) animals there are also a proportion that are resistant to infection (up to 
58% but generally below 20% of the non-vaccinated cats) (Uhl et al., 2002). A major 
problem with this vaccine is that there is no immunological marker of infection to 
differentiate vaccinated cats from non-vaccinated cats, which can lead to non-infected 
vaccinated cats being euthanized (Uhl et al., 2002). This problem, the apparently low 
level of protection and the cost have prevented the acceptance of this vaccine in many 
veterinary clinics and animal shelters. These problems demonstrate the difficulty 
faced when developing a commercial lentiviral vaccine, particularly for animals. 
Other potential difficulties faced with the development of new veterinary vaccines are 
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adverse effects including the presence of endotoxins, the registration process, and the 
acceptance of the vaccine in the veterinary community (Streefland, 2003).  
Live attenuated vaccines 
Live attenuated vaccines use viruses that are either naturally occurring or have been 
altered to reduce the virulence of the organism. The virus is able to infect cells and 
replicate within the host but is unable to cause disease (Gotch et al., 2000). These 
vaccines typically, but not always, produce a good immune response in the host with 
strong antibody and CTL responses and a long-lived immunity to the virus used. This 
type of vaccine has been used successfully to prevent bacterial infections such as 
cholera, typhoid, and tuberculosis. They have also been used successfully against viral 
infections such as hepatitis A, measles, mumps and smallpox in man (Rosen and 
Mackay, 2001). The acutely pathogenic nature of JDV infection, the inability to 
culture the virus in vitro and the possible reversion to virulence of the virus even if it 
were attenuated, indicate this type of vaccine is inappropriate for control of Jembrana 
disease in Indonesia. 
Inactivated or killed virus vaccines 
These vaccines are derived from whole viruses that have been inactivated, usually by 
alkylating agents such as formaldehyde. This type of vaccine has been successfully 
used to prevent mumps, influenza, FIV, poliomyelitis and Jembrana disease (Gotch et 
al., 2000; Hartaningsih et al., 2001; Hartaningsih et al., 1995a; Mazzetti et al., 1999). 
These vaccines are not infectious and cannot replicate within the host, adding a degree 
of safety, and they can often provide adequate protection against infection. Generally 
there is a good antibody response to the core antigens of the virus but a poor CTL 
response (Letvin, 2002). Unfortunately, this type of vaccine can lead to an 
enhancement of infection in some lentivirus infections such as FIV (Hosie et al., 
1992). Another common problem with these vaccines is that the chemical agents used 
to inactivate the virus may remove or structurally alter the outer envelope surface 
proteins preventing them from being recognized by the immune system which can 
lead to restricted specificity of neutralizing antibodies, as most neutralizing antibodies 
target the outer envelope proteins of the virus (Gotch et al., 2000). Early studies with 
inactivated FIV were promising when a low challenge dose was used and the vaccine 
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1991). However, if a higher vaccine dose was used the results were varied and there 
was no protection if a heterologous challenge was used (Hosie et al., 1995). The use 
of FIV vaccine Fel-O-Vax® (Fort Dodge) has provided up to 84% protection against 
infection with heterologous FIV strains in kittens but the efficacy drops rapidly when 
a larger challenge dose is used, and there is evidence for enhancement of infection in 
some cases (Dunham et al., 2006; Matteucci et al., 2000; Uhl et al., 2002).  
Recombinant protein vaccines 
This type of vaccine is produced by the expression of viral proteins in vector systems 
such as mammalian, insect, yeast, plant or bacterial cells (Letvin, 2002). Production of 
virus proteins by these methods is generally easy and low cost but unfortunately these 
antigens often fail to elicit a CTL or neutralizing antibody response (Letvin, 2002). 
These vaccines do, however, remove the difficulties associated with the use of 
attenuated viruses and overcome the problems associated with the use of large scale 
cell cultures needed for the production of inactivated virus vaccines. In HIV research, 
a recombinant fused Tat-glutathione-s-transferase (GST) protein vaccine was found to 
lower plasma virus load and produce an attenuated disease profile to SIV/HIV 
infection (Pauza et al., 2000). Studies on the use of HIV-1 recombinant Tat-GST as a 
vaccine have shown that the protein and the tag were internalized and a good antibody 
and CTL immune response were detected to the antigen (Borsutzky et al., 2006; Tyagi 
et al., 2001). This approach has also been used for other HIV vaccines with varying 
degrees of success and a recombinant hepatitis B vaccine is commercially available 
(Gotch et al., 2000; McElrath et al., 2000; Rusche et al., 1987).  
JDV vaccine development 
A JDV inactivated virus vaccine was developed using a tissue-derived (spleen) 
homogenate from an infected donor animal and the addition of Triton-X100 to 
inactivate the virus (Hartaningsih et al., 1995a; Ramachandran, 1995). This vaccine 
has been shown to ameliorate the disease and reduce mortality (Hartaningsih et al., 
2001; Hartaningsih et al., 1995a). However, it is expensive to produce as 
approximately 3,000 doses only are prepared from one donor animal. In addition there 
could be contaminating bacteria or viruses in the donor animal that are able to resist 
the inactivation process. Inactivation will also probably vary between different 
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sacrificing increasing numbers of donor cattle (Hartaningsih et al., 1995a). 
JDV recombinant protein vaccine candidates 
Tat 
Tat is potentially encoded for by 2 ORF’s, tat1 and tat2. During HIV infection, 
multiply spliced tat transcripts are produced early in the viral replication cycle before 
and during the integration phase which leads to the translation of Tat proteins 
sufficient to initiate transcription of HIV (Fulcher and Jans, 2003). During HIV-1 
infection, Tat levels can reach up to 1 ng/mL of serum in chronically infected patients 
(Albini et al., 1998; Miller et al., 2000a).  
In JDV and BIV, there is an in frame stop codon prior to the splice donor on exon 1 
that suggests only the tat1 is translated during the acute phase of infection 
(Setiyaningsih et al., 2008). The Tat1 protein of JDV is 97 amino acids with a 
predicted molecular weight of 10.7 kDa. The predicted protein encoded by JDV tat2 
is 114 amino acids with a predicted molecular weight of 12.5 kDa and as yet no 
research has been undertaken to determine the importance and biological role of this 
second protein. JDV Tat is the most potent of all the characterized lentiviral Tat 
proteins and can transactivate other lentiviral LTR regions (Chen et al., 1999; Deng et 
al., 2006).  
The remainder of this review of the biological roles of Tat involve HIV-1, unless 
stated, as this is the best characterized of all the lentiviral Tat proteins. 
Structure of Tat  
Tat is usually present in monomers and does not form stable multimers in living cells 
(Rice and Carlotti, 1990; Stauber and Pavlakis, 1998). HIV-1 Tat has 5 conserved 
regions: an N-terminal, a cysteine rich, a core, a basic and a C-terminal or glycine rich 
region (Fulcher and Jans, 2003; Jones and Peterlin, 1994; Taube et al., 1999). The Tat 
family of proteins contain small highly basic stretches rich in arginine and lysine in 
the N-terminal, core and cysteine rich regions which are involved in RNA 
recognition, although on its own these regions are not sufficient for RNA recognition 
(Chen and Varani, 2005; Garber et al., 1998). Another important region of Tat is a 9 
amino acid arginine rich region (RKKRRQRRR) in the basic region which allows the 
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et al., 1999; Vives et al., 1997). The N-terminal, core and C-terminal regions are 
important in the structural stability of the protein and the cysteine rich region interacts 
with cellular proteins involved in transcription elongation (Figure 2.7) (Fulcher and 
Jans, 2003).  
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Figure 2.7. Schematic diagram of HIV-1 Tat structure. The 5 structural domains are the N-
terminal, cysteine-rich, core, basic and C-terminal domains (Adapted from Fulcher and Jans, 
2003).   
 
Intracellular role of Tat 
One important feature of all Tat proteins is their ability to translocate through the 
plasma membranes of cells by matrix-associated heparin sulfate (HS) proteoglycan 
receptors which allow Tat to penetrate the cell membrane and alter the physiological 
state of the cell (Chang et al., 1997; Tyagi et al., 2001; Vives et al., 1997). The Tat 
proteins then localize predominantly in the cytoplasm and they are only transiently 
present in the nucleus of the host cell even thought they exert effects in the cytoplasm 
and nucleus (Stauber and Pavlakis, 1998). Once Tat is inside the host cell it can then 
shuttle between the cytoplasm and nucleus of the host cell.  
HIV-1 Tat is essential for late viral replication and its main role is the regulation of 
transcription which it achieves by activating the viral LTR region to allow efficient 
transcription of viral genes needed for viral replication (Brady and Kashanchi, 2005; 
Chen et al., 1999; Jeang et al., 1999; Stauber and Pavlakis, 1998). The Tat protein 
activates the LTR region by recruiting cellular cyclin T1 and cdk9 which forms the 
positive transcription elongation factor b (P-TEFb). This complex then binds to cis 
acting RNA enhancer elements (transactivation-responsive region; TAR) leading to 
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this increases the processing speed of RNA polymerase II (Brady and Kashanchi, 
2005) (Figure 2.7). HIV Tat may also induce chromatin remodeling of proviral LTR-
mediated gene expression by recruiting histone acetyltransferases that relocate to the 
chromatin regions leading to histone acetylation (Dandekar et al., 2004).  
In JDV and BIV it has been shown that the Tat proteins bind with high affinity and 
adopt distinct β-hairpin conformations, that when bound to the RNA are sufficient for 
viral transcription (Chen et al., 1999; Deng et al., 2006; Xie et al., 2003). The Tat of 
small ruminant lentiviruses such as MVV and CAEV differ from that of primate and 
bovine lentiviruses as their Tat protein has significantly lower trans-activation activity 
than the primate and bovine models (Villet et al., 2003).  
Other important roles of Tat are its interaction with nuclear factor kappa B (NFκB) 
enhancer which is an important regulator of numerous cellular genes (Dandekar et al., 
2004). Tat has been shown to modulate the expression of many cellular genes such as 
cytokines, adhesion molecules, oncogenes and MHC class I proteins (Chang et al., 
1997). Tat also interacts with many cellular proteins such as TBP, TAFII250, TFIIB 
with unknown effects (Kashanchi et al., 2000; Marcello et al., 2001). All the 
biological functions of the Tat protein have yet to be fully elucidated but much of the 
HIV-1 research on the Tat proteins has shown that this protein is an ideal candidate 
for a vaccine as it is essential for viral survival and fitness.  
Extra cellular role of Tat 
HIV-1 Tat has many diverse and poorly understood extra cellular biological roles and 
only the roles that are most relevant for pathogenesis and vaccination are reviewed.  
Extra-cellular Tat induces uninfected CD4+ cells to become more permissive to 
infection with HIV and is a potent chemo-attractant for susceptible 
monocytes/monocyte-derived dendritic cells (Albini et al., 1998; Bartz and Emerman, 
1999). To achieve this, Tat mimics β-chemokine features which may recruit 
chemokine receptor expressing monocytes/macrophages to virally infected cells 
(Figure 2.8) (Albini et al., 1998).  
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Figure 2.8. Alignment of the HIV-1 Tat protein with the mature peptide sequences of the ß-
chemokine MCP-3, MCP-2, MCP-1, RANTES, MIP-1a and MIP-1b. Conserved residues are 
shaded in black and the location of the Tat peptides in brackets. The residues shown in italics 
(amino acids 87–101), not present in some HIV isolates, were not included in the Tat1–86 
synthetic peptide used (adapted from Albini et. al., 1998) 
 
Tat also induces monocytes to kill uninfected CD4+ cells through a TNF-related 
apoptosis-induced ligand (TRAIL)-mediated mechanism (Yang et al., 2003). Other 
important biological roles of Tat are its involvement in a pro-apoptotic effect on 
bystander cells and the interaction with viral gp120 to modulate viral entry into the 
host cell (Giacca, 2005; Marchio et al., 2005). HIV-1 Tat has also been shown to exert 
angiogenic activity in vitro and in vivo, and to induce CNS neurotoxicity (Mitola et 
al., 2000; Rusnati et al., 2000; Tyagi et al., 2001). HIV-1 Tat has also been shown to 
increase the infectivity of endothelial cells to Kaposi-sarcoma associated herpesvirus 
(KSHV) by facilitating entry into the host cells (Aoki and Tosato, 2004; Aoki and 
Tosato, 2007). 
Tat vaccines 
The extensive intracellular and extra cellular biological roles of Tat and its essential 
role for viral replication have suggested that Tat is a promising vaccine candidate 
(Brady and Kashanchi, 2005; Fanales-Belasio et al., 2002; Fulcher and Jans, 2003). 
The tat gene is an early lentiviral regulatory gene and these early genes are generally 
more conserved than the structural genes transcribed later in viral infection (Stittelaar 
et al., 2002) and antigenic conservation of the epitopes of Tat would be an important 
consideration for vaccine development (Caputo et al., 2004).  
Tat vaccines have been used in a multitude of different forms, including native Tat, a 
synthetic peptide, a DNA vaccine, a toxoid and as recombinant proteins (Burgers et 
al., 2006; Fanales-Belasio et al., 2002; Fulcher and Jans, 2003; Noonan et al., 2003; 
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inactive forms. Vaccines that contained biologically active Tat have had substantial 
side effects such as toxicity, fever, cellular apoptosis and multi-organ lymphoid 
hyperplasia in the vaccinated animals (Benjouad et al., 1993; Goldstein, 1996; 
Vellutini et al., 1995; Vellutini et al., 1994). To combat this, many of the vaccines 
have contained Tat inactivated by chemicals such as hydrogen peroxide or mutated in 
the active sites of the protein (Noonan et al., 2003).  
There are numerous studies showing that vaccination with Tat ameliorates the disease 
or prevents infection in a proportion of animals (Caputo et al., 2004; Fanales-Belasio 
et al., 2002; Moreau et al., 2004). It was found that Tat-specific T lymphocyte 
frequencies were inversely correlated to rapid disease progression (van Baalen et al., 
1997) and that Tat neutralizing antibodies provided protection in rhesus monkeys 
vaccinated with Tat peptides and proteins (Belliard et al., 2005). HIV Tat proteins 
have also been used in conjunction with Env or Gag proteins and have been found to 
broaden the T cell responses against the antigens making it a novel adjuvant that may 
have numerous uses in vaccinology (Gavioli et al., 2008; Gavioli et al., 2004).  
Capsid vaccines 
Capsid protein lentivirus vaccines have been trialed in human and animals with 
varying degrees of success. The CA of lentiviruses is the immunodominant protein 
produced during infection and it contains B and T cell epitopes (Burkala et al., 1998; 
Hammond et al., 1997; Horton et al., 2001; Whetstone, 1995). However, if used as a 
vaccine in either a peptide, recombinant protein or whole virus form, little or no 
protection has been reported and it is, therefore, generally used in conjunction with 
the Env protein or as a part of the whole Gag antigen or with the accessory proteins 
(Egan, 2004; Gavioli et al., 2008; Stittelaar et al., 2002). While the Gag antigens can 
elicit a protective T cell response, studies have shown that the B cell response to these 
antigens can actually enhance early stage disease similar to what is found with B cell 
responses directed against certain epitopes on the Env antigen (Chung et al., 2004; 
Chung et al., 2005; Jolly et al., 1989; Tirado and Yoon, 2003; Torsteinsdottir et al., 
2007). There is also evidence that some T cell responses can also enhance infection to 
certain epitopes on this protein, making the addition of this antigen to vaccine 
compositions problematic (Nenci et al., 2007). Interestingly, it has been found that 
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with FIV CA and challenged with a homologous strain of FIV (Coleman et al., 2005). 
This suggests that cross-species vaccination may be more effective than homologous 
vaccines due to the removal of deleterious functions of the CA vaccine component. 
Diagnostic assays for lentiviruses 
The development of diagnostic assays for lentiviruses is fraught with difficulties as 
the viruses infect and compromise  the function of immune cells and the potent 
immuno-modulators like the Tat protein which are produced during infection (Albini 
et al., 1998; Dandekar et al., 2004; Gavioli et al., 2004). Another problem with 
diagnosis of lentiviral infections is the window between infection and the 
development of a serological response, and the undulating antibody response in long 
term infected animals (Andersson et al., 1997; Pantaleo and Walker, 2000; Saman et 
al., 1999). Other factors that also affect the sensitivity and specificity of diagnostic 
tests are population variation, pregnancy status, health status and nutritional status of 
sub-populations (Greiner and Gardner, 2000). For all these reasons there is no single 
diagnostic assay for any lentiviral infection that is 100% sensitive or specific, and 
generally a combination of assays is needed to confirm infection. 
Detection of JDV 
Detection of JDV is achieved via a number of different techniques, but a low cost- 
commercial assay with the required degree of sensitivity and specificity is unavailable 
and is required. JDV infection has been detected using serological tests, particularly 
ELISA and Western immunoblotting with either native antigens to detect antibodies 
produced in infected cattle (Hartaningsih et al., 1995b) or recombinant protein 
antigens (Burkala et al., 1998). The use of native antigen (sucrose gradient purified 
whole virus present in plasma of infected animals) is an accurate way of detecting the 
antibodies to the virus but it is not viable for large-scale screening; the production of 
this antigen requires the infection of cattle and harvest of the virus from plasma of the 
infected cattle, as efforts to culture JDV have thus far been unsuccessful 
(Kertayadnya, 1995).   
The production of recombinant proteins represents an easy and cost-effective method 
of producing JDV antigens. Unfortunately, such proteins often lack the sensitivity and 
specificity of native antigens (Abed and Archambault, 2000), which may be due to the 
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those that occur in natural infections. Other limitations of recombinant proteins are 
that they do not have all the antigenic proteins of a virus, and they do not overcome 
the problem of cross-reactivity with JDV and BIV (Barboni et al., 2001). The use of 
an ELISA with recombinant protein antigens appears to be appropriate for detection 
of JDV infections, but problems such as the purification of antigen and cross-
reactivity need to be overcome before a testing program can be implemented. Proviral 
PCR with JDV-specific primers is also used to detect JDV infection but this method, 
whilst extremely sensitive and specific, is time-intensive, costly, and thus not viable 
as a large-scale diagnostic test (Stewart et al., 2005).  
In situ hybridization (ISH) can also be used to detect JDV in tissue samples and viral 
RNA is present in a large range of host tissues (Chadwick et al., 1998).  While this 
technique is relatively sensitive and accurate it is unfortunately also time consuming 
and its use restricted to post-mortem samples (Chadwick et al., 1998). 
Antibody response to JDV infection 
In cattle experimentally infected with JDV, an ELISA with a whole virus antigen 
initially detected an antibody response in a low percentage of 19 cattle but it was not 
until 11 weeks after infection until an antibody response was detected in a majority of 
cattle, and 23 weeks before all cattle were positive.  The antibody persisted until 59 
weeks after infection, when the observations were discontinued (Hartaningsih, 1993).  
Western immunoblot examination of 3 of the infected cattle detected a JDV CA 
antibody response 6 weeks post-infection and it was longer before antibodies against 
other virus proteins were detected (Hartaningsih, 1993). Ditcham et al. (2007) used 
recombinant protein antigens and Western immunoblotting to initially detect 
antibodies against CA and TM proteins 5-15 weeks after infection in most cattle. 
Identification of BIV infection 
Identification of BIV infection can be achieved via PCR, real-time PCR (Lew et al., 
2003), nested PCR (Suarez et al., 1995), seroconversion to the Gag proteins (CA 
and/or MA) and TM protein (Scobie et al., 1999), or a combination of all of the above 
but as yet no method has been able to consistently achieve high sensitivities and 
specificities (Abed et al., 1999; Zhang et al., 1997b). The lack of a “gold standard” 
diagnostic test is due to a combination of factors, including the difficulty of detecting 
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of JDV, and the loss of antibody response over time in some infected animals (Orr et 
al., 2003). The current serological tests for BIV can only determine whether the 
animal has been infected within the last 2 years and the whole virus agar gel 
immunodiffusion (AGID) assay was found to be the most sensitive and specific 
compared to ELISA and an immunofluorescence assay (IFA) for the detection of 
antibody (Orr et al., 2003). Comparisons between ELISA and Western 
immunoblotting found that whilst there was generally good agreement between the 2 
techniques, immunoblotting was more sensitive but less specific than the ELISA 
(Bhatia et al., 2008; Zheng et al., 2000). A CA-based competition ELISA had a much 
higher concordance to immunoblotting than the typical indirect CA antigen ELISA 
suggesting this may overcome sensitivity issues with the indirect CA ELISA (Bhatia 
et al., 2008).   
Antibody response to BIV 
The antibody response of cattle infected with BIV strains R29 and FL112 can be 
detected earlier than with JDV, as soon as 22 days post-infection, with a high titre of 
antibodies against the CA (p26) protein appearing first and lasting for at least 30 
months post-infection, indicating CA is the immunodominant protein during infection 
(Battles et al., 1992; Whetstone, 1995). Antibodies to the p110, p55 (SU), p24 (Vif), 
p18 (Tmx), p15 (MA) and p13 (NC) were also detected within 31 days post-infection. 
Antibody to the p110 was detected transiently after the initial infection but was 
detected again 270 days post-infection and was maintained until 16 months post-
infection (Whetstone et al., 1990b). Isaacson et al. (1995) reported that the p26 
antibody response declined 10 months post-infection, which conflicted with a report 
by Whetstone et al. (1990). TM antibodies were detected by (Scobie et al., 1999) 
approximately 4 weeks post-infection and they remained detectable until 50 weeks 
post-infection in most cattle, suggesting that detection of TM antibody could be used 
in conjunction with other markers to produce a reliable serological marker of infection 
(Scobie et al., 1999).  
Because of the differences observed in the antibody response between cattle there is 
no “gold standard” serological test for BIV but an antibody response to a combination 
of virus protein antigens provides the best indicator of infection (Abed et al., 1999; 
Burkala et al., 1998). It is interesting that cattle in a Jembrana disease-free region of 
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seropositive. It is likely, due to the homology between JDV and BIV (Burkala et al., 
1998), that this is antibody to a non-pathogenic BIV-like virus, and this antibody 
could lead to false positive results during immunosurveillance for JDV (Hartaningsih, 
Personal Communication).   
Antigenic cross-reactivity of lentivirus proteins 
A major impediment to the specificity of the serological diagnosis of lentiviruses in 
animals is the cross-reactivity of antigens in different species of lentiviruses, 
particularly troublesome when different species infect the same host. Grund et al. 
(1994) showed that the EIAV CA protein has cross-reactive epitopes to HIV-1 CA 
epitopes, Rosati et al. (1999) showed that CAEV CA epitopes cross-reacted with 
MVV CA epitopes, Battles et al. (1992) found that BIV CA epitopes cross-reacted 
antigenically with HIV-1 CA epitopes, and Kertayadnya et al. (1993) and Desport et 
al. (2005) demonstrated that the CA proteins of BIV and JDV contained several cross-
reactive epitopes. This degree of cross-reactivity makes serological differentiation 
between lentivirus infections of the same species extremely difficult e.g. JDV and 
BIV-like lentiviruses in Indonesian cattle. A highly conserved region within the CA 
protein of lentiviruses, the MHR contains conserved epitopes that cross-react 
antigenically in all lentiviruses. There appears to be a greater degree of specificity in 
the proteins encoded by the pol and env genes but recent evidence has shown that 
conserved epitopes on the surface envelope protein of lentiviruses are also present on 
the surface envelope proteins of other retroviruses and may lead to serological cross-
reactivity with these viruses (Hotzel and Cheevers, 2000). 
 
Chapter 3. Development of a recombinant protein antigen 
for the serological diagnosis of Jembrana disease virus 
infection 
 
Summary 
  45Several different hexahistidine tagged recombinant CA and TM proteins were 
produced and tested as antigens for the detection of antibody against Jembrana disease 
virus (JDV) in cattle, as alternatives to the current reliance on a whole virus antigen 
prepared from tissues of infected cattle. A recombinant CA protein used in an ELISA 
provided the greatest concordance (98.5%) with the whole virus antigen immunoassay 
and a high sensitivity and specificity made it an ideal and relatively inexpensive 
replacement for the whole virus antigen. Other recombinant protein antigens produced 
were not suitable for use, including a fused CA/TM protein antigen which when used 
in ELISA had high specificity but a low sensitivity, and a fused CA/TM protein that 
when used in Western immunoblots provided low concordance with results obtained 
with the whole virus antigen. 
 
Introduction 
Diagnosis of lentivirus infections by serological methods, such as ELISA and Western 
immunoblotting, has typically been difficult (Hecht et al., 2002; Janssen et al., 1998) 
as the viruses principally infect cells of the immune system, including macrophages, 
B-cells and T-cells, leading to a compromised immune system (Levy, 1993d). 
Lentiviruses have many mechanisms for evading immune responses or killing 
immune effector cells which can further interfere with serological diagnosis (Bartz 
and Emerman, 1999; Chien et al., 2004; Kerkau et al., 1997). The initial phase of 
infection presents a special problem for the diagnosis of all lentivirus infections as 
there is often an extended period where the animal is infected with virus but there is 
no detectable serological evidence for infection (Houwers and Nauta, 1989; Janssen et 
al., 1998). Following this initial phase, most but not all animals seroconvert to the 
CA, followed by seroconversion to other virus proteins as the antibody response 
matures over time (Battles et al., 1992; Cole et al., 1998; Straub and Levy, 1999). 
Other factors that further complicate the serological detection of lentiviruses are that 
the antibody response against the CA antigen cycles over time and has been shown to 
become undetectable after a prolonged period in some animals (Hammond et al., 
1997; Isaacson et al., 1995b).  
To overcome these difficulties with regard to the reliable detection of antibody, 
various strategies have been implemented such as using a combination of peptides 
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different whole antigens, and developing constructs that express the CA protein with a 
TM peptide attached for extra specificity (Hodinka et al., 1998; Rosati et al., 2004). 
JDV has been routinely diagnosed by indirect ELISA and Western immunoblot using 
whole virus antigens prepared from plasma of infected cattle and purified by sucrose 
gradient centrifugation (Hartaningsih et al., 1995b). The limitations of this assay 
include the need to harvest the virus from infected cattle, which creates ethical 
problems and would also inevitably lead to considerable variation in quantity and 
quality of the antigen preparations from different animals, the need for expensive 
equipment for purification of the virus, and the cost. Alternative recombinant GST 
fusion protein antigens for JDV were initially developed by Burkala et al. (1998) and 
more recently a recombinant biotinylated CA antigen expressed in the Pinpoint 
(Promega) system was tested by (Desport et al., 2005). Unfortunately, the assays 
developed had poor concordance when compared to the whole virus assay making the 
production of a reliable means of detecting JDV infection a priority for research. 
This Chapter describes the development of different systems for the expression of the 
CA and TM proteins as antigens for ELISA and Western immunoblot. The results 
obtained with these antigens were compared to those obtained with Western 
immunoblot with a whole virus antigen.  
 
 
 
 
Materials and methods 
Primers and cloning 
Plasmid DNA from a JDV clone Jgag6 (Desport et al., 2005) containing the entire 
JDV CA derived from JDVTab87 was used as template for production of a fused JDV 
CA/TM polyprotein similar to studies with other lentiviruses (Bertoni et al., 1994; 
Dufour et al., 2002; Pancino et al., 1995; Soutullo et al., 2001). Amplification was 
performed using primers jCABamF and jCATmEcoR (Table 3.1) and the amplified 
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digested with BamHI and EcoRI. Plasmids were transformed into competent Top 
10F’ Escherichia coli and the resulting construct, containing JDV CA sequence (nt 
604 – 1222 of JDVTab87) fused directly to the putative TM principal immunodominant 
domain epitope, was confirmed by direct sequencing of the PCR products obtained 
using the pTrcHisF and pTrcHisR primers. The plasmid was also transformed into 
E. coli BL21 for expression of JDV CA/TM. The entire JDV capsid gene (nt 604-
1222 of JDVTab87) was digested out using BamH1 from purified JDV clone CAΔTat 
(Chapter 4) and ligated into a pTrcHisA plasmid digested with BamH1 
(jCApTrcHisA). Amplification of a second PCR product containing the truncated tm 
gene (6688-6742 of JDVTab87) (Chadwick, 1995) using the jTmBgIIIF and the 
jTmEcoR primers (Table 3.1) was performed and the PCR product ligated into the 
jCApTrcHisA digested with EcoR1 and BgIII. Plasmids were transformed into 
competent Top 10F’ E. coli and cloning was confirmed by sequence analysis. The 
plasmid was then transformed into E. coli JM109 for expression of the protein JDV 
CAΔTM. 
 
Table 3.1. Primer sequences used for the amplification, sequencing and development of 
recombinant plasmid constructs used for the production of recombinant proteins.  
Primer  Sequence (5′ → 3′)  Genome Nucleotide 
position in 
JDVTab87 genome 
jCABamF  GGACGGatccCCACAACTTAGAAAGAACTTC  JDV 604-627 
jCA/TMEcoR  CCTTTAGGGCCCTCAGCC/CCGGTACAAACT
GGGCTAGGGTGTGTGCCGAGAGGAAGATAT
TGCCATTTTGATGaattc 
JDV 1222-1205 
6688-6742 
jTmBgIIIF  GATCATTAgatctCAGCCGTGGGGATGGTCATA  JDV 6464-6483 
jTmEcoR  TCAGTCAAAATGGCAATAGaattc  JDV 6742-6725 
pTrcHisF  GAGGTATATATTAATGTATCG  pTrcHis 370-390 
pTrcHisR  GATTTAATCTGTATCAGG  pTrcHis 614-597 
 
 
Production of hexahistidine-fused recombinant viral proteins 
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gene in a pTrcHisC plasmid, CAΔTM containing the full length JDV capsid gene and 
an 87 a.a. carboxy terminus truncated tm gene in a pTrcHisA plasmid. A third 
construct CA/TM containing the entire capsid gene fused to the principal 
immunodominant domain of the tm gene in a pTrcHisC plasmid was also developed 
(as described above). Recombinant JDV CA was produced from a recombinant 
pTrcHisC plasmid kindly supplied by Margaret Collins (Royal Veterinary College) 
containing the entire JDV capsid gene (Barboni et al., 2001). This plasmid was 
transformed into E. coli (JM109) for protein expression. The optimum expression of 
the CA was obtained using 2YT plus 1 mM ampicillin inoculated with a 1:25 volume 
of an overnight culture, and induced at an OD600 of 1.0 by the addition of 0.1 mM 
IPTG for 6 h. The optimum expression of the CAΔTM was obtained using 2YT plus 1 
mM ampicillin with a 1:25 inoculum of overnight culture induced at an OD600 of 1.0 
with 0.1 mM IPTG for 4 h. After induction, pelleted bacterial cells were resuspended 
in cell lysis buffer (50 mM Tris-HCl pH 7.5, 50 mM NaCl, 10 mM imidazole and 5% 
[v/v] glycerol) and lysed by sonication (8 pulses of 30 seconds with 30 seconds rest 
between pulses) and the lysate was centrifuged (10,000 g, 15 min). The pellets were 
discarded and 10 volumes of lysate were added to 1 bed volume of Ni-NTA agarose 
resin (QIAGEN) in a chromatography column (BioRad) and incubated at 4ºC for 2 h 
on a slow rotating mixer. These lysates were allowed to flow through the resin and 4 
wash steps were performed using native wash buffer pH 8 (250 mM NaH2PO4, 2.5 M 
NaCl and 50 mM imidazole). Four bed volumes of elution buffer pH 8 (250 mM 
NaH2PO4, 2.5 M NaCl and 250 mM imidazole) were then added to the column and 
collected. The purified antigens were analysed by SDS-PAGE and Coomassie 
Brilliant Blue staining to determine yield and purity. Western immunoblotting was 
also performed to confirm that the proteins were recognized by sera from 
experimentally infected cattle. 
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SDS-PAGE gels were immobilized on a nitrocellulose membrane using a Mini 
Protean II transfer tank (BioRad) in transfer buffer (192 mM glycine, 25 mM Tris and 
20% [v/v] methanol) overnight at 30 V at 4°C. Once removed from the transfer tank 
the nitrocellulose membrane was stained using Ponceau stain and placed in a 
skimmed milk blocking solution (Diplomat skimmed milk powder 5% [w/v] in 
PBS/T) for 30 min on a horizontal rocker. The blocking solution was then removed 
and the membrane incubated in skimmed milk blocking solution containing a 1:2,000 
dilution of mouse anti-hexahistidine monoclonal antibody (ICN) for 1 h with gentle 
agitation at room temperature. The membranes were washed 3 times for 5 min with 
PBS/T and a 1:2,000 dilution of HRP cojugated goat anti-mouse IgG (ICN) in 
skimmed milk blocking solution for 1 h with gentle agitation at room temperature, 
followed by an additional 3 washes with PBS. The reaction was then developed using 
a horseradish peroxidase (HRP) substrate solution (BioRad HRP substrate 10 mg, 
16.6 mL PBS pH 7.4, 3.325 mL methanol and 10 µl of hydrogen peroxide) and the 
strips developed in the dark for 1 h at room temperature. The reaction was then 
stopped by washing with de-ionized water. 
Quantification of protein concentration 
Densitometry was used to quantify the concentration of protein in the vaccine 
preparations and diagnostic reagents. Appropriate dilutions of each preparation were 
subjected to SDS-PAGE (Laemmli, 1970) in a MiniProtean system (BioRad) with 
12.5% polyacrylamide gels, and the resulting gels stained with Coomassie Brilliant 
Blue. A range of concentrations between 125 ng and 1 µg/lane of standard proteins, 
bovine serum albumin (BSA) (66 kDa) and lysozyme (16 kDa), were run on each gel. 
After de-staining, washing and re-hydrating in distilled water, the gels were imaged 
on a ProExpress Imaging System (PerkinElmer), and the resulting high resolution 
images subjected to image analysis with ProPick software (PerkinElmer). Pixel 
density mapping was used to calculate the amounts of protein present in each non-
saturated band on the imaged gel. The amount of protein present was then deduced 
from the standard curves derived from the bands of known amounts of the standard 
proteins, lysozyme and BSA.  
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A range of whole virus antigen preparations supplied by Dr Nining Hartaningsih (DIC 
Denpasar) were tested by SDS-PAGE analysis and Western immunoblotting and the 
best preparations were selected and pooled for use as the “gold standard” to compare 
the diagnostic antigens to determine sensitivity and specificity. 
SDS polyacrylamide gels (SDS-PAGE) 
The proteins of interest were visualized by SDS-PAGE using a resolving gel (12.5% 
[w/v]) and a stacking gel (4% [w/v]) in a Mini Protean gel system (BioRad) 
containing 0.1% SDS [w/v] as described by (Laemmli, 1970) for 54 min at 200 V 
with a running buffer containing 25 mM Tris, 192 mM glycine and 1% [w/v] SDS. 
Precision Plus (BioRad) 100 kDa molecular weight markers (5 µL per lane) were 
added in the marker lane and the protein of interest (diluted 1:1 in 2X loading buffer) 
was loaded into a single large well. Gels were removed and either stained with 
Coomassie Brilliant Blue or blotted onto nitrocellulose. Briefly gels were added to 50 
mL of Coomassie Brilliant Blue stain (45% [v/v] methanol, 45% [v/v] distilled water, 
10% [v/v] glacial acetic acid and 0.05% [v/v] Coomassie Brilliant Blue) were stained 
overnight at room temperature on a horizontal rocker. Once stained, the excess stain 
was removed using a de-stain solution (40% [v/v] methanol, 50% [v/v] distilled water 
and 10% [v/v] glacial acetic acid). This de-stain solution was replaced at least twice 
until the gel was fully de-stained. A gel drying solution was then added (20% [v/v] 
ethanol, 3% [v/v] glycerol and 77% [v/v] distilled water) to the gel and left for 30 
min. The de-stained gels were then dried between cellulose sheets and stored.  
Serum samples  
Thirty serum samples from cattle sourced from the Jembrana disease-free island of 
Nusa Penida (Hartaningsih et al., 1995b) were used as reference negative sera for 
establishing a cut-off value between negative and positive samples; these samples did 
not react in Western immunoblots with whole virus antigen.  
Ten serum samples from cattle experimentally infected with JDV (Soeharsono et al., 
1990) and with virus-specific antibody confirmed by whole-virus Western 
immunoblotting were used as positive reference sera.  
  51Serum from a well-characterized long-term multiply infected heifer (A4) was used as 
the positive control for all ELISA and Western immunoblots. A second positive 
control was taken from a hyper-immunized heifer (A577) and was used for Western 
immunoblotting to detect responses against all viral proteins. This animal was 
vaccinated weekly for a 5-week period with inactivated virus as described by 
Hartaningsih et al. (2001). 
Two hundred additional cattle sera were obtained from adult cattle in the Tabanan 
region of Bali, a Jembrana disease-endemic area.  These 200 sera were tested by 
Western immunoblot with whole virus antigen (Hartaningsih et al., 1995b) to 
determine the presence of antibody against JDV, and also examined for reactivity 
against the recombinant protein antigens. 
Development of ELISA using recombinant proteins  
All recombinant proteins were tested by ELISA using 50 µL volumes of reagents 
except in the blocking step where a 100 µL volume was added to the wells. The 
ELISA plates used were Maxisorb (NUNC) and the standard blocking solution used 
for both the ELISA and the Western immunoblot was a 5% solution of skimmed milk 
powder (Diplomat) in PBS/Tween 20 (0.05% [v/v]). Wells were coated with 75 ng (2 
rows), 50 ng (2 rows), 25 ng (2 rows) and 10 ng (2 rows) of protein in 0.1 M 
carbonate buffer pH 9.5 (160 mL of 0.2 M Na2CO3 and 340 mL of 0.2 M NaHCO3) 
and the plates incubated overnight at 4°C. The plates were then washed once with 
PBS/T, and blocking solution was added for 30 min at room temperature. The 
blocking solution was then removed and the plates rinsed twice with PBS/T. Serial 
dilutions of the reference negative and positive sera in PBS/T with 5% skimmed milk 
were added to the appropriate wells on the ELISA plate. ELISA plates were incubated 
for 1 h at 37°C, and then washed 3 times with PBS/T. A 1:2,000 dilution of rabbit 
anti-bovine IgG conjugated to HRP (secondary antibody) in PBS/T (MPBio) was 
added and then incubated for 1 h at 37°C. The plates were then washed twice with 
PBS/T and twice with PBS (pH 7.4). HRP colour substrate reagent (BioRad) was 
added to the wells and the reaction developed for 15 min. The reaction was stopped 
by the addition of 2% [w/v] oxalic acid and the absorbance determined at OD405. The 
optimum quantity of protein was assessed by the highest signal to noise ratio (mean of 
the positive reference serum/mean of the negative reference serum). 
  52A high background noise to signal ratio was observed when PBS/T only was used as 
the blocking agent and various alternate blocking solutions containing 1% casein and 
1-5% skimmed milk solutions were tested on plates that were incubated with the 
optimum amount of protein per well and rinsed once with PBS/T. The reactions were 
completed as described above and the optimum blocking solution and diluent was 
chosen for each protein according to the difference in absorbance between the 
negative and positive samples at OD405. The absorbance of the proteins was read 5, 10 
and 15 min after the addition of substrate with the optimal time being chosen 
according to the development of substrate (OD405 of 2-3 with the positive controls).  
Determining ELISA cut-off values and statistical analysis 
ELISA plates were incubated overnight with an optimum quantity of protein and 
blocked with the optimum blocking solution. The plates were then rinsed with TBS/T 
and 1: 200 dilutions of each serum (the 30 reference negative samples and 10 
reference positive samples) were added in duplicate to the wells of the ELISA plate 
and incubated at 37°C for 1 h. The assay was then completed as described above and 
the OD405 of the negative samples was recorded. A mean absorbance of the negative 
sera was calculated and then a cut-off value for a negative/positive value was 
determined as the mean absorbance of the negative sera plus 3 standard deviations 
(SD) of the mean. User-defined two-graph receiver operating characteristic (TG-
ROC) (Greiner et al., 1995) was used with a Microsoft EXCEL (version 2003) 
spreadsheet to validate the cut-off values for the different antigens using known 
positive (n=10) and negative (n=30) reference serum. TG-ROC analysis plots the 
sensitivity and specificity against the selected cut-off value assuming the latter to be 
an independent variable. This generated a range in which the samples are deemed 
borderline with a pre-selected accuracy level of 95% sensitivity and selectivity. The 
agreement between the ELISA and Western immunoblot assays was assessed by 
concordance (percentage overall test agreement) and by kappa values (to test that the 
observed agreement is beyond chance agreement). Kappa values can vary from 0.0 to 
1.0, with values above 0.75 representing excellent agreements beyond chance. Values 
ranging from 0.4 to 0.75 indicated a fair to good agreement beyond chance whilst 
values below 0.4 represented poor agreement beyond chance and 0.0 indicated that 
the agreement was entirely attributable to chance (Fleiss, 1981). 
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reference sample (A4) and a known negative reference sample (CB15) which were 
run on ELISA plates in duplicate to standardize the plate to plate differences. If the 
known positive and negative reference serum were within an acceptable range (2 SD), 
(OD4051.62-1.98 and OD405 0.18-0.22) then the results were considered valid. 
Western immunoblotting 
Western immunoblotting was performed as described above.  Recombinant proteins 
were loaded (2,000 ng/well) into an SDS-PAGE gel. Electrophoresis was performed 
using the minigel sytem described previously and the gel was then transferred onto a 
nitrocellulose membrane as described by (Towbin et al., 1979) in ice cold transfer 
buffer overnight at 30 V at 4°C. The nitrocellulose membrane was then placed in 10 
mL of Ponceau stain for 30 sec to stain the transferred protein bands. The membrane 
was then rinsed with de-ionized water and incubated at room temperature for 1 h in 
blocking solution (5% skimmed milk powder in PBS/T). After removal of the 
blocking solution, the membrane was cut into strips; each strip was used to test 
individual serum samples. The appropriate dilution of serum to be tested (either 1:25 
or 1:50) was added and gently agitated for 1  h at room temperature. Individual strips 
were then washed 3 times with PBS/T for 5 min on a horizontal rocker at room 
temperature.  Rabbit anti-bovine IgG HRP-conjugated (1:2,000 dilutions in 5% 
skimmed milk powder blocking solution) was then added and agitated gently for 1 h 
at room temperature. The strips were washed 3 times with PBS pH 7.4 before 
immersing in substrate solution (BioRad substrate HRP 10 mg, 16.6 mL PBS pH 7.4, 
3.325 mL methanol and 10 µL of hydrogen peroxide) and the strips developed in the 
dark for 1 h at room temperature. These strips were then lined up with the protein 
marker and fixed to a cardboard block for comparison and identification of antibody 
response to the protein band of interest. 
  54Results 
Optimisation of growth of constructs and induction times for expression 
of hexahistidine tagged proteins 
2YT was selected as the growth medium and a the bacterial growth curves were 
assessed for each of the 3 different constructs by comparing inoculation with 3 
different dilutions of overnight culture over an 8 h period. The growth of the 
constructs containing JDV CA and CA/TM (1:25 dilution of overnight inoculum) 
started to plateau 5 h post-inoculation and thus a 4 h post-inoculation at an OD600 of 
1.5 was selected as the optimum for induction of protein expression (Figure 3.1). 
Expression of JDV CA and CA/TM was detected until 24 h post-induction with no 
significant protein degradation and an induction time of 12 h was implemented as this 
gave a similar yield to a 24 h post-induction period. However the fused JDV CAΔTM 
protein started to degrade 2 h post-induction and was completely degraded 4 h post-
induction (Figure 3.2). The CA and the CA/TM peptide fused proteins were of 
sufficient purity and concentration for use in a recombinant protein ELISA (Figure 
3.3) but the CAΔTM polyprotein yield and purity was insufficient for ELISA and the 
protein was used for Western immunoblotting only. The best yield of purified CA 
recombinant protein obtained was 46.3 mg/L of culture with purity greater than 95%. 
The best yield of CA/TM recombinant protein was 5.6 mg/L with 90% purity.  
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Figure 3.1. Growth curves of the CA, CA/TM and CAΔTM constructs used in the 
development of a serological antigen for JDV; the constructs were seeded into the medium 
using a 1:100, 1:50 or 1:25 dilution of the overnight seeding culture to determine the optimum 
dilution for enhanced bacterial growth. (Top) JDV CA construct in E. coli BL21 grown in 
2YT medium plus ampicillin, (Middle) JDV CA/TM construct in E. coli BL21 grown in 2YT 
medium plus ampicillin; (Bottom) JDV CAΔTM construct in E. coli BL21 grown in 2YT 
medium plus ampicillin. 
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Figure 3.2. Western blots to determine optimum expression time and relative level of protein 
expression from the CA, CA/TM and CAΔTM constructs. (a) JDV CA construct in E. coli 
BL21 grown in 2YT media plus ampicillin induced for up to 24 h; lane 1, 1 h; lane 2, 2 h; 
lane 3, 3 h; lane 4, 4 h; lane 5, 5 h; lane 6, 6 h; lane 7, 12 h; lane 8, 18 h; lane 9, 24 h. (b) JDV 
CA/TM construct in E. coli BL21 grown in 2YT media plus ampicillin induced for periods up 
to 24 h: lane 1, 1 h; lane 2, 2 h; lane 3, 3 h; lane 4, 4 h; lane 5, 5 h; lane 6, 6 h; lane 7, 12 h; 
lane 8, 18 h; lane 9, 24 h. (c) JDV CAΔTM construct in E. coli BL21 grown in 2YT media 
plus ampicillin induced for periods up to 24 h: lane 1, 1 h; lane 2, 2 h; lane 3, 3 h; lane 4, 4 h; 
lane 5, 5 h; lane 6, 6 h; lane 7, 12 h; lane 8, 18 h; lane 9, 24 h. Expression of JDV CA and 
CA/TM was detectable at all periods up to and including 24 h post-induction with no 
significant protein degradation. Fused JDV CAΔTM protein was detectable at 1, 2 
and 3 h post-induction but started to degrade 2 h post-induction and was completely 
degraded 4 h post-induction. 
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Figure 3.3. An SDS-PAGE gel showing the expression level and final purity of the JDV 
recombinant CA and CA/TM proteins. Lanes 1 and 3, total bacterial lysates expressing JDV 
CA and JDV CA/TM, respectively; lanes 2 and 4, Ni-NTA affinity purified JDV CA and JDV 
CA/TM, respectively; lane 5, empty and lane 6, JDV whole virus antigen preparation.  
Molecular weight markers are shown on the left hand side, and proteins of interest on the 
right hand side.  Lanes 1 and 3 show the expression levels of the protein relative to whole 
bacterial lysate and lanes 2 and 4 show the relative purity of the final recombinant proteins.   
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Whole virus antigen Western immunoblots 
Whole-virus Western immunoblots were conducted on 200 field serum samples as a 
reference immunoassay for the detection of antibody to bovine lentiviruses. The 
seroprevalence of JDV in the 200 cattle was 11.5% (Figure 3.4b). Of the 23 positive 
sera only one had a response to TM, and this sample also had a weak reaction to CA 
(Figure 3.4a). 
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Figure 3.4. (a) An example of the whole virus Western immunoblotting of field sera, with 
selected lanes shown on top, the size of the selected molecular weight markers on the LHS, 
and proteins of interest on the RHS. All field sera shown on this Western immunoblot gave a 
negative reaction except for one serum with a weak CA reaction (lane 1), one reacting with 
TM (lane 3) and one with a strong CA reaction (lane 12).  The reference sera included a 
negative serum (lane 26), a reference positive serum (lane 27) and serum from a hyper 
immunized animal (lane 28). (b) Graphical representation of the antibody status of the 200 
sera that were examined.  
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Recombinant CA protein ELISA 
Negative cattle sera (1:200 dilutions) were tested by ELISA using 200 ng/well of JDV 
CA to determine the cut-off values as the mean OD405 of the negative samples plus 3 
SD of the mean. Positive sera from 10 experimentally infected and recovered cattle 
were also tested to determine specificity and sensitivity of the assay (Table 3.2 and 
Figure 3.5). All ELISA cut-offs were validated using TG ROC. 
Whole-virus antigen Western immunoblotting was conducted on the 200 field serum 
samples and 23 of the sera (11.5%) reacted with the 26 kDa CA protein and one or 
more other JDV proteins (Figure 3.4). The CA ELISA detected 22 of the 23 Western 
immunoblot-positive sera with 1 false negative and 2 false positives giving a 
concordance of 98.5% with a kappa value of 0.9277. The specificity of the assay was 
98.9% with a sensitivity of 95.8% using the previously described cut-off value of 
0.499 at OD405 (Table 3.3 and Figure 3.6). 
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Table 3.2. Examples of descriptive indices for the JDV CA ELISA using reference negative 
and positive sera. In this series of assays, a cut-off of 0.499 was calculated from the mean 
OD405 + 3 SD of the mean of the reference negative samples, which provided a sensitivity and 
specificity of 100% for the reference positive serum samples.  
 
Measurement Positive  Negative 
Number sera examined  10 30 
Mean OD405 nm  1.79615 0.295662 
Median OD405 nm  1.9985 0.2905 
SD of mean  0.746806 0.067654 
Minimum OD405 nm  0.7465 0.153 
Maximum OD405 nm  2.593 0.4565 
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Figure 3.5. Scatter plot of ELISA OD405 with the recombinant JDV CA as a coating antigen 
using 30 reference-negative and 10 reference-positive sera (identified by whole virus Western 
immunoblotting). The central horizontal line represents the mean of the groups whilst each 
dot is representative of a single serum sample. 
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Table 3.3. Descriptive indices for the JDV CA ELISA using positive and negative field sera 
determined by whole virus Western immunoblotting. In this series of assays, a cut-off of 
0.499 was calculated from the mean OD405 + 3 SD of the mean of the reference negative 
samples, which provided a sensitivity of 95.8% and specificity of 98.9%. 
 
Measurement Positive  Negative 
Number of sera   23 177 
Mean OD405 nm  1.406617 0.227673 
Median OD405 nm  1.18815 0.2161 
SD of mean  0.755021 0.102673 
Minimum OD405 nm  0.5649 0.07315 
Maximum OD405  3.14895 0.63345 
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Figure 3.6. Scatter plot of OD405 of the JDV CA ELISA with 177 negative and 23 positive 
field sera (identified by whole virus Western immunoblotting). The central horizontal line 
represents the mean of the groups whilst each dot is representative of a single serum sample. 
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The reference negative serum samples were tested by JDV CA/TM ELISA using 50 
ng per well of protein to determine the cut-off value. The cut-off value with a 1:100 
serum dilution was 0.557 (mean OD405 0.28229 plus 3 SD [0.091588]) as shown in 
Table 3.4 and Figure 3.7.  The reference positive sera all provided a positive result 
indicating a sensitivity and specificity of 100%. 
 
Table 3.4. Descriptive indices for the results of the JDV CA/TM ELISA using reference 
negative and positive reference sera.  In this assay, a cut-off of 0.557 was calculated using the 
mean + 3 SD of the mean of the reference negative samples, providing a sensitivity and 
specificity of 100% in the reference serum samples. 
Measurement Positive  Negative 
Numbers sera examined  10 30 
Mean OD405  2.060695 0.28229 
Median OD405  2.13905 0.270525 
SD of mean  0.941998 0.091588 
Minimum OD405  0.913 0.1213 
Maximum OD405  3.36315 0.47025 
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Figure 3.7. Scatter plot of OD405 of JDV CA/TM ELISA with 30 reference negative and 10 
reference positive sera. The central horizontal line represents the mean of the groups whilst 
each dot is representative of a single serum sample. 
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samples but failed to detect 14 of the other Western immunoblot positive samples 
(false negatives) and gave positive values with 4 other sera (false positives) with an 
overall concordance of 91% and a kappa value of 0.4547. The specificity of this assay 
was 97.8% with a sensitivity of 62.2% (Table 3.5 and Figure 3.8).  
Table 3.5. Descriptive indices for the JDV CA/TM ELISA using field sera. A cut-off of 0.557 
(mean OD405 + 3 SD of mean) provided a sensitivity of 62.2% and specificity of 97.8% when 
compared to the results obtained using whole virus Western immunoblots. 
 
Measurement Positive  Negative 
Numbers sera examined  23 177 
Mean OD405 nm  0.755376 0.267696 
Median OD405 nm  0.4303 0.254075 
SD of mean  0.719279 0.138756 
Minimum OD405 nm  0.15995 0.06795 
Maximum OD405 nm  2.4 0.7724 
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Figure 3.8. Scatter plot of OD405 for JDV CA/TM ELISA with 177 negative and 23 positive 
field sera (previously identified by a whole virus Western immunoblot). The central 
horizontal line represents the mean of the groups whilst each dot is representative of a single 
serum sample. 
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Western immunoblots with recombinant protein antigens 
The JDV CA Western immunoblot had a specificity of 93.7% and a sensitivity of 
88.5% with an overall concordance of 92.5% (kappa value 0.6851) when compared to 
the whole virus antigen Western immunoblot (Figure 3.9). The JDV CAΔTM Western 
immunoblot had a specificity of 95.7% and a sensitivity of 71.9% with an overall 
concordance of 91.5% when compared to the whole virus antigen Western 
immunoblot (kappa value 0.5743) (Figure 3.10). 
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Figure 3.9. (a) Example of results of Western immunoblotting using the recombinant CA 
antigen, the size of the selected molecular weight markers on the LHS, and the protein of 
interest on the RHS. Lanes of interest are numbered (on top). All field sera (lanes 1-18) were 
negative except for the serum sample in lane 3.  A reference negative serum is shown in lane 
19, a reference positive serum in lane 20 and serum from a hyper-immunized animal in lane 
21. (b) Graphical representation of the JDV antibody status of 200 field sera by JDV CA 
Western immunoblot by comparison to results obtained using a whole virus antigen Western 
immunoblot. 
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Figure 3.10. (a) Western immunoblot demonstrating typical results obtained using the 
CAΔTM recombinant protein antigen, the size of the molecular weight markers on the LHS, 
and the protein of interest on the RHS.  In the Western immunoblot shown, all field sera were 
negative except one with a weak CA reaction (lane 5) and one with a strong CA reaction (lane 
10).  Also shown are a reference negative serum (lane 26), a reference positive serum (lane 
27) and serum from a hyper-immunized animal (lane 28). (b) Graphical representation of the 
results obtained in 200 field sera by JDV CAΔTM immunoblotting by comparison to results 
obtained using a whole virus Western immunoblotting. 
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Discussion  
Serological assays for JDV infection in cattle reported previously include an ELISA 
and an agar gel immunodiffusion test which made use of purified whole virus antigens 
(Hartaningsih et al., 1993; Hartaningsih et al., 1994) and an ELISA utilising 
recombinant protein antigens (Burkala et al., 1998) which detected antibodies against 
the individual CA and TM proteins. Preparation of a whole virus antigen for Western 
immunoblotting (Hartaningsih et al., 1995b) required ultracentrifugation facilities that 
are currently unavailable in Indonesia and limited supplies of this antigen have been 
utilized mainly for Western immunoblotting.  For ELISA, a recombinant JDV CA-
GST fusion protein antigen has been used (Burkala et al., 1998) but the GST tag 
attached to the CA protein is an antigenic Schistosoma japonicum-derived protein 
which gave a high rate of false positive results as cattle which have been infected with 
Schistosoma japonicum (endemic in Indonesia) react to the GST portion rather than 
the CA of the recombinant protein.  
The current ELISA recombinant JDV CA protein with an E. coli-derived biotinylated 
tag was replaced with a full length JDV CA protein with a much smaller hexahistidine 
  65tag. This 3 kDa hexahistidine residue was much smaller than the 13 kDa biotinylated 
E. coli-derived tag making it much less likely to be antigenic and result in false 
positive results. The hexahistidine tagged CA production was also less time intensive 
and expensive to produce than the biotinylated E. coli-derived CA protein with a 
greater final yield and purity. For comparison of various serological assays, generally 
a “gold standard” assay is used against which estimations of sensitivity and specificity 
have to be applied (Enoe et al., 2000; Greiner et al., 2000). The selection of a gold 
standard assay for JDV was problematic but as greatest reliance has in Indonesia been 
placed on the use of a whole virus Western immunoblot to confirm whole virus 
ELISA results, and more recently to confirm recombinant protein antigen ELISA 
results, this was used as the reference with which to compare the recombinant protein 
ELISA and Western immunoblots that were developed in this current study. This 
assay was unlikely to detect all JDV antibody-positive sera for several reasons: 
generally whole virus serological assays have good specificity but poor sensitivity 
(Brinkhof and van Maanen, 2007); there may be genetically and antigenically 
different strains of JDV in Indonesia, which would lead to false negatives, although 
JDV isolates from Bali appear to be remarkably genetically stable and this is unlikely 
to be a problem (Desport et al., 2007); studies by (Hartaningsih et al., 1994; Putra and 
Sulistyana, 1995) have shown that  the antibody response in some cattle fluctuates 
from positive to negative which suggests the levels of circulating antibodies are close 
to the limit of detection of the assay.  
In these current studies, recombinant CA and TM proteins were selected as targets for 
alternate antigens. A previous study showed that the CA and TM proteins were 
recognized for up to 21 weeks post-infection with the immunodominant response 
being to the CA protein (Hartaningsih, 1993). A further study demonstrated that the 
recombinant CA and TM proteins of JDV provided greater sensitivity for detection of 
JDV specific antibody than did the nucleocapsid, matrix and truncated surface 
envelope proteins (Lewis, 2004). These results are similar to what has been found 
with CAEV, MVV, FIV, BIV and EIAV for which the CA and TM antigens are most 
commonly selected as antigens for serological diagnosis (Calzolari et al., 1995; de 
Andres et al., 2005; Kwang et al., 1993; Saman et al., 1999). In JDV infections, an 
antibody response to the CA is generally the first detectable response and therefore 
JDV p26 is an essential component of a diagnostic assay for infections with this virus. 
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with BIV and JDV. BIV CA antibodies were detectable from 2 weeks until at least 2.5 
years post-infection (Whetstone et al., 1990a) and in another study (Isaacson et al., 
1995a) Gag responses were found to have declined by 40 weeks post-infection and 
remained low or undetectable until 190 weeks post-infection. Serological detection of 
the genetically related small ruminant lentiviruses (SRLV) was improved by using the 
combination of Maedi visna virus (MVV) CA and a TM peptide as coating antigens in 
an ELISA (Celer and Celer, 2001). This has been further improved by expressing the 
entire CA and TM in a single fusion protein for serological detection of SRLV, FIV 
and EIAV infections (Rosati et al., 2004). 
Generally there was a good concordance amongst all the assays with the strongly 
positive cattle but the CA/TM ELISA and the CAΔTM Western immunoblot failed to 
detect the borderline positives that were recognized by the CA ELISA and whole 
virus Western immunoblot (results not shown). The CA antigen ELISA showed an 
excellent agreement beyond chance (98.5% concordance with a kappa value of 
0.9277) with the whole virus Western immunoblot in both the experimentally infected 
cattle (n=10) and the field serum (n=200) which indicated that this antigen can 
reliably replace the whole virus Western immunoblot for detection of JDV-infected 
cattle. Surprisingly, there was very little difference between the sensitivity and the 
specificity of the experimentally infected and the field sera whereas most lentiviral 
diagnostic assays have a decreased sensitivity and specificity with field sera, but this 
may be due to the small sample size (n=200) in this current study as generally greater 
sample sizes have been used (Brinkhof and van Maanen, 2007; de Andres et al., 2005; 
Greiner et al., 2000; Mboloi et al., 1999). This high level of concordance will have to 
be further tested in a larger epidemiological and statistical study to validate the 
sensitivity and specificity of the test. The current study was a preliminary 
investigation only as only 30 negative and 10 positive sera were used to test and 
validate the cut-offs for the various ELISA assays whilst the OIE recommends a 
minimum of 1000 negative sera and 300 positive sera (OIE Manual of Standards for 
Diagnostic Tests and Vaccines,(2000).  Further investigation must also be undertaken 
on sera from fluctuating borderline antibody-positive cattle to determine if the assay 
fails to continuously detect antibody-positive cattle as was observed when the whole 
virus antigen was used (Putra & Sulistyana, 1995).  
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sensitivity of 88.5% with a good agreement beyond chance with a concordance of 
92.5% with a kappa value of 0.6851 to the whole virus Western immunoblot. This 
specificity and sensitivity is within the normal ranges for other serological diagnostic 
assays for lentiviruses and is typical of other studies with CAEV/MVV and FIV 
where the CA Western immunoblot has identified more seropositive animals than 
ELISA (Calzolari et al., 1995; de Andres et al., 2005; Zheng et al., 2000). This could 
be due to higher sensitivity of the Western immunoblot when compared to indirect 
CA ELISA and whole virus Western immunoblotting but this is unlikely as there were 
3 false negative sera which were detected by both whole virus Western immunoblots 
and the indirect CA ELISA. There may be some interfering factors present in certain 
cattle such as endogenous cross-reactive antibodies, maternal antibodies or reactive 
pathogens (Greiner and Gardner, 2000). Due to the time consuming nature of the 
assay and the lower correlation with the whole virus Western immunoblot it is 
recommended that this assay should only be used to confirm borderline ELISA 
results. 
Attempts were made to incorporate the TM protein into the assays by producing a 
single fused CA and TM polyprotein antigen because earlier studies have shown that 
all experimentally infected cattle develop a TM response after infection (Ditcham, 
2007). The fused CA/TM antigen ELISA provided only a low sensitivity when used 
to detect antibody in field sera, less than obtained with the whole virus Western 
immunoblot and recombinant CA ELISA (Greiner and Gardner, 2000). There was 
borderline poor to fair agreement beyond chance with a kappa value of 0.4547 
between the CA/TM ELISA and the whole virus Western immunoblot. This assay 
also had the lowest concordance of 91% and the CA/TM ELISA failed to detect most 
borderline positives making it unsuitable for use in Jembrana disease surveillance. A 
possible reason for the loss of sensitivity may be due to a truncation of a portion of the 
carboxy terminus of the CA, which may contain previously unrecognized epitopes, or 
to alterations in the folding of the protein due to the presence of the TM peptide 
sequence. Further studies are needed to confirm if there is an important diagnostic 
epitope in this region. Other studies in small ruminant lentiviruses testing recombinant 
CA/TM fusion peptides have generally reported an increase in sensitivity with the 
fusion protein with values ranging from 64-100% sensitivity so the low sensitivity 
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peptide construct should be developed and tested to see if this improves the sensitivity 
of the assay in further studies. 
The TM portion of the CAΔTM construct was truncated to increase the expression 
and stability of the TM protein. Unfortunately, even though the CAΔTM protein 
expression levels were higher than previous constructs the stability of the protein was 
still poor with protein degradation occurring within 1 h post-induction. The JDV 
CAΔTM Western immunoblot had a low concordance with the whole virus Western 
immunoblot of 91.5% with a fair agreement beyond chance of 0.5743. This low 
concordance and agreement beyond chance was associated with all of the constructs 
that contained any portion of the TM protein and may be associated with the binding 
properties of this protein altering the conformation of the final protein. This is 
supported by the observation that when the tm gene was added to the CA construct 
there was a dramatic reduction in protein expression, stability and purity. It is 
important to note that one study of MVV found a similar lack of sensitivity of the 
combined CA/TM fusion protein with sensitivity dropping from 88% using the 
indirect whole virus ELISA to 64% with the indirect fusion protein ELISA 
(DeMartini et al., 1999). Due to stability and expression problems with the protein it 
provided the least reliable of the all the diagnostic ELISA reagents. 
In conclusion, the indirect CA ELISA had the highest concordance to the whole virus 
Western immunoblot and appeared to be the most sensitive and specific of all the 
assays tested whilst the CA Western immunoblot may be useful for determining the 
status of borderline sera. Neither of the fusion proteins increased sensitivity or 
specificity and were difficult to express, stabilize and purify making them less 
desirable as diagnostic reagents. This assay is the first recombinant protein assay with 
a high concordance to the whole virus assays and reduced dramatically the incidence 
of false positives due to cross reactive tag proteins. It appeared from this study that 
the JDV indirect CA ELISA could be used to replace the whole virus Western 
immunoblot for the detection of antibodies to JDV.  
 
  69Chapter 4. Production of a novel recombinant JDV Capsid 
and Tat polyprotein as a potential vaccine for Jembrana 
disease  
 
Summary 
Methods were determined for the small scale production of a GST-tagged 
recombinant polyprotein containing both JDV CA and Tat proteins, with potential for 
use as a vaccine for the control of Jembrana disease. A series of quality control 
procedures including sterility testing, methods for the quantification of protein and 
methods for the detection of nucleic acid and endotoxin contamination, were also 
developed for the expressed and purified protein. In small scale experiments, the 
CA/Tat-GST polyprotein was produced with yields of up to 1.2 g/L of 95% pure 
recombinant protein. Endotoxin contamination was detected at a level of 4 EU/mg of 
recombinant polyprotein protein.  Nucleic acid contamination was also detected but 
was completely removed by treatment with 75 U/mL of benzonase at room 
temperature for 45 min.  
 
Introduction 
There are several advantages to the use of recombinant proteins for vaccines.  They 
are generally easy to produce at a relatively low cost and they have been successfully 
used for many virus induced diseases (McElrath et al., 2000; Pauza et al., 2000; Uhl et 
al., 2002). Recombinant GST-tagged proteins JDV capsid (CA), matrix (MA), surface 
unit (SU), transmembrane (TM) and Tat expressed in Escherichia coli have been 
tested as potential vaccines against Jembrana disease in Indonesia, where it has been 
possible to immunize susceptible cattle and then challenge them with live virus under 
controlled conditions. When a subunit vaccine consisting of a combination of 
recombinant JDV CA and Tat in incomplete Freund’s adjuvant (IFA) was 
administered 3 times, it was found to decrease the severity of the febrile response and 
leucopenia that typically occur during Jembrana disease and to also cause a significant 
reduction in virus load during the early phase of disease (Ditcham, 2007).   
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CA protein, the major structural protein of the virus, can be detected at high levels in 
the serum of infected cattle (Stewart et al., 2005).  The CA protein is also the 
immunodominant protein in the tissue-derived inactivated virus vaccine that has been 
shown to ameliorate the clinical signs of Jembrana disease in vaccinated cattle 
(Hartaningsih et al., 2001). While it is difficult to detect Tat in tissues of cattle during 
Jembrana disease (Setiyaningsih et al., 2008) the tat protein is extremely important in 
replication of bovine lentiviruses.  Tat has been shown to transactivate the viral LTR 
needed for transcription of viral genes (Barboric et al., 2000; Chen et al., 1999; Jeang 
et al., 1999), and regulates many cellular genes such as cytokines, oncogenes and 
adhesion molecules (Kashanchi et al., 2000; Marcello et al., 2001), acts as a potent 
extra-cellular chemo-attractant for virally susceptible cells, and induces apoptosis in 
bystander cells (Albini et al., 1998; Bartz and Emerman, 1999; Giacca, 2005; Marchio 
et al., 2005; Yang et al., 2003). JDV Tat is the most potent of all the characterized 
lentiviral Tat proteins and has been shown to transactivate other lentiviral LTR 
regions using both the primate cellular cyclin T1 protein-dependant binding to the 
transactivation region and directly to the bovine transactivation region adopting the ß-
hairpin conformation needed for transactivation (Chen et al., 1999; Deng et al., 2006; 
Xie et al., 2004; Xie et al., 2003). The diverse but essential biological functions of Tat 
and the low natural antigenicity make Tat an ideal vaccine candidate, and there are 
currently many HIV vaccine trials and publications describing the use of Tat as a 
potential vaccine (Fulcher and Jans, 2003; Pauza et al., 2000; Theisen et al., 2006). 
While Tat is potentially encoded by 2 ORF’s, tat1 and tat2, in JDV there is an in-
frame stop codon prior to the splice donor on exon 1 suggesting that only tat1 is 
translated during the acute phase of infection (Setiyaningsih et al., 2008).  The Tat1 
protein of JDV is 97 amino acids with a predicted molecular weight of 10.7 kDa and 
was selected as the potential vaccine candidate, rather than Tat2, as it is known to be 
translated during peak viraemia and is sufficient on its own to generate a functional 
Tat (Chen et al., 1999).  
To further investigate the value of combinations of recombinant CA and Tat proteins 
for use as vaccines for the control of Jembrana disease in Indonesia, methods to 
produce the recombinant proteins at the lowest cost possible were required.  Only a 
low cost vaccine could be expected to have significant acceptance and use in 
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be likely to make production costs too high and an attempt was therefore made to 
express both the proteins as a single polyprotein so the vaccine could be produced in a 
single operation, thereby reducing production costs and increasing the likelihood of 
successful implementation of the vaccine. Although there appears to be no precedent 
for the use of an E. coli-expressed recombinant polyprotein vaccine, there are 
numerous examples of DNA lentivirus vaccines expressing multiple proteins (Burgers 
et al., 2006; Kong et al., 2003) and this is the first trial with an E. coli expressed 
recombinant polyprotein containing 2 fused viral proteins as a vaccine. Rigorous 
quality control procedures would be required if the polyprotein were to be produced 
commercially for use as a vaccine, involving tests for sterility, methods of 
quantification of the proteins, stability of the proteins and the detection of nucleic acid 
and endotoxin contamination (Aucouturier et al., 2001; Fanales-Belasio et al., 2002; 
Hansson et al., 2000; Tomasulo et al., 1977).  
The investigation into the expression of a single fused CA and Tat polyprotein, and 
requisite quality control procedures, are reported in this Chapter. Analysis of the 
immunological responses of cattle to this polyprotein is reported separately in Chapter 
5. 
Materials and methods 
Serum samples  
Serum from a well-characterized long-term experimentally-infected heifer (A4) was 
used as the positive control for all ELISA and Western immunoblots.  
A second positive control was taken from a hyper-immunized heifer (A577) and used 
in Western immunoblotting to try and detect responses against all viral proteins. This 
animal was vaccinated weekly for a 5-week period with inactivated virus as described 
by Hartaningsih et al. (2001).  
Serum from a heifer (CB76) vaccinated 3 times with the tissue-derived inactivated 
whole virus in a mineral oil adjuvant as described by Hartaningsih et al. (1995) was 
also used to confirm the antigenicity of the fused protein.  
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and 2 mg of recombinant Tat-GST in incomplete Freund’s adjuvant (IFA) was also 
used to confirm the antigenicity of the fused protein (Ditcham, 2007). 
Expression and purification of individual recombinant GST-tagged JDV 
CA and Tat proteins 
Recombinant CA and Tat proteins were expressed as single proteins from JDVTab87 
genes previously ligated into pGEX6-P-1 (Pharmacia) by Burkala et al. (1998) and 
Setiyaningsih (2006) and the constructs were designated JDV CA-GST and JDV Tat-
GST, respectively. Proteins expressed in this bacterial system are N-terminally fused 
to glutathione-S-transferase (GST), to aid in purification and identification. The 
constructs contained the full-length JDV capsid gene (Chadwick et al., 1995b) and 
exon1 of the JDV tat1 gene (nt 5010-5299) (Setiyaningsih et al., 2008). 
Recombinant JDV CA-GST and JDV Tat-GST proteins were expressed in BL21 
E. coli. For expression of the CA-GST protein, bacteria were grown to an OD600 of 
1.0 in 2YT broth plus 1 mM ampicillin and expression induced by the addition of 0.1 
mM IPTG (final concentration) for 6 h before the cells were centrifuged and then 
lysed to release the recombinant protein. For expression of the Tat-GST protein, 
bacteria were grown to an OD600 of 1.5 in 2YT broth plus 1 mM ampicillin and 
induced by the addition of 0.1 mM IPTG (final concentration) for 6 h before 
centrifugation and cell lysis. The proteins from the lysed pellets were in an insoluble 
form, and were initially purified by 4 wash steps (15 min each on a rotary washer at 
4ºC) with a 1% Triton X-100 wash buffer (Tris-HCl 10 mM, EDTA 5 mM and 1% 
[w/v] Triton X-100) and then the insoluble protein was solubilised with a 2 M 
urea/Tris based solution (urea 2 M, Tris 2 M, DTT 20 mM and PMSF 1 mM). The 
purified proteins were separated by SDS-PAGE and stained with Coomassie Brilliant 
Blue to determine yield and purity (using procedures described below). Western 
immunoblots were also performed to confirm the reactivity of the recombinant 
proteins with sera from cattle naturally infected with JDV, cattle vaccinated with a 
whole virus vaccine (Hartaningsih, 1993) and cattle immunized with recombinant CA 
and Tat proteins. 
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tagged CA and Tat polyprotein 
A pTrcHisCA/Tat construct was initially produced for expression of a histidine-
tagged JDV CA/Tat polyprotein.  Briefly, the capsid gene was amplified by standard 
PCR from JDVTab87 plasmid 139# (Chadwick, 1995) with the primers shown in Table 
4.1. The PCR product was then digested with BamH1 and then cleaned using a PCR 
clean-up kit (QIAGEN). The pTrcHis-Tat plasmid (Setiyaningsih et al., 2008) was 
also digested with BamH1 and the purified PCR product was ligated into the digested 
pTrcHisTat vector by a standard ligation reaction. The re-ligated plasmid was then 
transformed into Top10 E. coli cells using standard transformation conditions. The 
positive clones were identified by directional PCR and then cultured and glycerol 
stocks prepared. The clones were grown overnight in 2YT plus ampicillin (1 mM) and 
plasmid was purified using a Plasmid Miniprep Kit (QIAGEN). This purified plasmid 
was transformed into BL21 E. coli using standard transformation conditions and 
directional PCR with the primers shown in Table 4.1 was used to identify the clones 
containing the recombinant plasmid.   
The expression levels of pTrcHisCA/Tat were low and to improve expression the 
insert was then ligated into a pGEX6-P-1 plasmid and this construct transformed into 
Top10, BL21 and JM109 E. coli for expression of a GST-tagged CA/Tat polyprotein.  
Briefly, the insert was amplified with JCaBamF and JTatBamR primers (Table 4.1) 
using Pfu DNA polymerase, from the pTrcHisCA/Tat construct. This PCR product 
was then digested with Sma1 and cleaned with a PCR clean up kit (QIAGEN). The 
pGEX6-P-1 plasmid was digested with Sma1 using a standard digestion reaction and 
the purified JDV capsid/tat1 fragment ligated in using a standard ligation reaction. 
The purified plasmid was then transformed into Top10, BL21 and JM109 E. coli and 
positive colonies were selected by directional PCR. Correct protein expression was 
determined using the methods described in Chapter 3 and clones providing high level 
of expression of recombinant protein were chosen and glycerol stocks of them were 
prepared stored at -80˚C until required. The plasmid was sequenced to confirm that 
both proteins would be expressed in-frame.  
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recombinant plasmid constructs. 
Primer  Sequence (5′ → 3′)  Genome Nucleotide 
position in 
JDVTab87 
jCaBamF GACCGGatccCCACAACTTAGAAAGAACTTC JDV  604-624 
jCaBamR  GGatccCAAGAATTGCATCTTCTGT JDV  1222-1204 
jTatBamR GACCGGatccGCGCAGTTAGGTGCCC JDV  5299-5283 
jCa604F CCCACAACTTAGAAAGAAC  JDV  604-622 
jCa1030R CGGTCATGTTATCCTTGTGC  JDV  1030-1011 
pGexF CCGGGAGCTGCATGTGTCAGAGG  pGEX-6P  869-891 
pGexR GGGCTGGCAAGCCACGTTTGGTG pGEX-6P  1056-1034 
 
Expression of GST-tagged fused JDV CA/Tat polyprotein 
BL21 E. coli stably transformed with the JDV CA/Tat construct were grown to an 
OD600 of 1.5 in 2YT medium plus 1 mM ampicillin and expression of the JDV CA/Tat 
protein was induced by the addition of 0.1 mM IPTG (final concentration) for 12 h. 
The cells were then lysed by sonication (8 cycles of 30 seconds sonication and 30 
seconds rest) and centrifuged (10,000 g for 15 min). The polyprotein was in an 
insoluble form and the centrifuged pellet was then further purified by 6 wash steps (1 
h each on a rotary washer at 4ºC), the first 2 washes with a 2% Triton X-100 wash 
buffer (Tris-HCl 10 mM, EDTA 5 mM and 2% [w/v] Triton X-100) followed by 
centrifugation (10,000 g x 15 min), then 2 washes with wash buffer containing 1% 
Triton X-100 and a further 2 washes with a wash buffer containing 0.5% Triton X-
100. The final pellet was solubilised with a 2 M urea/Tris solution overnight (urea 
2 M, Tris 2 M, DTT 20 mM and PMSF 1 mM). A 10 µL sample of the purified and 
solubilised protein preparation was subjected to SDS-PAGE and the polyprotein 
identified by Coomassie Brilliant Blue staining to enable the yield and purity of the 
protein to be determined. Western immunoblots were also performed to confirm the 
reactivity of the recombinant polyprotein with sera from cattle experimentally 
infected with JDV, cattle vaccinated with a whole virus vaccine and cattle immunized 
with recombinant CA and Tat proteins (Ditcham, 2007; Hartaningsih, 1993).  
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compared to sonication as described above, including freeze-thawing (5 cycles of       
-186˚C to +42˚C), the addition of various concentrations of Triton X-100 and the use 
of Bugbuster® (Novagen) a proprietary preparation containing a mix of detergents 
and benzonase for which full details were unavailable. Triton X-100 at 0.5, 1.0, 2.0 
and 5.0% concentrations in wash buffer (Tris-HCl 10 mM, EDTA 5 mM and 0.5-5% 
[w/v] Triton X-100) was added to cell pellets prepared from 100 mL of the same 
culture, for 30 min on a vertical mixing rotor at 4ºC. After treatment, all samples were 
washed as described above. A sample of each was then plated onto 2YT plates and 
grown overnight at 37 ºC to detect viable bacteria.  A second sample was stained with 
0.4% trypan blue (Sigma Aldridge) to detect viable cells.  
Production of non-GST tagged proteins for qualitative analysis of the 
serological response to GST-tagged proteins antigens 
Recombinant proteins with fusion tags other than GST were also prepared to analyse 
the antibody responses specific to the CA and Tat components of the vaccine.  
A recombinant biotinylated JDV Tat1 was expressed using a Pinpoint (Promega) 
expression system, with a recombinant plasmid construct jTat1 (Figure 2.2) provided 
by Dr Moira Desport (this laboratory) that contained tat1 (nt positions 5,010-5,303) of 
the JDVTab87 genome (Chadwick et al., 1995a). This insert was expected to encode a 
protein of 92 amino acids.  Optimum expression of Tat was achieved by inoculation 
of a 1:50 volume of overnight culture of BL21 E. coli in 2YT broth plus 1 mM 
ampicillin, then allowing the E. coli to replicate to an OD600 of 0.6 before induction of 
expression by the addition of IPTG (0.1 mM final concentration) for 4 h.  The 
majority of the protein was expressed in an insoluble form in inclusion bodies 
(Ditcham, 2007). To purify the insoluble protein in inclusion bodies, the bacterial 
cells were resuspended in cell lysis buffer (50 mM Tris-HCl pH 7.5, 50 mM NaCl and 
5% [v/v] glycerol) and lysed by sonication (as described above). The suspension was 
then centrifuged (10,000 g for 15 min) and the lysed cell pellet containing the 
inclusion bodies was resuspended in 10 mL of PBS (adjusted to pH 7 with HCl) and 
agitated overnight at 4°C on an orbital mixer. The cell pellet was collected by 
centrifugation (10,000 g for 15 min at 4°C). The pellet was washed 4 times (10-30 
min per wash in PBS [pH 7]) at 4°C followed by centrifugation (10,000 g for 15 min). 
Nine mL of solubilisation buffer (urea 2 M, Tris 2 M, DTT 20 mM, PMSF 1 mM) 
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4°C for 2 h. The solubilised pellet was added slowly to 390 mL of Refolding Buffer 
(Tris pH 8 100 mM, 350 mg CHAPS and 0.53 g DTT made up to 350 mL with 
deionized water) and the refolded protein was concentrated in an ultrafiltration cell 
(Amicon) until a volume of 20 mL was obtained. The final protein was filtered 
through a 0.22 μM exclusion filter (Millipore) to remove aggregated proteins and then 
dispensed into 1 mL amounts and stored at -80°C. 
Recombinant histidine-tagged JDV CA was produced from a pTrcHis C plasmid 
kindly supplied by Margaret Collins (Royal Veterinary College) containing the entire 
JDV capsid sequence (Barboni et al., 2001) and purified as previously described 
(Chapter 3). Western immunoblots with experimentally infected and vaccinated 
animal sera were also performed to confirm antigenicity of the protein.  
Quality control assays of the GST-tagged recombinant protein 
preparations 
Determination of sterility of recombinant proteins 
All purified protein preparations were plated in triplicate on 2YT agar and 2YT agar 
plus 1 mM ampicillin agar and incubated at 37ºC for 2 days. Protein preparations 
were also inoculated into triplicate 2YT and 2YT plus 1 mM ampicillin broths and 
incubated overnight at 37ºC at 225 rpm on a bench top shaker, and then forwarded to 
a commercial diagnostic laboratory for bacterial culture. 
Quantification and stability of recombinant proteins 
Densitometry was used to quantify the concentration of protein in the protein 
preparations, as described in Chapter 3. To determine recombinant protein stability all 
proteins were diluted to 2 mg/mL with or without the addition of 5% glycerol to help 
stabilize the protein and prevent degradation. These proteins were left for 1 year at 
4°C and quantified by densitometry to determine percentage degradation and 
percentage stability. 
Determination of purity of recombinant proteins  
The proteins of interest were visualized by SDS-PAGE using a resolving gel (12.5% 
[w/v]) and a stacking gel (4% [w/v]) in a mini-gel (BioRad) system containing 0.1% 
SDS [w/v] as described by (Laemmli, 1970). Molecular weight markers (Precision 
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interest (diluted 1:1 in 2X loading buffer) was loaded into a single large well of a 
Mini Protean II cell (BioRad). Electrophoresis was for 54 min at 200 V with a running 
buffer consisting of 25 mM Tris, 192 mM glycine and 1% [w/v] SDS. Gels were 
removed and either stained with Coomassie Brilliant Blue or Western blotted onto 
nitrocellulose membranes. For Coomassie Brilliant Blue staining, gels were added to 
50 mL of Coomassie Brilliant Blue stain (45% [v/v] methanol, 45% [v/v] distilled 
water, 10% [v/v] glacial acetic acid and 0.05% [v/v] Coomassie Brilliant Blue) and 
left overnight at room temperature on a horizontal rocker. The excess stain was 
removed using a de-stain solution (40% [v/v] methanol, 50% [v/v] distilled water and 
10% [v/v] glacial acetic acid) which was replaced at least twice until the gel was fully 
de-stained. A gel drying solution (20% [v/v] ethanol, 3% [v/v] glycerol and 77% [v/v] 
distilled water) was then added to the gel and left for 30 min. The de-stained gels were 
then dried between cellulose sheets and stored.  The identity of the proteins was 
confirmed by Western immunoblotting as described in Chapter 3. 
Detection of nucleic acid contamination in recombinant proteins 
The solubilised recombinant proteins were tested for DNA and RNA contamination 
using a NanoDrop® ND-1000 kit (Biolab). A range of dilutions of the protein from 
1:2 to 1:32,768 were tested and a mean nucleic acid concentration obtained.  To 
determine if any of the DNA/RNA from the bacterial cells was of plasmid origin, 
PCR assays were performed on the dilutions using pTrcHisF and pTrcHisR primers 
(Table 4.1). 
Benzonase treatment of recombinant proteins to degrade contaminating nucleic 
acid 
Benzonase is used in large scale production of vaccines to degrade contaminating 
RNA and DNA. The benzonase protocol (Novagen) recommended a working 
concentration of 50 enzyme units/mL for 10 min at room temperature to degrade all 
nucleic acid. This proved insufficient for the plasmid nucleic acid and extra benzonase 
was added to the lysis buffer to determine the optimal concentration and time for 
complete nucleic acid degradation.  Incubation times of 15, 30 and 45 min were tested 
with concentrations of benzonase of 50, 55, 60, 75, 100, 150 and 500 U/mL of 
solubilised CA/Tat-GST protein.  
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The presence of endotoxin in the JDV recombinant proteins was detected using an E-
Toxate® (Limulus Amoebocyte lysate) (LAL) assay (Sigma Aldrich) as 
recommended by the manufacturer. The assay was performed under stringent aseptic 
conditions with pyrogen-free glassware, plastic ware and reagents to avoid endotoxin 
contamination. Standard quantities of endotoxin were used to create a standard curve 
from which results obtained with serially diluted protein samples were compared 
(Tomasulo et al., 1977). All controls were as described by the manufacturer and the 
standards provided results within the range expected. 
Assay of recombinant proteins for cytotoxicity  
Cytotoxicity of the CA/Tat-GST polyprotein was detected using the 
Celltiter96®Aqueous One Solution Cell Proliferation Assay (Promega) which 
determined changes in the number of viable cells exposed to the protein. Two 
standard curves were produced as described by the manufacturer, one for African 
green monkey kidney (VERO) cells and a second for primary foetal bovine lung 
(FBL) cells. To each well of a 96-well microtitre cell culture tray, 50,000 cells were 
added and left for 4 h at 37ºC in the presence of differing concentrations of JDV 
CA/Tat-GST, CA-GST and GST only (negative control). All samples were tested in 
quadruplicate and a mean was obtained which was then plotted on a graph with a 
downward trend indicating cytotoxicity and an upward trend indicating a proliferative 
response. The absorbances were then plotted on the standard curves of the VERO and 
FBL cells and the total number of cells/well was determined. The standard curve of 
the VERO cells had an R
2 value of 0.9572 and the equation used for determining the 
number of cells/well was OD at a wavelength of 490 nm (OD490) =0.0043X+0.2952. 
The standard curve of the FBL cells gave an R
2 value of 0.9856 and the equation for 
determining the number of cells/well was A490 =0.003X+0.2452. 
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Optimisation of JDV CA/Tat-GST polyprotein expression 
A growth curve for the cultures inoculated with 3 different dilutions of overnight 
inoculum are shown in Figure 4.1 .Exponential growth slowed 4-6 h post-inoculation 
and started to plateau about 7 h post-inoculation, irrespective of the initial dilution of 
starter culture.  
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Figure 4.1. The effects of differing dilutions of inoculum on the growth curve of BL21 E. coli 
containing the CA/Tat-GST constructs grown in 2YT with 1 mM ampicillin. Three different 
dilutions of the inoculum were added and the growth dynamics of the bacteria containing the 
recombinant plasmid was determined.  
 
 
The expression of the CA/Tat-GST polyprotein after induction with IPTG of cultures at 
an OD600 of 1 and 1.5 for periods from 1-24 h is shown in Figures 4.2 and 4.3. From 
the data, induction of expression of cultures at an OD600 of 1.5 for 12 h was chosen for 
further recombinant protein production.  
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Figure 4.2. SDS PAGE gel showing the relative expression of the CA/Tat-GST polyprotein in 
BL21 E. coli grown in 2YT and induced with IPTG at an OD600 of 1.0. (a) Lanes 1-12, after 
expression for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 h respectively. (b) Lanes 13-24, after 
expression for 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 h, respectively.  
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Figure 4.3. SDS PAGE gel showing the relative expression of the CA/Tat-GST polyprotein in 
BL21 E. coli grown in 2YT induced with IPTG at an OD600 of 1.5. (a) Lanes 1-12, after 
expression for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 h, respectively. (b) Lanes 13-24, after 
expression for 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 h, respectively.  
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Comparison of methods of chemical cell lysis 
Ultrasonication resulted in total lysis of bacterial cells as indicated by the inability to 
detect viable cells by either culture or trypan blue staining. Similar results were 
obtained after freeze-thawing and when a combination of ultrasonication and freeze-
thawing was used. BugBuster® resulted in complete lysis of the bacterial cells within 
the 30 min period recommended by the manufacturer. Triton X-100 at concentrations 
of ≥ 1% for 30 min provided complete cell lysis comparable to sonication, 
  81freeze/thawing or commercial cell lysis solutions (Table 4.2). Suspensions treated 
with 0.5% Triton X-100 for 30 min still had detectable colonies on the 2YT agar 
plates (30 colonies/mL) indicating that concentrations of Triton X-100 less than 1% 
were insufficient to lyse all cells in a 30 min period. None of the treatments with 
Triton X-100 appeared to affect the final yield of protein, although BugBuster® did 
appear to reduce yield but full quantification of this was not attempted. 
 
 
Table 4.2. Degree of lysis detected after treatment of BL21 E .coli expressing the recombinant 
JDV CA/Tat-GST protein with various concentrations of Triton X-100 for periods up to 30 
min, compared to a commercially available chemical lysis method (BugBuster®). As an index 
of cell lysis, the presence of viable cells was determined by trypan blue staining the cells and 
determining the percentage viable bacterial cells.  
 
Duration of 
treatment  
(min) 
Triton X-100 (%)   BugBuster® 
(Novagen)  
 
0.5 1  2 5 
5 No 
lysis 
No lysis 
 
No lysis 
 
~30% 
 
NT
a 
10 ~10%    ~15% 
 
~30% 
 
~95%   NT 
20 ~15%    ~30% 
 
~50% 
 
Complete   NT 
30 ~25%  ~40%    Complete Complete  Complete 
a NT denotes not tested 
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Purification and quantification of the recombinant protein 
The JDV CA/Tat-GST polyprotein was not solubilised during the 6 washes with wash 
buffers containing Triton X-100 but was solubilised by the addition of urea, with 
~95% purity as shown in Figure 4.4. The predicted yield of the polyprotein from 1 L 
of culture, deduced from the batch shown in Figure 4.4 was 676 mg (Table 4.3). 
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Figure 4.4. (a) Coomassie Brilliant Blue stained SDS-PAGE gel of the second, fourth and 
sixth wash fractions and the final purified protein. Lane 1, no product; lane 2, wash buffer 
from the second wash in wash buffer containing 2% Triton X-100; lane 3, wash buffer from 
the fourth wash in wash buffer containing 1% Triton X-100; lane 4, wash buffer from the 
sixth (final) wash in wash buffer containing 0.5% Triton X-100; lane 5, wash buffer 
consisting of PBS after 1 wash; lane 6, no product; lanes 7 and 9, CA/Tat-GST polyprotein 
after solubilisation in solubilisation buffer containing 2 M urea, lane 8, no product. The 
results demonstrate that the CA/Tat-GST polyprotein was not solubilised during washing 
steps with buffers containing 2% or less Triton X-100 (lanes 2, 3 and 4) or PBS (lane 5) but 
that most of the contaminating E. coli proteins were removed by washing (lanes 7 and 9). (b) 
An example of a Coomassie Brilliant Blue stained SDS-PAGE for quantification of the 
CA/Tat-GST polyprotein by densitometry, and for assessing the purity of the product. Lane 1, 
1000 ng BSA; lane 2, 500 ng BSA; lane 3, 250 ng BSA, lane 4, 125 ng BSA, lane 5, 1 µL of 
CA/Tat-GST preparation; lane 6, 0.5 µL of CA/Tat-GST preparation; lane 7, 0.25 µL of 
CA/Tat-GST preparation; lane 8, 0.1 µL of CA/Tat-GST preparation; lane 9, 0.05 µL of 
CA/Tat-GST preparation. 
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  83Table 4.3. Examples of the final protein concentration, purity and expected yield obtained 
with various recombinant protein preparations produced in small scale cultures. 
Protein Concentration  Purity  Yield/L 
Tat-GST  8,248 ng/μL  <85% 80  mg 
CA-GST  6,456 ng/μL  <85% 65  mg 
CA/Tat-GST  6493 ng/μL  >95% 676  mg 
 
 
The production of a recombinant GST-tagged CA/Tat polyprotein instead of separate 
GST-tagged CA and Tat proteins would have resulted in an overall increase in the 
ratio of CA and Tat relative to the GST component of the polyprotein (Table 4.4).   
 
 
Table 4.4. Comparison of the content of each component protein/mg in the recombinant 
protein preparations. A 4 mg quantity of JDV CA/Tat-GST polyprotein (the anticipated dose 
per vaccination) contained 1.6 mg of CA, 0.67 mg of Tat and 1.73 mg of GST, whilst 2 mg 
of the individual JDV CA-GST contained 0.96 mg of CA and 1.04 mg GST, and 2 mg of 
JDV Tat-GST contained 0.55 mg of Tat and 1.45 mg GST). 
Protein Content  per  mg  of expressed protein 
CA Tat GST 
CA/Tat-GST 
polyprotein 
0.4 mg  0.1675 mg  0.4325 mg 
CA-GST   0.48 mg  -  0.52 mg 
Tat-GST  -  0.275 mg  0.725 mg 
 
 
 
  84Endotoxin assay 
All the positive and negative controls provided with the kit provided results in the 
range suggested by the manufacturer. The Tat-GST (2 mg/mL) recombinant protein 
contained 16 U/mg and a CA/Tat-GST (2 mg/mL) polyprotein contained 4 EU/mg.  
Cytotoxicity of purified protein preparations 
VERO cells exposed to 0.1-20 µg protein/well, a purified CA-GST preparation caused 
a decrease in number of viable cells from 47,860 (GST control) to 33,150 cells/well 
(containing recombinant protein) whilst a CA/Tat-GST polyprotein preparation 
resulted in an increase in number of viable cells from 47,860 (GST control) to 
108,670 cells/well (exposed to polyprotein) (Figure 4.5). In primary FBL cells 
exposed to 20 mg protein/well, the JDV CA-GST caused an increase in numbers of 
viable cells 47,860 (GST control) to 66,430 (containing recombinant protein) whilst 
the JDV CA/Tat-GST preparation resulted in an increase in viable cell numbers from 
68,430 cells/well (GST only) to 128,680 in the wells containing 20 µg of CA/Tat-
GST (Figure 4.6).  
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Figure 4.5. Results obtained with a Celltiter96®Aqueous One Solution 
Cytotoxicity/Proliferation assay using differing amounts of JDV CA/Tat-GST per well over a 
4 h period to measure the cytotoxic/proliferative effect of 2 protein preparations in VERO 
cells (50,000 cells/well) tested for cytotoxicity or proliferation. Results indicated an increase 
in the cell numbers in the presence of CA/Tat-GST. 
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Figure 4.6. Results obtained with a Celltier96®Aqueous One Solution 
Cytotoxicity/Proliferation assay using differing amounts of JDV CA/Tat-GST 
polyprotein/well over a 4 h period to measure the cytotoxic/proliferative effect of 2 protein 
preparations in primary FBL cells (50,000 cells/well) tested for cytotoxicity or proliferation. 
Results indicated an increase in the cell numbers in the presence of the JDV CA/Tat-GST 
polyprotein. 
  
 
Presence of DNA in purified protein preparations 
A purified JDV CA/Tat-GST preparation diluted to contain 4 mg protein/mL 
contained 81.7 ng of DNA/µl, determined using the NanoDrop® ND-1000 Biolab for 
DNA quantification. A high level of plasmid contamination was detected by PCR in 
all dilutions (Figure 4.7).  
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Figure 4.7. Conventional PCR using j604f and j1030r primers (Table 4.1) to detect plasmid 
DNA in a purified CA/Tat-GST polyprotein preparation. Lane 1, 1 Kb DNA ladder; lane 2, 
1:2 dilution of preparation; lane 3, 1:4 dilution; lane 4, 1:8 dilution; lane 5, 1:16 dilution; lane 
6, 1:32 dilution; lane 7, 1:64 dilution; lane 8, 1:128 dilution; lane 9, 1:256 dilution; lane 9, 
1:512 dilution; lane 10, 1:1,024 dilution; lane 11, 1:2,048 dilution; lane 12, 1:4,096 dilution;, 
lane 13, 1:8,192 dilution; lane 14, 1:16,384 dilution; lane 15, 1:32,768 dilution; lane 16, 
positive control (clone #139); lane 18, negative control with no DNA; lane 19, negative 
control with water only; lane 20, 100 bp DNA ladder. The positive bands of the correct size 
indicate that there was a high level of plasmid in the vaccine preparations. 
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Benzonase degradation of free nucleic acid in purified polyprotein 
preparation 
The addition of 75 U/mL of benzonase at room temperature for 45 min but not 15 or 
30 min degraded the majority of the DNA and RNA in the purified polyprotein 
preparation (Figure 4.8). No detectable plasmid DNA was amplifiable by PCR after 
benzonase treatment of the vaccine preparation. 
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Figure 4.8. Agarose gel electrophoresis to determine the effect of benzonase on DNA/RNA 
present in a 20 µg of JDV CA/Tat-GST polyprotein preparation. (a) Differing concentrations 
of benzonase at room temperature for 15 min; (b) differing concentrations of benzonase at 
room temperature for 30 min; (c) differing concentrations of benzonase at room temperature 
for 45 min.  In each gel, lane 1 contained 50 U/mL of benzonase, lane 2 contained 55 U U/mL 
of benzonase, lane 3 contained 60 U/mL of benzonase, lane 4 contained 75 U/mL of 
benzonase, lane 5 contained 100 U/mL of benzonase, lane 6 contained 150 U/mL of 
benzonase, lane 7 contained 500 U/mL of benzonase, lane 8 was a negative control with no 
substrate. Treatment with benzonase for 15 and 30 min (gels a and b) resulted in only partial 
degradation of the nucleic acids at all concentrations of benzonase but treatment for 45 min 
(gel c) shows that 75 U/mL  of benzonase destroyed most of the nucleic acid present in the 
purified polyprotein preparation.  
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Stability of the polyprotein at 4ºC 
The JDV CA-GST and CA-GST proteins with or without an additional 5% glycerol 
did not degrade over a 12 month period at 4°C. The Tat-GST was more unstable and 
there was a reduction of 0.759 mg/mL of the original protein content whilst the Tat-
GST plus 5% glycerol had a reduction of 0.4287 mg/mL over the same period. The 
CA/Tat-GST polyprotein was relatively stable for 12 months both with and without 
5% glycerol, with an overall reduction of 0.2783 mg/mL without glycerol and 0.238 
mg/mL with 5% glycerol (Figure 4.9).  
 
 
 
  880
10
20
30
40
50
60
70
80
90
100
CA-GST
CA-GST+Glycerol
Tat-GST
Tat-GST+Glycerol
CA/Tat-GST
CA/Tat-GST+Glycerol
P
e
r
c
e
n
t
a
g
e
 
% degradation
% stability
Figure 4.9. A comparison of the stability of recombinant protein preparations at 4ºC over a 
12 month period.  All recombinant proteins were diluted to 2 mg/mL at the start of the 
experiment with or without 5% glycerol and their concentration measured 12 months later. 
The CA-GST was the most stable recombinant protein whilst the Tat-GST was the least 
stable. 
 
 
Discussion 
A prokaryotic expression system was chosen for the production of a JDV recombinant 
vaccine as this was a technology considered feasible in Indonesia. The vector system 
chosen was the pGEX6-P-1 GST plasmid vector system (Amersham) which 
incorporates the 26 kDa GST protein of the Schistosoma japonicum to the 
recombinant proteins of interest. This system had been previously used for the 
production of other JDV proteins (Burkala et al., 1998; Burkala et al., 1995) and 
earlier JDV vaccines (Ditcham, 2007) with success. The advantages of this system 
were that the recombinant proteins are often folded into inclusion bodies which make 
the purification simpler and less expensive than other systems, some of which require 
specialized columns for affinity purification (LaVallie and McCoy, 1995; Yin et al., 
2007). In addition, the GST tag is derived from S. japonicum which produces a 
zoonotic disease that is endemic in many areas of Indonesia (Chitsulo et al., 2000;  
  89Engels et al., 2002). Vaccination of Chinese cattle in endemic regions with the 26 kDa 
GST protein was reported to reduce worm burden by up to 30% (Wu et al., 2004). 
This effect is a potentially significant advantage as the vaccine may not only protect 
against JDV but may also offer some protection against S. japonicum. A disadvantage 
of the pGEX6-P-1 (GST) system is that it does not differentiate infected from 
vaccinated cattle as cattle naturally infected with S. japonicum will have antibodies 
against the GST. A possible way to differentiate naturally-infected from vaccinated 
cattle would be to detect JDV Tat antibodies as these are not normally present in 
naturally infected cattle (Setiyaningsih et al., 2008). 
The recombinant proteins used in this Chapter were purified from the insoluble 
inclusion bodies that were washed with varying concentrations of Triton X-100 and 
then solubilised in a urea, DTT and Tris based solution (Kopito, 2000). Soluble 
proteins were also produced, ranging from 20-50% of the total protein produced by 
the E. coli but these were not purified and used due to the likely costs involved 
(Ditcham, 2007). These bacterial inclusion bodies are refractile aggregates of 
protease-resistant misfolded protein that occur when there is an over-expression of a 
protein in the cell (Carrio and Villaverde, 2002). The excess of protein produced in 
relation to various chaperone proteins leads to the protein being mis-folded and stored 
in an aggregate within the cell (Carrio and Villaverde, 2001; Schwarz et al., 1996). 
This inclusion body formation allows the bacteria to store protein for prolonged 
periods of time which can then be refolded correctly into an active form at a later date 
when needed by the bacterium (Carrio et al., 1999; Carrio and Villaverde, 2001). The 
purification of recombinant proteins from inclusion bodies offers many advantages, 
including ease of purification, high purity of the protein present in the inclusion 
bodies and the resistance of inclusion bodies to proteases, temperature and pH 
changes (Carrio and Villaverde, 2002). The main disadvantage of purifying protein 
from inclusion bodies is that sometimes the protein can be incorrectly folded which 
leads to a loss of conformational epitopes or loss of activity in the case of enzymes. 
These inclusion bodies can also be toxic to the bacterial cells (Gonzalez-Montalban et 
al., 2005). It is usually important to correctly re-fold the protein after purification 
from inclusion bodies to retain the activity and the binding properties (Lilie et al., 
1998) but particularly for Tat a loss of enzymatic function was desirable due to the 
likely deleterious effects of Tat on the vaccinated cattle. Furthermore, a study using a 
  90soluble and a urea/dithiothreitol (DTT) solubilised recombinant Taenia ovis vaccine 
(45W-GST) found increased immunogenicity and protection using the urea/DTT 
solubilised inclusion body vaccine compared to the native soluble vaccine (Rothel et 
al., 1997).  
Several methods of cell lysis were shown to be effective and to release the inclusion 
bodies from bacterial cells.  Triton X-100 treatments achieved similar results to 
sonication and freeze/thawing, demonstrating that a chemical means of lysis was 
feasible. However, numerous factors can affect chemical lysis, such as incomplete 
agitation, temperature, time and incomplete mixing of the lysis buffer and most large 
scale lysis protocols use sonication, a French press or freeze/thawing as a method of 
cell lysis (Feliu et al., 1998). 
Considerable amounts of nucleic acid were detected in the purified protein 
preparations produced, consisting of plasmid DNA which was demonstrated to be 
present and presumably also bacterial RNA and DNA.  This was degraded by the 
addition of benzonase to the lysis buffer. The optimum concentration of benzonase for 
degradation was 75 U/ mL for 45 min which is similar to the recommended working 
concentration of 50 U/ mL for 10 min (Novagen) and concentrations reported in 
previous publications (Friedhoff et al., 1996; Meiss et al., 1995).  
Protein yields were quantified using high quality gel imaging densitometry 
(ProExpress, PerkinElmer) rather than by biochemical protein assay (Bradford, 
BioRad) so that only the protein of interest was quantified rather than the total protein 
content. This allowed accurate quantification of the protein of interest and the 
percentage purity of the final protein preparation to be determined.  
Endotoxin contamination was detected in the purified protein preparations using a 
Limulus Amoebocyte lysate (LAL) assay (Levin and Bang, 1964; Poole et al., 2003; 
Tomasulo et al., 1977). This assay is one of 2 assays commonly used to measure 
endotoxin levels in vaccine preparations, the other being a rabbit pyrogen test which 
measures endotoxin but also other pyrogens. Recently, one-plate assays for pyrogen 
detection have also been developed but these are expensive and were unavailable for 
this current study (Gaines Das et al., 2004). The level of endotoxin detected was 8-
fold greater in the individual JDV recombinant CA-GST and Tat-GST preparations 
than the fused JDV CA/Tat-GST polyprotein/mg of protein obtained. This was 
  91expected as there is a greater yield of the polyprotein/cell and a higher purity of the 
final polyprotein preparation compared to the individual recombinant protein vaccine.  
It is important that endotoxin contamination should be detected in any protein 
preparation intended for injection. They are a lipopolysaccharide (LPS) complex that 
form part of the outer membrane of Gram-negative bacteria such as Salmonella, 
Pseudomonas, Shigella and E. coli (Bennett and Cluff, 1957). The majority of these 
endotoxins are released when the bacterial cells are lysed and they are extremely 
difficult to remove or inactivate and remain in the environment for prolonged periods 
making them a medically important contaminant of protein preparations (Poole et al., 
2003). In ruminants, endotoxins induce increased blood lactate, hyperglycaemia, 
leucopenia followed by granulocytosis, and disseminated intravascular coagulation 
which can lead to endotoxic shock and death. Gross pathological lesions of the heart, 
brain, adrenals and lungs are also commonly associated with endotoxic exposure 
(Nagaraja et al., 1979). This endotoxic shock followed by a later second exposure to 
endotoxin will produce an anaphylactic response in ruminants. Safe endotoxin levels 
in proteins for injection in ruminants have not been determined but they are probably 
equivalent to levels in human vaccines which are 5 EU/kg parenterally or 0.2 EU 
intrathecally (Magalhaes et al., 2007). 
Despite the presence of endotoxins in all the purified protein preparations, not all 
were cytotoxic as determined by a cytotoxicity/proliferation assay in VERO and 
primary FBL cells. The GST and the CA-GST appeared to have little cytotoxic or 
proliferative effect on either VERO or primary FBL cells. The addition of JDV 
CA/Tat-GST polyprotein actually led to hyper-proliferation of these cells. This 
proliferation may have been due to the JDV Tat component of the vaccine as HIV Tat 
has been shown to induce abnormal levels of cellular cytokines in infected cells 
leading to cell hyper-proliferation in a dose dependant manner (Albini et al., 1998; 
Badou et al., 2000; Conaldi et al., 2002; Vellutini et al., 1995) although BIV Tat has 
been reported to have an apoptotic effect in vitro (Xuan et al., 2008). Since the 
CA/Tat polyprotein was used as a vaccine (Chapters 5 and 6), the possible 
proliferative effect of the Tat component needs further investigation to determine if 
the polyprotein would need to be further modified by oxidization or mutated to 
remove all Tat activity whilst retaining immunogenicity, as has been attempted with 
HIV Tat (Bennasser et al., 2002; Caselli et al., 1999; Noonan et al., 2003).  
  92With the exception of Tat-GST all of the proteins produced, including the CA/Tat-
GST polyprotein had less than 25% degradation when held at 4°C for 12 months. 
Glycerol, which can act as a stabilising agent for enzyme activity and protein 
conformation (Gekko and Timasheff, 1981) had no significant effect on the stability 
except for the Tat-GST protein individually.  While the degradation that was observed 
would need to be factored into the dose used if the polyprotein was used as a vaccine, 
the stability at 4ºC would make it suitable were it to gain acceptance as a vaccine in 
Indonesia.   
In conclusion, the successful production of JDV CA/Tat-GST polyprotein in a single 
fermentation reaction would decrease costs of production and enable higher purity and 
lower levels of endotoxin contamination to be achieved than were obtained with the 
individual CA-GST and Tat-GST preparations. Nucleic acid contamination of the 
proteins was detected but could be removed by the addition of benzonase, which 
would not add prohibitive additional costs to the purification process. Further work 
will need to be undertaken to determine the stability and potency of the polyprotein if 
it is used for a vaccine and the proliferative effect of the protein noted in vitro should 
also be investigated further. The Tat portion of the vaccine should also be tested to 
determine the level of activity present. If necessary, methods of inactivation of the Tat 
component without affecting its immunogenicity and antigenicity should be 
investigated. 
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GST polyprotein Jembrana disease vaccine 
Summary 
This chapter describes the use of bacterial expressed recombinant JDV CA/Tat-GST 
polyprotein as a vaccine and a comparison with a vaccine containing a combination of 
individual CA-GST and Tat-GST recombinant proteins. Groups of cattle were 
vaccinated twice and then challenged with a pathogenic JDVPul01 strain. Vaccination 
elicited very high titres of CA and Tat antibody of IgG, IgM and IgA subclasses prior 
to challenge with JDV. The vaccine ameliorated the hyperpyrexia and severe 
lymphopenia typically seen in cattle infected with JDV but did not provide complete 
protection. 
Introduction 
The current vaccine used in Indonesia for Jembrana disease is a whole virus tissue-
derived inactivated virus vaccine prepared from spleen tissue obtained from cattle 
experimentally infected with JDV.  The spleen is homogenized and treated with 
Triton X-100 to inactivate the virus, then emulsified in a mineral oil adjuvant 
(Hartaningsih et al., 2001). This vaccine has been demonstrated to provide partial 
protection, ameliorating the disease process in animals challenged after vaccination, 
but not preventing infection (Hartaningsih et al., 2001). This vaccine is not only 
expensive to produce but its use is associated with safety and ethical issues 
(Hartaningsih et al., 2001; Hartaningsih et al., 1995a). Alternative vaccines consisting 
of recombinant JDV proteins, including CA, SU, TM and Tat, have been expressed 
with a glutathione-S-transferase tag (GST) in E. coli and tested for efficacy as 
vaccines.  A vaccine preparation consisting of 2 mg of CA-GST plus 2 mg of Tat-
GST in an oil adjuvant and administered 2-3 times was selected as the most promising 
recombinant protein vaccine, although again protection was limited to amelioration of 
the disease process after infection (Ditcham, 2007).  
As the production of 2 separate recombinant protein antigens was expected to increase 
the difficulty of producing a vaccine based on these proteins, a single plasmid 
construct expressing both CA and Tat as a single GST-tagged polyprotein (JDV 
CA/Tat-GST) was developed (Chapter 4).  In this Chapter, the polyprotein was 
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the CA/Tat-GST polyprotein was compared with the administration of 2 single JDV 
protein preparations, CA-GST and Tat-GST.  
Materials and methods 
Preparation of recombinant proteins as vaccines 
Individual JDV CA-GST and JDV Tat-GST recombinant proteins were produced and 
purified as described previously (Chapter 4) and adjusted to a concentration of 4 
mg/mL in PBS (pH 7.4).  The purity of the proteins is demonstrated in Figure 5.1. 
Western immunoblots were performed to confirm that the recombinant polyproteins 
were recognized by antibody from naturally infected, conventionally vaccinated and 
CA/Tat-GST vaccinated cattle sera as previously described (Chapter 4). The 
individual protein suspensions were mixed in equal volumes and then emulsified with 
an equal volume of incomplete Freund’s adjuvant (IFA) and a dose of 2 mL 
(containing 2 mg of each GST-tagged protein) was administered to cattle. 
 
 
Figure 5.1. Coomassie Brilliant Blue stained SDS-PAGE gel showing the purity of the 
recombinant proteins used for vaccination. Lane 1, Tat-GST; lane 2, CA-GST; lane 3, CA-
Tat-GST; lane 4, GST only. The gel demonstrates the purity of the GST preparation and 
>90% purity of the other recombinant proteins. 
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The JDV CA/Tat-GST recombinant polyprotein was produced as previously described 
(Chapter 4).  Briefly, JDV CA/Tat-GST transformed BL21 E. coli were grown to an 
OD600 of 1.5 in 2YT medium plus 1 mM ampicillin before induction of expression by 
the addition of 0.1 mM IPTG (final concentration) for 12 h. The cells were then lysed 
by sonication and centrifuged. The fusion protein from the lysed pellet was in an 
insoluble form, and was further purified by 6 wash steps (1 h each on a rotary mixer at 
4ºC) with a 0.5-2% Triton X-100 wash buffer (Tris-HCl 10 mM, EDTA 5 mM and 
  950.5-2% [w/v] Triton X-100) followed by centrifugation; the first 2 washes contained 
2% Triton X-100, the next 2 washes contained 1% Triton X-100 and the final 2 
washes 0.5% Triton X-100.  The protein in the final pellet was then solubilised 
overnight after the addition of a urea/Tris solution (urea 2 M, Tris 2 M, DTT 20 mM 
and PMSF 1 mM). The purified antigens were analysed by SDS-PAGE and 
Coomassie Brilliant Blue staining to determine yield and purity as previously 
described (Chapter 4) and the purity of the final protein used is demonstrated in 
Figure 5.1. The proteins were then diluted in PBS (pH 7.4) to the desired 
concentration and mixed with adjuvant for use as the vaccine. Western immunoblots 
were also performed to confirm that the recombinant polyprotein was recognized by 
antibody from naturally infected, conventionally vaccinated and CA/Tat-GST 
vaccinated cattle sera as described in Chapter 4. The protein suspension was adjusted 
to a concentration of 4 mg/mL, emulsified with an equal volume of IFA, and a dose of 
2 mL (containing 4 mg of GST-tagged polyprotein) was administered to cattle. 
GST for mock vaccination of cattle was prepared from BL21 E. coli containing the 
pGEX6-P-1 plasmid with no JDV inserts. The plasmid-containing E. coli were grown 
in 2YT broth supplemented with 1 mM ampicillin to an OD600 of 0.6. Expression of 
the recombinant protein was then induced with IPTG (0.1 mM final concentration) for 
4 h.  The bacteria were then harvested by centrifugation, washed in PBS, resuspended 
in 25 mL of lysis buffer and lysed by sonication. After clarification of the lysate by 
centrifugation, the supernatant was passed 3 times through a glutathione/Sepharose 
resin column of 0.2 mL, equilibrated with PBS. Soluble bound GST protein was then 
displaced with 10 column volumes of 30 mM glutathione in PBS. The eluted GST 
was then tested for purity by SDS-PAGE (Figure 5.1) and quantified by densitometry 
as previously described (Chapter 4). The protein suspension was adjusted to a 
concentration of 2 mg/mL, emulsified with an equal volume of IFA, and a dose of 2 
mL (containing 2 mg of GST) was administered to cattle. 
Preparation of non-GST tagged proteins as antigens for analysis of 
antibody responses to vaccine antigens 
Histidine (his)-tagged CA was produced as previously described (Chapter 3). 
Biotin-tagged Tat (Tat-biotin) was produced with a Pinpoint (Promega) recombinant 
plasmid clone jTat1, previously constructed by Dr Moira Desport (this laboratory), 
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(Chadwick et al., 1995a); this plasmid was predicted to encode a JDV Tat1 protein 92 
amino acids in length.  Optimum expression of Tat was achieved by adding a 1:50 
volume of an overnight culture of E. coli in 2YT broth plus 1 mM ampicillin to 1 L of 
2YT broth plus 1 mM ampicillin.  The culture was grown to an OD600 of 0.6 before 
induction of expression by the addition of IPTG (0.1 mM final concentration) for 4 h, 
and the cells were then pelleted by centrifugation (10,000 g for 15 min at 4°C). The 
recombinant protein was produced in inclusion bodies in an insoluble form. The cells 
were resuspended in cell lysis buffer (50 mM Tris-HCl pH 7.5, 50 mM NaCl and 5 % 
[v/v] glycerol) and lysed by sonication. After centrifugation (10,000 g for 15 min) the 
cell pellet containing the inclusion bodies was resuspended in 10 mL of PBS (pH 7 
adjusted with HCl) and agitated overnight at 4°C on an orbital mixer. The cell pellet 
was collected by centrifugation (10,000 g for 15 min at 4°C). The pellet was washed 
for 10-30 min in PBS (pH 7) at 4°C and centrifuged (10,000 g for 15 min at 4°C), 
repeating this wash step 4 times. The protein in the final pellet was solubilised by the 
addition of 9 mL of solubilisation buffer (urea 2 M, Tris 2 M, DTT 20 mM and PMSF 
1 mM) on an orbital mixer at 4°C for 2 h. The solubilised pellet was added slowly to 
390 mL of Refolding Buffer (Tris pH 8 100 mM, 350 mg CHAPS and 0.53 g DTT 
made up to 350 mL with deionised water) and the refolded protein was concentrated 
in an ultrafiltration cell (Amicon) until a volume of 20 mL was obtained. The final 
protein was filtered using a standard 0.22 μ syringe exclusion filter (Millipore) to 
remove aggregated E. coli proteins and then dispensed in 1 mL amounts and stored at 
-80°C. These individual non GST-tagged proteins were used to determine the protein 
specific antibody titres induced by the vaccine. 
Vaccination trial 
Twenty female 12-month-old Bali cattle were obtained from Nusa Penida, an island 
adjacent to Bali where Jembrana disease does not occur, transported to Bali, housed in 
insect-free animal houses, and maintained as previously described (Soeharsono et al., 
1990). On arrival, the cattle were vaccinated with Haemorrhagic Septicaemia vaccine 
(PUSVETMA) and confirmed as being JDV antibody-negative by ELISA and 
Western immunoblotting, and housed for 7 days prior to further use to adapt to the 
conditions.  
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by Western immunoblot and ELISA. Briefly, 2,000 ng of Tat-biotin and CA-his, were 
subjected to SDS-PAGE and transferred to nitrocellulose membrane using standard 
methods. The membranes were blocked in 5% skimmed milk powder in TBST. 
Nitrocellulose strips were reacted with a 1:100 dilution of sera for 1 h with constant 
rocking, and then washed in TBST. Bound bovine IgG was detected with HRP 
conjugated anti-bovine IgG (1:1,000 dilution in TBST) and excess conjugated 
antibody was removed by washing in TBST.  The presence of specific antibody to the 
JDV proteins was revealed by reaction with the chromogenic substrate 4-
chloronaphthol (BioRad; prepared as a 1 mg/mL solution in methanol and diluted 1:5 
in TBS with an additional 1 µL/mL of 30 % H2O2). 
The 20 cattle were divided into 4 groups of 5: groups A and D received 2 vaccinations 
at days 28 and 56 whilst groups B and C had 3 vaccinations at days 0, 28 and 56. 
Group A was vaccinated twice, at day 28 and 56, each time with 4 mg of the fused 
polyprotein vaccine in IFA. Group B was vaccinated 3 times at days 0, 28 and 56 with 
4 mg of the fused polyprotein in IFA. Group C was vaccinated 3 times at days 0, 28 
and 56 with a mix of 2 mg of CA-GST and 2 mg of Tat-GST per vaccination in IFA. 
Group D (controls) were vaccinated 3 times with 2 mg GST in IFA.   
Table 5.1. Groups of cattle inoculated with recombinant purified proteins emulsified in IFA 
and subsequently challenged 28 days after the final vaccine dose with 1,000 ID50 of JDVPul01. 
Group and 
number 
(n) of 
cattle 
Vaccine   Dose (mg)  Number of doses 
Group A 
(n=5)  CA/Tat-GST  4 mg  2 
Group B 
(n=5)  CA/Tat-GST  4 mg  3 
Group C 
(n=5)  Tat-GST + CA-GST  2 mg + 2 mg  3 
Group D 
(n=5)  GST  2 mg  2 
 
All cattle were challenged with 1,000 50% infectious doses (ID50) of the heterologous 
JDVPul01 on day 84 of the trial, 28 days after the final vaccine dose (Table 5.1) as 
  98described by Soeharsono et al. (1990).  The infectious JDVPul01 was obtained from 
additional JDV antibody-negative cattle that had been inoculated with JDVPul01 as 
previously described (Soeharsono et al., 1990).  Briefly, on the second day of the 
febrile reaction after inoculation with JDVPul01, heparinized blood was collected from 
the these additional cattle and the approximate ID50 of virus in the blood determined 
indirectly by antigen capture ELISA as previously described (Stewart et al., 2005) in 
order to calculate the dilution required to provide a challenge dose of 1,000 ID50. 
Viral RNA was extracted from plasma samples taken from the donor animals and 
virus RNA quantified by qRT-PCR (see below) to retrospectively confirm the 
estimated infectious dose (Stewart et al., 2005). 
Following inoculation of the vaccinated and control cattle with JDVPul01, serum 
samples were collected from all cattle at the times shown in Table 5.2. Total leucocyte 
counts were performed at times shown in Table 5.2. Blood smears were prepared and 
used to determine the differential leucocyte response; these smears were dried for 15 
min before being stained with Diff-Quik differential leucocyte stain (Difco). Two 
hundred leucocytes were examined per slide to determine the differential leucocyte 
response. Total leucocyte counts were also performed on the same days using 
heparinised blood samples as described previously (Soeharsono et al 1995) and rectal 
temperatures were taken from days 0-110 of the trial and a rectal temperature             
≥ 39.3ºC used to define the occurrence of fever.  Aspects of the febrile response, 
including the time for onset of fever (>39.3ºC) after infection, the mean febrile 
temperature during the febrile response, the maximum febrile temperature and the 
duration of fever with low rectal temperatures (39.3-40.2ºC), moderate rectal 
temperature (40.3-41.2ºC) and high rectal temperatures (hyperpyrexia) of >41.3ºC, 
were calculated. Fever score was used as a measure of the severity of the febrile 
period, and calculated as the area under the body temperature curve, but above the 
39.3
ºC cut-off line (Ditcham, 2007). Group data was analysed using a Students 2 
sample t-test to identify significant differences. 
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vaccination, time of subsequent challenge with JDV and the sampling dates. 
Day 
No 
Vaccination and/or challenge 
with JDV 
Days post-
challenge 
with JDV  
Sample collected/examination 
Plasma Serum  PBMC  Rectal 
temp 
WBC 
count 
-7     X  X  X     
-1              
0  1st vaccination group B and C    X  X  X  X  X 
7       X    X   
14       X    X   
21       X    X  X 
28  1st  vaccination  group A and D      X    X  X 
28  2nd vaccination  groups B and C          X   
35       X    X  X 
42        X     
49        X     
56  2nd vaccination groups A and D      X       
56  3rd vaccination  group B and C             
63        X     
70        X     
77        X     
84  Challenged with JDV   0  X  X  X  X  X 
85   1  X    X  X  X 
86   2  X    X  X  X 
87   3  X    X  X  X 
88   4  X    X  X  X 
89   5  X    X  X  X 
90   6  X    X  X  X 
91     7  X  X  X  X  X 
92   8  X    X  X  X 
93   9  X    X  X  X 
94   10  X    X  X  X 
95   11  X    X  X  X 
96   12  X    X  X  X 
97   13  X    X  X  X 
98     14  X  X  X  X  X 
99   15  X    X  X  X 
100   16  X    X  X  X 
101   17  X    X  X  X 
102   18  X    X  X  X 
103   19        X   
104   20  X    X  X   
105   21        X   
106      22  X  X X X  
107   23        X   
108   24  X    X  X   
109   25        X   
110      26  X  X X X  
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
to determine plasma virus load 
RNA was extracted from plasma samples which were centrifuged (8,000 g for 5 min) 
prior to extraction of RNA. Total RNA from 140 µL of plasma was extracted using a 
QIAmp Viral RNA mini kit (QIAGEN) as recommended by the manufacturer. 
Extracted RNA was stored at –80
oC until required.  
Primer and probe sequences (Table 5.3) for the qRT-PCR were designed to amplify a 
121 bp fragment of the JDV gag and were derived from the previously published 
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protocol for the qRT-PCR was based on the method described by Stewart et al. 
(2005).  
Table 5.3. Primers and probe used for the qRT-PCR for the determination of viral load from 
plasma of the experimentally challenged cattle. 
Primer Sequence 
Nucleotide  
position in 
JDVTab87 genome 
JDV gag1f  5’-GGGAGACCCGTCAGATGTGGA-3’  536-555 
JDV gag1r  5’-TGGGAAGCATGGACAATCAG-3’  635-654 
Probe FAM-5’-CCCACAACTTAGAAAGAACTTCCCCGCTG-3’-BHQ-1 604-632 
 
The fluorogenic probe (Geneworks) was labelled at the 5’ end with the reporter dye, 
6-carboxyfluorescein, and at the 3’ end with the Black Hole-2 quencher dye. A 
premixed 2X mastermix (Iscript; BioRad) was used, with the addition of both primers 
and fluorogenic probe to a final concentration of 100 nM, and ultra pure water added 
to give a final 1X concentration. MMLV reverse transcriptase was used in this assay 
following the manufacturer’s instructions. One µL of RNA sample was added to 9 µL 
of master mix in 100 µL tubes (Axygen) and the one-step RT-PCR protocol consisted 
of an RT step of 50°C for 10 min, a 5 min inactivation step at 95°C with a 2 second 
pause at 92°C to prevent thermal overshoot, followed by 40 cycles of 92°C for 2 
seconds, 95°C for 15 seconds, 58°C for 30 seconds. 
A standard curve was generated in each run by amplification of duplicate serial 10-
fold dilutions of plasmid pCR2.1 (Invitrogen) containing nucleotides 19-2881 of the 
sequence of the JDVTab87 encompassing the target amplicon. Copy numbers of the 
plasmid added to each standard reaction were calculated, with 1 copy of plasmid 
equivalent to 1 viral genome. Estimation of the relative efficiency of the RT step was 
performed by including a standard RNA sample and blanks (no probe, no template, no 
RT, template but no RT) in each run. The results were analysed using Rotor-Gene 
proprietary software Version 6.0. Group data was analysed using a Students 2 sample 
t-test to identify significant differences between groups and between vaccinated and 
control cattle. 
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Western immunoblotting was performed as described above but with biotin-tagged 
JDV Tat and his-tagged JDV CA which was produced as described before. 
Antibody titres were determined by ELISA using Maxisorb™ plates (Nunc) coated 
with 200 ng/well of his-tagged JDV CA (4 µg/mL in 0.1 M carbonate buffer pH 9.6).  
These plates were incubated overnight at 4ºC then washed twice in PBST (0.05 %) 
and blocked with 5 % skimmed milk powder in PBST at room temperature for 30 
min. A starting dilution of 1:20 was then added to the first wells diluted in PBST with 
5 % skimmed milk powder. This was then incubated for 1 h at 37ºC then washed 3 
times with PBST (0.05 %) and 100 µL of anti-bovine IgG (ICN), IgM (Bethyl) or IgA 
(Bethyl) conjugated to HRP diluted in skimmed milk PBST at a dilution of 1:2,000 
and incubated for 1 h at 37°C. These plates were then washed once in PBST (0.05%) 
then twice in PBS (pH 7.4). A HRP colour development reagent (BioRad) was then 
added for 15 min and the reaction was then stopped with 2% oxalic acid solution. The 
plates were read at OD405 and the endpoint titre was determined as the reciprocal of 
the last dilution with an OD405 more than 3 times that of sera from the same animal 
collected at day 0. By definition, therefore, samples collected at day 0 had no protein-
specific antibody titre. 
Group serological data was analysed using a Students 2 sample t-test to identify 
significant differences. 
Results 
Humoral immune response to vaccine proteins 
IgG response to vaccination 
The cattle vaccinated 3 times with the recombinant JDV CA/Tat-GST polyprotein 
(Group B) and those vaccinated only twice with the same preparation all developed 
high titres of JDV CA and Tat antibody. The titres of antibody to the CA protein were 
greater than those to the Tat protein. The CA and Tat antibody titres were higher in 
those vaccinated 3 times with the polyprotein (Group B) than those vaccinated 2 times 
with the polyprotein (Group A). The 2 groups of cattle vaccinated with the JDV 
CA/Tat polyprotein (Groups A and B receiving 2 and 3 vaccine doses, respectively) 
had higher CA and Tat antibody titres than those cattle vaccinated 3 times with the 
  102mixture of individual JDV CA-GST and JDV Tat-GST proteins (Group C) (Table 5.4 
and Figure 5.2). 
Table 5.4. The vaccine specific IgG antibody responses against the JDV CA and Tat antigens 
at days 28, 56 and day 84 (day of challenge) in groups A, B and C. The antibody titres were 
determined as the reciprocal of the last dilution with an OD405 more than 3 times that of sera 
from the same animal collected at day 0. By definition, therefore, samples collected at day 0 
had no protein-specific antibody titre. 
Group and 
animal  Antigen 
Days after initial vaccination 
Mortality 
28 56 84 
Group A (2X CA/Tat-GST)      
CB139 CA  1:163,840  >1:327,680  NT Survived 
 Tat  1:160  1:5,120  NT   
CB140 CA 1:20,480  1:81,920 NT  Died 
 Tat  <1:20  1:2,560  NT   
CB141 CA 1:81,920  1:81,920 NT Survived 
 Tat  1:320  1;1280  NT   
CB142 CA 1:10,240  1:40,960 NT Survived 
 Tat  1:20  1:2,560  NT   
CB143 CA 1:20,480  1:40,960 NT Survived 
 Tat  <1:20  1:2,560  NT   
Group B (3X CA/Tat-GST)         
CB144 CA 1:40,960  1:163,840  1:81,920  Survived 
 Tat  <1:20  1:640  1:2,560   
CB145 CA  >1:327,680  >1:327,680  >1:327,680  Survived 
 Tat  1:5,120  1:1,280  1:10,240   
CB146 CA  1:163,840  1:163,840  >1:327,680  Survived 
 Tat  <1:20  <1:20 <1:20  
CB147 CA 1:40,960  >1:327,680  >1:327,680  Survived 
 Tat  1:160  1:5,120  1:20,480   
CB148 CA 1:81,920  1:163,840  >1:327,680  Survived 
 Tat  <1:20  1:320  1:2,560   
Group C (3X CA-GST + Tat-
GST      
CB149  CA  1:20,480 1:20,480 1:81,920 Survived 
 Tat  1:160  1:80  1:1,280   
CB150 CA 1:40,960  1:40,960  1:163,840  Survived 
 Tat  1:640  1:320  1:1,280   
CB151 CA 1:81,920  1:163,840  >1:327,680  Survived 
 Tat  1:1,280  1:1,280  1:1,280   
  103CB152 CA 1:10,240  1:10,240  1:163,840  Died 
 Tat  1:2,560  1:1,280  1:1,280   
CB153 CA  1:640  1:10,240  1:163,840  Survived 
 Tat  <1:20  <1:20  1:640   
 
NT denotes not tested 
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Figure 5.2. Graphical representation of the protein-specific IgG titres ± SE to the JDV CA and 
Tat antigens at different time prior to challenge with JDV. (a) JDV anti-CA IgG titres; (b) 
JDV anti-Tat specific IgG titres. The cattle inoculated with the CA/Tat-GST polyprotein had 
higher IgG anti-CA responses at all time points and higher IgG anti-Tat by the day of 
challenge (day 84) than did those cattle inoculated with the individual recombinant proteins. 
The cattle inoculated 3 times with the CA/Tat-GST polyprotein had significantly higher 
(p=0.00334) anti-CA specific titres at day 56 and approached significance at day 28 and 84 
(p=0.055426 and 0.079964, respectively). The cattle inoculated 3 times with the CA/Tat-GST 
polyprotein had higher anti-Tat specific titres at all time points than those receiving the 
individual proteins, and the differences approached significance (p=0.073527) at day 84. 
 
 
  104IgM response to vaccination 
All cattle in Groups A, B and C developed a CA-specific IgM antibody response 
which was detected 28 days after the initial vaccine dose and continued until the time 
of virus challenge but a JDV IgM anti-Tat response was detected in one animal only, 
CB147 in Group B, 84 days after the initial vaccine dose.  At day 56 after the initial 
vaccine dose, the cattle in Group A had a higher mean anti-CA IgM titre than in 
Group B but those cattle in Group B developed higher mean IgM anti-CA titres 28 
days after the third vaccine doses. The cattle vaccinated with the individual JDV CA-
GST and JDV Tat-GST (Group C) had similar mean IgM anti-CA titres to those 
receiving the JDV CA/Tat polyprotein (Table 5.5 and Figure 5.3). 
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Figure 5.3. Graphical representation of the mean IgM titres ± SE to the JDV CA antigen at 
different time points prior to challenge with JDV. The CA/Tat-GST vaccinated cattle all had 
similar IgM anti-CA responses to the CA-GST + Tat-GST vaccinated cattle prior to challenge 
(day 84). 
 
 
  105Table 5.5. The protein specific IgM antibody responses of cattle in groups A, B and C against 
the JDV CA and Tat antigens at days 28, 56 and day 84 (day of challenge with JDV). The 
antibody titres were determined as the reciprocal of the last dilution with an OD405 more than 
3 times that of sera from the same animal collected at day 0. By definition, therefore, samples 
collected at day 0 had no protein-specific antibody titre.  
 
Group and animal  Antigen 
Days after initial vaccination 
Clinical outcome  28 56 84 
Group A (2X CA/Tat-GST)        
CB139 CA  1:640  1:2,560  NT  Survived 
 Tat  <1:20  <1:20  NT   
CB140 CA  1:160  1:640  NT Died 
 Tat  <1:20  <1:20  NT   
CB141 CA  1:640  1:1,280  NT  Survived 
 Tat  <1:20  <1:20  NT   
CB142 CA  1:20  1:1,280  NT  Survived 
 Tat  <1:20  <1:20  NT   
CB143 CA  1:80  1:160  NT  Survived 
 Tat  <1:20  <1:20  NT   
Group B (3X CA/Tat-GST)       
CB144 CA  <1:20  1:320  1:1,280  Survived 
 Tat  <1:20  <1:20  <1:20   
CB145 CA  1:640  1:640  1:2,560  Survived 
 Tat  <1:20  <1:20  <1:20   
CB146 CA  <1:20  <1:20  <1:20  Survived 
 Tat  <1:20  <1:20  <1:20   
CB147 CA  1:320  1:1,280  1:5,120  Survived 
 Tat  <1:20  <1:20  1:160   
CB148 CA  <1:20  1:320  1:1,280  Survived 
 Tat  <1:20  <1:20  <1:20   
Group C (3X CA-GST + Tat-GST      
CB149 CA  <1:20  <1:20  1:320  Survived 
 Tat  <1:20  <1:20  <1:20   
CB150 CA  1:320  1:160  1:1,280  Survived 
 Tat  <1:20  <1:20  <1:20   
CB151 CA  1:1,280  1:1,280  1:5,120  Survived 
 Tat  <1:20  <1:20  <1:20   
CB152 CA  1:2,560  1:1,280  1:2,560  Died 
 Tat  <1:20  <1:20  <1:20   
CB153 CA  <1:20  <1:20  <1:20  Survived 
 Tat  <1:20  <1:20  <1:20   
NT denotes not tested. 
 
 
  106IgA response to vaccination 
All 3 groups of cattle immunized with the recombinant CA and Tat proteins 
developed anti-CA IgA. The titres were highest in cattle vaccinated 3 times with the 
fused recombinant JDV CA/Tat-GST polyprotein (Group B), less in the cattle 
vaccinated twice with the fused recombinant JDV CA/Tat-GST (Group A) and least 
in the cattle receiving the individual JDV CA-GST and JDV Tat-GST proteins (Group 
C). None of the cattle in any of the groups developed a detectable IgA antibody 
response to JDV Tat (Table 5.6 and Figure 5.4). 
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Figure 5.4. Graphical representation of the mean vaccine specific IgA titres ± SE to the JDV 
CA antigen at different times prior to challenge with JDV. Group A, vaccinated 3 times with 
the CA/Tat-GST polyprotein had higher IgA anti-CA responses than group C vaccinated with 
the individual CA-GST and Tat-GST proteins, with levels significantly higher at day 56 
(p=0.048356) and approaching significance (p=0.090705) at day 84. 
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Table 5.6. The protein specific IgA antibody responses of cattle in groups A, B and C against 
the JDV CA and Tat antigens at days 28, 56 and day 84 (day of challenge with JDV). The 
antibody titres were determined as the reciprocal of the last dilution of serum with an OD405 
more than 3 times that of serum from the same animal collected at day 0. By definition, 
therefore, samples collected at day 0 had no protein-specific antibody titre.  
 
Group and 
animal  Antigen 
Days post-vaccination 
Clinical 
outcome 
28 56 84 
Group A (2X CA/Tat-GST)   
CB139 CA 1:160 1:160 NT  Survived 
Tat <1:5 <1:5 NT 
CB140 CA   1:20 1:80 NT  Died 
Tat <1:5 <1:5 NT 
CB141 CA 1:20 1:40 NT  Survived 
Tat <1:5 <1:5 NT 
CB142 CA <1:5 1:10 NT  Survived 
Tat <1:5 <1:5 NT 
CB143 CA 1:40 1:40 NT  Survived 
Tat <1:5 <1:5 NT 
Group B (3X CA/Tat-GST)   
CB144 CA 1:80 1:160 1:160  Survived 
Tat <1:5 <1:5 <1:5 
CB145 
 
CA 1:640 1:640 1:640  Survived 
Tat <1:5 <1:5 <1:5 
CB146 
 
CA <1:5 1:80 <1:5  Survived 
Tat <1:5 <1:5 <1:5 
CB147 
 
CA 1:160 1:320 1:640  Survived 
Tat <1:5 <1:5 <1:5 
CB148 
 
CA 1:40 1:40 1:80  Survived 
Tat <1:5 <1:5 <1:5 
Group C (3X CA-GST + Tat-GST)   
CB149 
 
CA <1:5 <1:5 1:160  Survived 
Tat <1:5 <1:5 <1:5 
CB150 
 
CA 1:40 1:40 1:40  Survived 
Tat <1:5 <1:5 <1:5 
CB151 
 
CA 1:160 1:80 1:80  Survived 
Tat <1:5 <1:5 <1:5 
CB152 
 
CA 1:80 1:80 1:160  Died 
Tat <1:5 <1:5 <1:5 
CB153 
 
CA <1:5 <1:5 1:40  Survived 
Tat <1:5 <1:5 <1:5 
NT denotes not tested. 
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Response of vaccinates to infection with JDVPul01  
Clinical outcome  
All cattle inoculated with JDVPul01 developed typical clinical signs of Jembrana 
disease, including swollen superficial lymph nodes, diarrhoea, loss of appetite and 
lethargy. One of the control cattle (CB156) died 13 days post-infection, one of the 
cattle vaccinated with the CA/Tat-GST polyprotein died 14 days post-infection 
(CB140; Group A) and one of the cattle inoculated 3 times with the individual CA-
GST and Tat-GST proteins (CB152; Group C) died 14 days post-infection. A post-
mortem examination was not conducted. 
Febrile response after infection 
An analysis of the febrile response in vaccinated and control groups is shown in 
Tables 5.7 and 5.8. All cattle inoculated with JDVPul01 developed a febrile response 7-
9 days after infection, and no differences in this incubation period were observed 
between any vaccinated group (Groups A, B and C) and the control group (Group D)  
The maximum febrile temperature in Group A and Group C was significantly lower 
than in the control Group D (p=0.01802 and 0.027167, respectively) and when all 
vaccinated cattle (Groups A, B and C) were compared to the control group (Group D) 
vaccination significantly reduced maximum febrile temperatures (p=0.00676). 
The fever score or area under the curve was lower in Group A than in the controls but 
not significantly different between cattle in Group B and the controls. The cattle that 
died (CB140, CB152 and CB156) had significantly lower fever scores (p=0.023502) 
than the cattle that survived and fever score did not, therefore, correlate with 
protection. 
The duration of the febrile period categorized as the duration of low (39.3-40.2), 
moderate (40.3-41.2) or high (41.3+) fever or hyperpyrexia. All CA and Tat 
vaccinated groups had the same duration of low grade fever, the duration of moderate 
fever was longer in Group B than in the controls, and all vaccinated cattle had a 
significantly shorter period of high grade fever than the controls (p=0.003843). 
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the onset of the febrile response, the maximum temperature response, fever score (based on a 
standard area under the curve calculation), mean febrile temperature, the duration of fever and 
clinical outcome. Vaccinated cattle generally had lower mean febrile responses and 
significantly lower maximum febrile responses: only 4 vaccinated cattle out of 15 developed a 
rectal temperature of ≥ 41ºC whereas this occurred in 4 of the 5 control cattle. 
Group 
and 
animal 
Onset of 
fever after 
infection 
(days) 
Max 
temperature 
Fever 
score* 
Mean 
febrile 
temp (ºC) 
Duration of fever (h)**  Clinical 
outcome 
Low  Moderate  High 
 
Group A (2X CA/Tat-GST) 
CB139 8  40.7 3.5  40.375  24 72  0  Survived 
CB140 8  40.6 2.9  40.225  48 48  0  Died  day  14 
CB141 7  41  4.1  40.32  96 48  0  Survived 
CB142 7  40.5 2.6  40.15  96 24  0  Survived 
CB143 8  40.8 2.9  40.225  96 48  0  Survived 
Mean 7.6  40.72 3.2  40.259  72 48 0  1/5 
 
Group B (3X CA/Tat-GST) 
CB144 7  41.2  6 40.5  72 96 0  Survived 
CB145 7  41.2 6.6  40.44  72 96 0  Survived 
CB146 7  40.9 4.7  40.44  72 48 0  Survived 
CB147 8  40.8 4.9  40.31  72 96 0  Survived 
CB148 7  40.6 3.9  40.28  48 72 0  Survived 
Mean 7.2  40.94  5.22  40.394  67.2  81.6 0  0/5 
 
Group C (3X CA-GST + Tat-GST) 
CB149 8  40.8  5  40.333  72 72 0  Survived 
CB150 9  40.7 4.9  40.48  48 96 0  Survived 
CB151 8  40.7 4.5  40.4  48 96 0  Survived 
CB152  8  40.3  3.2  40.033  120  24  0  Died day 14 
CB153 8  41.1 4.6  40.265  96 72 0  Survived 
Mean 8.2  40.72  4.44  40.302  76.8  72  0  1/5 
Group D (3X GST) 
CB154 8  41.1 5.6  40.62  48 96 0  Survived 
CB155 7  41.3 5.1  40.58  96 48 24  Survived 
CB156 8  41  3.1  40.12  72 48 0  Died  day  13 
CB157 9  40.8 2.6  40.15  96 24 0  Survived 
CB158 9  41.8 4.7  40.44  48 48 24  Survived 
Mean 8.2  41.2 4.28  40.382  72  52.8  9.6  1/5 
*Fever score was calculated using area under the curve above 39.3°C 
**Low fever 39.3-40.2ºC, moderate 40.3-41.2 ºC and high (hyperpyrexia) ≥ 41.3 ºC. 
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Table 5.8. Statistically significant differences in the febrile response between vaccinated and 
control groups after challenge with JDVPul01. 
Parameter Group 
 A 
2 x CA/Tat-GST 
polyprotein 
B 
3 x CA/Tat–GST 
polyprotein 
C 
3 x CA-GST + Tat-GST 
proteins 
Time from infection 
to onset of fever 
NSD  Reduced (p=0.01)   NSD 
Maximum febrile 
temperature 
Reduced (p=0.02)   NSD  Reduced (p=0.01)  
Mean febrile 
temperature 
Significantly reduced 
10-14 days post-
infection 
Increased 7-9 days 
post-infection 
Significantly reduced 10 
days and 13 days post-
infection 
Fever score  Reduced but not 
significantly (p=0.07) 
NSD NSD 
Duration of fever 
(total) 
NSD NSD  NSD 
Duration of fever 
(low) 
NSD NSD  NSD 
Duration of fever 
(moderate) 
NSD Increased  (p=0.05)  NSD 
Duration of fever 
(high) 
Reduced but not 
significantly (p=0.07) 
Reduced but not 
significantly 
(p=0.07) 
Reduced but not 
significantly (p=0.07) 
NSD denotes no significant difference between vaccinated group and control group 
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Peripheral blood leucocyte changes  
In response to infection there was a typical decrease in the numbers of circulating 
leucocytes was detected following infection with JDVPul01 corresponding to the onset 
and duration of the febrile response but there were no detectable differences in mean 
leucocyte counts between the various cattle groups (Figure 5.5).  However, the 
differential counts showed that the control group had less circulating lymphocytes and 
more granulocytes compared to the vaccinated groups of cattle (Figure 5.6 and 5.7). 
The lymphocyte numbers declined gradually in all cattle until day 11 post-infection 
when the lymphocyte numbers gradually rise again. All cattle developed a 
neutrophilia 3-9 days post-challenge and this was followed by a transient neutropenia 
lasting for 2-3 days before the numbers returned to their original levels. All cattle had 
high monocyte numbers from day 13 post-challenge onwards. There was little 
variation in eosinophil and basophil numbers due to their low numbers in blood 
except for the control group where increased granulocyte numbers were observed 
(Figure 5.6). 
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Figure 5.5. The mean total leucocyte counts of cattle in each of Groups A, B, C and D after 
infection with JDVPul01 indicating only minor differences in total leucocyte levels between 
groups of cattle. 
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Figure 5.6. Comparison of leucocyte change shown as the group mean ± SE and mean rectal 
temperatures during the acute phase of infection in vaccinated and control groups. (a) Group 
A (JDV CA/Tat-GST vaccinated 2 times); (b) Group B (JDV CA/Tat-GST 3 times 
vaccinated); (c) Group C (JDV CA-GST + Tat-GST 3 times vaccinated); d, Group D (Control 
group, GST vaccinated 3 times); (e) 3 cattle that died during the trial. This shows that whilst 
the vaccinated cattle still developed lymphopenia it was not as severe as the control cattle and 
that the vaccinated cattle that died had a very similar profile to the control cattle indicating 
that these cattle failed to develop an adequate response to the vaccine by the day of challenge. 
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Figure 5.7. Mean lymphocyte counts in cattle in Groups A, B, C and D, and also in cattle 
that died during the course of the disease, following infection with JDVPUL/01 showing that 
the vaccinated cattle developed significantly less severe lymphopenia (p=0.0025) during the 
acute phase of disease. 
 
The vaccinated cattle all had less severe lymphopenia than the control cattle during 
the acute febrile period and did not develop the dramatic alteration in lymphocyte: 
neutrophil ratio typically seen in infection (Figure 5.8). The 2 vaccinated cattle that 
died had a very similar leucocyte dynamic response to the control group.  
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Figure 5.8. Graphs showing the mean percentage change in the leucocyte population in each 
group after infection with JDVPul01. (a) Group A (2x JDV CA/Tat-GST); (b) Group B (3x JDV 
CA/Tat-GST); (c) Group C (3x JDV CA-GST + Tat-GST); (d) Group D (Control group 
immunized with GST only); (e) 3 cattle that died (CB140, CB152 and CB156) during the 
course of the disease. The alterations in the leucocyte populations during the acute phase of 
infection were markedly less severe in the vaccinated cattle and the vaccinated cattle that died 
had a very similar profile to the control cattle. 
 
There were a number of haematological observations during infection that have not 
been reported previously in JDV infected cattle. Seven of the 20 cattle had 
anisocytosis 8-10 days post-infection at the onset of the febrile response (Figure 5.9) 
and vacuoles were detected in the cytoplasm of lymphocytes and neutrophils 11-16 
days post-infection (Figure 5.9). There was a marked regenerative left-shift seen in all 
20 cattle 12-16 days post-infection with band neutrophils outnumbering neutrophils in 
the peripheral blood (Figure 5.9). A transient monocytosis was observed 14-15 days 
post-infection in 15 of the 17 cattle that survived.  
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c                                                                 d 
     
e                                                                f 
     
 
Figure 5.9. Abnormal bovine blood smears stained using the DiffQik (Difco) at 100X 
magnification: a, red blood cells showing marked anisocytosis; b, poikilocytosis (crenulated 
red blood cells); c, febrile period showing severe lymphopenia and neutrocytosis (20x 
magnification); d, neutrophil during the febrile period showing a segmented nucleus with 
grainy vacuolated cytoplasm.; e, Large activated lymphocyte showing grainy vacuolated 
cytoplasm with 2 neutrophils during the post-febrile period and f shows a regenerative left 
shift (band neutrophils outnumber mature neutrophils).   
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Table 5.8. Statistically significant differences in the WBC total numbers between vaccinated 
and control groups after challenge with JDVPul01. 
Parameter Group 
 A 
2 x CA/Tat-GST 
polyprotein 
B 
3 x CA/Tat–GST 
polyprotein 
C 
3 x CA-GST + Tat-GST 
proteins 
Leucocytes  Higher at days 1 and 11 
Lower at days 9 and 10 
Higher at days 1 and 11 
Lower at days 5, 6 and 8 
NSD  
Lymphocytes  Higher at days 1, 10 and 
11 
Higher at day 10  Higher at day 10 
Neutrophils  Lower at days 9 and 10  Lower at days 10 and 11  Lower at day 10 
Monocytes  Lower at days 5, 10 and 
11 
Lower at days 1, 5, 11, 12, 
13 and 14 
Lower at days 1, 5, 11, 12, 
13 and 14 
Eosinophils  Lower at days 1, 4, 5, 6, 7 
and 12 
Lower at days 5 and 7  Lower at days 1, 4, 5, 6 
and 11 
Basophils  Lower at days 1, 3, 5, 8 
and 11 
Lower at days 8 and 11  Lower at day 7 
NSD denotes no significant difference between vaccinated group and control group. 
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Vaccinated cattle had significantly higher viral load in plasma at days 3, 4 and 5 
(p=0.021758, 0.036741 and 0.049547) and a higher but not significantly higher load 
at day 6 (p=0.061936). Two of the vaccinated cattle that died CB152 (Group C) and 
CB156 (GST control Group D) had developed very high viral loads at the time of 
death.  The other animal that died (CB140, Group A) had a decreasing virus load at 
the time of death (Figures 5.10 and 5.11).   
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Figure 5.10. Graphs showing the mean change in viral titre/mL of plasma in each group after 
infection with JDVPul01. The graph depicts the mean plasma virus load during the course of 
the disease after infection of Group A (2x JDV CA/Tat-GST polyprotein), Group B (3x JDV 
CA/Tat-GST polyprotein), Group C (3x JDV CA-GST + Tat-GST), Group D (control group 
immunized with GST) and the 3 cattle that died (CB140, CB152 and CB156).  
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Figure 5.11. Natural log of viral load (genome copies/mL) determined by qRT-PCR in 
plasma of individual cattle in each group after infection with JDVPul01. (a) Group A; (b) 
Group B; (c) Group C; (d) Group D. Demonstrating the animal to animal variation between 
cattle in all groups.  
 
 
Table 5.9. Statistically significant differences in the viral load between vaccinated and control 
groups after challenge with JDVPul01. 
Parameter Group 
 A 
2 x CA/Tat-GST 
polyprotein 
B 
3 x CA/Tat–GST 
polyprotein 
C 
3 x CA-GST + Tat-GST 
proteins 
Viral load  Higher at days 4, 5, 7, 8 
and 9 
Higher at days 4, 5, 6 
and 7 
Higher at day 1 
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An antibody response to the vaccine proteins was the only measurable indicator of the 
immunological status of the vaccinated cattle; assays for the detection of cell-
mediated immunity were not considered feasible under the conditions available in 
Indonesia. The vaccinated cattle in all groups developed very high titre antibody 
responses to the JDV CA and Tat antigens, detected by both ELISA and Western 
immunoblot, and were very high at the time of infection with JDV. Cattle vaccinated 
with the fused JDV CA/Tat-GST developed higher titre vaccine specific responses 
than the cattle vaccinated with the individual CA-GST + Tat-GST. 
Assuming appropriate immunising antigens are selected for use in a vaccine, a strong 
antibody response to the vaccine proteins can be a good indicator of vaccine efficacy 
and duration of protection (Letvin, 2002). However in lentiviruses this is not always 
correct and a strong antibody response to vaccination is not necessarily beneficial and 
immune activation can sometimes be associated with enhanced lentiviral replication 
(Fauci et al., 1991; Tirado and Yoon, 2003). Antibody-dependant enhancement of 
viral replication has been described with anti-Env and anti-Gag antibody responses in 
most lentiviruses (Hammond et al., 1999b; Hosie et al., 1992; Nenci et al., 2007; 
Tirado and Yoon, 2003; Villinger et al., 2003) but it has not been observed in cattle 
vaccinated with the tissue-derived and inactivated whole virus JDV vaccine which has 
elicited a strong response to several viral proteins (Hartaningsih et al.,2001).  
There was a strong IgG, IgA and IgM antibody response to the JDV CA antigen, 
which should be advantageous in the provision of a protective immunity. An 
especially strong IgG response to CA and Tat developed in all cattle after vaccination 
but the cattle that died appeared to not have a lesser IgG response to the vaccine 
proteins. It was noted that the cattle that appeared to develop the strongest protective 
immunity were those vaccinated only twice with the CA/Tat-GST polyprotein and it 
is possible that this was due to the reduced dose (total 8 mg instead of 12 mg when 3 
vaccinations were administered) with less stimulation of the immune system. The IgG 
antibody is the main serum antibody and consists of IgG1, IgG2, IgG3 and IgG4 sub-
classes (Butler, 1983) that are involved in secondary immune responses (antigen 
recognition). For this study a generic anti-bovine IgG antibody was used which was 
unable to differentiate between the sub-classes such as IgG1 and IgG3 responses 
which have been shown to take longer to develop than the other IgG subclasses in 
  120horses and this may be important to vaccine efficacy (Hammond et al., 1997). Further 
investigation into the time necessary to develop a mature humoral immune response 
and the vaccine dose needed to elicit protection should be undertaken as some cattle 
vaccines  can take up to 21 weeks to elicit a mature protective humoral immune 
response (Wedlock et al., 2005).  
All the vaccinated cattle except for 2 (CB146 in Group B and CB153 in Group C) also 
developed a detectable CA-specific IgM response by the day of challenge but only 
one animal (CB147 in Group B) had developed a Tat-specific IgM response (this 
animal also had a high CA IgM titre) at challenge. IgM has low affinity but high 
avidity allowing the IgM to recognize a large variety of novel pathogens during the 
primary immune response. IgM is also a complement-activator and can stimulate 
antigen-specific IgG production necessary for immunity to pathogens (Boes, 2000).  
All of the vaccinated cattle also developed an IgA response to the CA antigen by the 
day of virus infection 28 days after the last vaccine dose. Tat-specific IgA was not 
detected against the Tat antigen but it may take longer for the IgA response to mature 
to the less immunogenic Tat. IgA is an important part of the body’s mucosal 
immunity but is also a potent neutralising antibody that can act on the epithelial 
surface or more importantly within the infected epithelial cells to prevent viral 
replication and allow effective viral clearance (Mazanec et al., 1993). An IgA 
response is therefore important due to its neutralising activity and its possible role in 
preventing infection through mucosal surfaces (Bomsel et al., 1998; Butler, 1983; 
Mazanec et al., 1992; Roitt and Delves, 2002).  One study found that HIV Env 
specific IgA transcytosed through the epithelial cell wall and efficiently neutralized 
HIV replication in the epithelial cells (Huang et al., 2005). It would be interesting to 
determine if in “atypical” responders to JDV infection (Ditcham, 2007) control 
replication via serum IgA-mediated neutralisation of virus similar to that seen in HIV-
2 non-progressors (Lizeng et al., 2004).  
While the strong antibody response to the polyprotein vaccine suggests it was highly 
immunogenic, the indications of the induction of a protective efficacy were less clear. 
There was, however, evidence of an amelioration of the disease process after infection 
in most vaccinated animals, especially regarding the febrile response to infection. 
Vaccinated cattle generally had longer febrile responses than control cattle but had 
significantly lower maximum febrile temperature and none developed hyperpyrexia 
  121which is often associated with the disease. This was particularly evident in those cattle 
vaccinated twice with the CA/Tat polyprotein (Group A). These cattle had reduced 
fever score, a reduced mean febrile temperature, a reduced maximum febrile 
temperature, and a reduced period of high fever (hyperpyrexia) compared to the 
controls. High grade fevers are often associated with increased pathogenesis and 
mortality (Blatteis, 2007; Blatteis and Sehic, 1998). The results obtained in the group 
vaccinated twice with the CA/Tat polyprotein were at least equivalent to those 
observed in the cattle vaccinated 3 times with the mixture of CA-GST and Tat-GST 
proteins (Group C) and surprisingly, better than those observed in the cattle 
vaccinated 3 times with the CA/Tat polyprotein. The cattle vaccinated 3 times with 
CA/Tat-GST had a reduced incubation period from infection until the onset of the 
febrile response, a higher mean fever than the controls 7-9 days post-infection, and an 
increased period of moderate fever compared to the controls. 
The 2 vaccinated cattle that succumbed to infection and died 14 days post-challenge 
failed to respond to vaccination in the manner seen by the other 13 vaccinated cattle 
and had very similar clinical signs and haematological changes to the control cattle 
with high febrile responses and severe lymphopenia. The duration of the period from 
the first day of fever to the peak of fever was significantly shorter in these cattle than 
in cattle that survived. The cattle that died (CB140, CB152 and CB156) had 
significantly lower fever scores than the cattle that survived indicating that this 
parameter did not correlate with protection and may therefore be useful for 
determining disease outcome.  
The vaccinated cattle had significantly higher levels of circulating lymphocytes and a 
disturbance of the typical lymphocyte: neutrophil ratio (1:0.5) by the day of challenge 
indicating that the cattle were still mounting a humoral immune response to the 
vaccine proteins at the time of virus infection. This is further supported by the ELISA 
results prior to challenge that show the titre of anti-CA IgG, IgM and IgA was still 
increasing on the day of challenge. The anti-Tat IgG response was also increasing on 
the day of challenge. This immune stimulation at the day of challenge is undesirable 
in vaccine trials because the immune response to the vaccine has not fully matured 
and vaccine efficacy cannot be evaluated accurately (Cole et al., 1998; Hammond et 
al., 1999b; Montelaro et al., 1998). It has been reported that an immature immune 
response can also be responsible for enhancement of infection or complete lack of 
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greater period of time should be left after the final vaccine dose before challenge to 
generate valid vaccine efficacy data, although this obviously adds to the cost of these 
already expensive trials as reported previously (Ditcham, 2007; Soeharsono et al., 
1995a)  
The level of leucopenia in the vaccinated and control animals did not appear to differ 
significantly but there was less reduction of lymphocytes in the vaccinated groups 
compared with the control group during the febrile period, although there was no 
significant difference between any of the vaccinated groups.  The vaccinated cattle 
had significantly greater minimum lymphocyte numbers and significantly less days of 
severe lymphopenia (<1,000 lymphocytes/µL of blood) suggesting that immunisation 
with the CA and Tat proteins induced a protective immune response in the majority of 
vaccinated cattle. Not surprisingly 3 of the 4 cattle with the lowest total number and 
percentage of lymphocytes were the cattle that died. 
The analysis of the leucocyte subpopulations yielded additional information about the 
effects of the disease that has not been previously reported. Soeharsono et al 2001 
reported a mild neutropenia associated with experimental JDV infection and while a 
mild neutropenia after the febrile period was observed in these cattle there was in fact 
a neutrocytosis or neutrophilia during the acute febrile period where up to 90% of the 
total circulating leucocytes were neutrophils. This up-regulation of circulating 
neutrophils is physiologically important because their half life is generally between 4 
to 10 h when not activated and once activated they rupture causing inflammation so 
all the daily changes in neutrophil numbers are due to up-regulation of neutrophils by 
JDV infection (Roitt and Delves, 2002). A similar pattern of up-regulation of 
neutrophils has been observed in HIV-1 infection where studies have shown that 
neutrophils bind the virions and transfer infection to activated lymphocytes more 
efficiently than HIV virions alone (Gabali et al., 2004). These changes may suggest 
that the neutrophilia may be associated with the spread of the virus to naïve tissues 
throughout the infected cattle 3 days before the peak of the febrile responses. A 
further study determined that the neutrophilic burst of reactive oxygen intermediates 
(ROI) strongly activated HIV-1 long terminal repeats (LTR) indicating that this may 
be an important mechanism of acute viral activation (Klebanoff and Headley, 1999). 
The decline in neutrophil levels from day 9-14 in all groups leading to the mild 
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(Hofmann-Lehmann et al., 1995; Soeharsono et al., 1995a; Soesanto et al., 1990). 
There was a strong correlation between the percentage of neutrophils in circulation 
and the rectal temperatures suggesting that the neutrophils were a significant cause of 
the inflammatory response during the acute febrile period. Coinciding with the peak in 
absolute and percentage change in neutrophils at 5 days post-challenge, there was also 
a rise in absolute numbers of the other granulocytes (basophils and eosinophils). This 
is similar to what has been found 2-4 weeks post-challenge with FIV, which 
suggested a Th2 response to components of the live virus challenge (Hofmann-
Lehmann et al., 1995).  
In this current experiment, vaccination with CA and Tat did not effect any reduction 
of the plasma virus load, in contrast to results reported previously (Ditcham, 2007). 
The CA/Tat-GST vaccinated cattle in this current experiment developed higher viral 
titres during infection particularly in the early phase of the disease (days 3, 4, 5 and 6) 
which may be due to the cattle still responding to the vaccine by the day of challenge 
and having higher circulating lymphocytes for the virus to infect. This conclusion is 
supported by the fact that the cattle with the highest circulating lymphocytes also had 
increased early viral replication and the cattle in group C which did not have 
significantly higher circulating lymphocytes by the day of challenge also did not have 
significantly higher early viral replication. Interestingly the increase in viral load in 
the vaccinated cattle did not necessarily increase clinical signs or severity of disease. 
This suggests that vaccination allows the cattle to respond better to higher titres of 
virus without the hyperpyrexia and severe lymphopenia usually associated with the 
pathogenesis. 
There may have been factors that reduced the efficacy of the recombinant CA/Tat-
GST polyprotein vaccine that need to be addressed in future experiments.  The 
procedures used in attempts to induce a protective immune response in the current 
experiment were in many cases based on arbitrary decisions and may not have been 
correct. Improved results could have been obtained with different methodology. The 
design of any vaccine trial must consider the dose, route of administration, time 
between vaccinations, time between final vaccination and challenge, identification of 
correlates of protection, whether to use homologous or heterologous challenge, route 
of challenge and challenge dose, all of which can affect the outcome (Dunham, 2006). 
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experiment was a continuation of a series of vaccine trials undertaken with limited 
resources and time.   
The quantity of recombinant protein in each vaccine dose in the current experiment 
was likely to have been excessive.  Preliminary work conducted by others had shown 
that 3 vaccinations with doses of 2 mg of JDV CA-GST and 2 mg of Tat-GST 
reduced viral load and ameliorated the disease after challenge (Ditcham, 2007). The 
dosage of 4 mg of he JDV CA/Tat-GST polyprotein in the current experiments was 
extremely large, compared to what has been used with other experimental lentivirus 
vaccination attempts. Horses have been vaccinated with between 50-200 µg per dose 
of recombinant EIAV Env protein, similar urea/DTT solubilised recombinant protein 
vaccines for sheep contained 50 µg per dose, and other recombinant protein cattle 
vaccines contain between 50 -200 µg per dose (Hammond et al., 1999a; Issel et al., 
1992; Purcell et al., 2003; Rothel et al., 1997; Shokri and Jafarzadeh, 2001; Wu et al., 
2004). Earlier recombinant protein vaccines tested had low purity, contained little 
viral antigen per dose, whereas the JDV CA/Tat-GST polyprotein had much higher 
purity than the earlier recombinant protein vaccines that were tested and the large 
dosage used in the current experiment could have been detrimental to vaccine efficacy 
(Fife et al., 2004). The next stage of vaccine development should include a 
dose/response trial with the polyprotein vaccine to determine the optimum dose that 
will maintain and perhaps increase efficacy and decrease the final cost of production. 
There was evidence that the immune response at the time of infection had not matured 
and was still developing, and that a longer time interval after infection should have 
been used. In the current experiment, the period between vaccinations was 28 days 
with either 2 or 3 vaccinations and viral challenge 28 days after the final vaccination. 
The short intervals of 28 days were chosen to reduce the total period required to house 
the cattle, to reduce costs and reduce stress for the animals in the tropical environment 
where the experiments were conducted. The short interval between vaccinations failed 
to take into account cell-mediated responses which can take up to 8 months post-
vaccination to develop (Fanales-Belasio et al., 2002; Hosie and Flynn, 1996). Two of 
the vaccinated cattle (CB140 and 152) be protected by vaccination and this was 
probably due to insufficient time for the vaccine-specific responses to mature and the 
humoral response to the vaccine was probably still developing when the cattle were 
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the humoral immune response and cell-mediated response to the viral antigens and 
compare efficacy of the different vaccine regimes especially in light of new research 
that the HIV-1 Tat protein broadens T-cell responses against the Gag and Env viral 
proteins (Gavioli et al., 2008; Gavioli et al., 2004). Maybe responses to T cell epitopes 
on the CA antigen important for protection against Jembrana disease may need more 
time to mature between vaccination and challenge. The challenge dose of 1,000 ID50 
of the JDVPUL/01 strain was previously found to reliably induce severe Jembrana 
disease in cattle (Ditcham, 2007; Stewart et al., 2005) and this is why it was used in 
these experiments but a challenge dose of 1,000 ID50 is considered extremely high in 
lentivirus challenge trials and most groups have attempted to use a low challenge dose 
to mimic naturally infections and this may have further masked vaccine efficacy 
(Finerty et al., 2000; Horton et al., 2002; Hosie and Flynn, 1996). The tissue-derived 
inactivated whole virus vaccine was tested for efficacy using 100-400 ID50 of a less 
pathogenic homologous JDVTab87 strain (Hartaningsih et al., 2001). It would have 
been preferable to use a lower standard and quantified challenge dose of JDV that 
could have been stored in liquid nitrogen and used repeatedly, to overcome 
experiment to experiment variation. However, supplies of  liquid nitrogen in 
Indonesia are unreliable and this has led to the use of donor animals to provide the 
infectious inoculum, which are infected with frozen (-80ºC) spleen tissue in which the 
infectious virus seems to survive for prolonged periods (Soeharsono et al., 1990).  
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Chapter 6.  The response to and safety of a recombinant CA/Tat-
GST polyprotein vaccine in cattle 
 
Summary 
A bacterially expressed recombinant JDV CA/Tat-GST polyprotein (Chapter 4) 
emulsified in a mineral oil adjuvant and previously tested in small scale laboratory 
trials as a potential vaccine for the control of Jembrana disease in Indonesia (Chapter 
5) was further tested for safety and immunogenicity in a field trial in Bali.  One 
hundred cattle were inoculated twice with the polyprotein vaccine and a similar 
number of cattle were inoculated with a control vaccine containing chicken ovalbumin 
and recombinant GST in a mineral oil adjuvant. Strong antibody responses to the CA 
and Tat proteins were detected for 12 months post-vaccination. A low prevalence of 
adverse reactions to CA/Tat-GST polyprotein vaccine occurred, including abortion 
and shock, but was also observed in the control group vaccinated with GST plus 
chicken ovalbumin only. 
 
Introduction 
In Indonesia, attempts are being made to control the spread of Jembrana disease by 
restricting the movement of cattle from endemic areas to Jembrana disease-free areas 
and ring vaccinating around new outbreaks in endemic areas with a tissue-derived 
inactivated whole virus vaccine (Hartaningsih et al., 2001). The preparation of this 
whole virus vaccine from spleen tissue requires the use of donor animals obtained 
from Nusa Penida, an island adjacent to Bali where the disease does not occur; the 
vaccine is expensive and its use is associated with production difficulties, safety and 
ethical issues that make it commercially unviable.  
A variety of JDV recombinant proteins have been tested during small scale laboratory 
trials for efficacy as potential vaccines against Jembrana disease (Ditcham, 2007). A 
combination of 2 separate GST-tagged recombinant JDV CA and Tat proteins 
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protection, in some experiments equivalent to those obtained using the tissue-derived 
inactivated whole virus vaccine. 
As the use of 2 separate proteins was thought to make the large scale production of a 
vaccine utilising these proteins too expensive and difficult in Indonesia, a single 
plasmid construct expressing both CA and Tat proteins as a GST-tagged polyprotein 
was developed (Chapter 4) and the expressed polyprotein was tested for efficacy in 
small scale laboratory experiments (Chapter 5).  In this Chapter, results of a further 
larger scale field trail of this polyprotein vaccine are reported. The vaccine was 
inoculated twice one month apart into 100 cattle and an additional 100 cattle were 
inoculated with a control vaccine containing recombinant GST and chicken 
ovalbumin.  All inoculated cattle were maintained under field conditions by the 
owners and were monitored for 12 months to assess the clinical and immune response 
to the vaccine components. 
 
Materials and methods 
Vaccine preparations 
A CA/Tat-GST recombinant polyprotein was produced as described in Chapter 4. The 
assessment of the polyprotein for purity and the presence of contaminating endotoxins 
and cell and plasmid-derived nucleic contamination was performed as described in 
Chapter 4.  The preparation of recombinant GST for inclusion in the control vaccine 
was as described in Chapter 5.  The JDV CA/Tat-GST recombinant protein vaccine 
that was produced was 95% pure by densitometry with a concentration of 6.48 
mg/mL, providing a final yield of 0.68 g/l of culture (Figure 6.1). The recombinant 
GST protein produced had purity greater than 95% by densitometry with a 
concentration of 4.87 mg/mL, providing a final yield of 0.13 g/L (Figure 6.2). The 
final CA/Tat-GST polyprotein used for vaccination contained 4 endotoxin units/mg of 
protein.  
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Figure 6.1. A Coomassie Brilliant Blue stained SDS-PAGE gel used to determine purity and 
concentration of the JDV CA/Tat-GST polyprotein incorporated into the vaccine. Lane 1, 
1,000 ng of BSA and lysozyme; lane 2, 500 ng of BSA and lysozyme; lane 3, 250 ng of BSA 
and lysozyme; lane 4, 125 ng of BSA and lysozyme; lane 5, 1 µl JDV CA/Tat-GST; lane 6, 
0.5 µl JDV CA/Tat-GST; lane 7, 0.25 µl JDV CA/Tat-GST; lane 8, 0.1 µl JDV CA/Tat-GST; 
lane 9, 0.05 µl JDV CA/Tat-GST. This SDS-PAGE gel shows the final purity and 
concentration of the CA/Tat-GST vaccine used for the safety trial. 
 
 
 
 
Figure 6.2. Coomassie Brilliant Blue stained SDS-PAGE gels to determine purity and 
concentration of the recombinant GST protein preparation incorporated into the control 
vaccine.  Lane 1, 1,000 ng of BSA; lane 2, 500 ng of BSA; lane 3, 250 ng of BSA; lane 4, 125 
ng of BSA; lane 5, 4 µl JDV recombinant GST; lane 6, 2 µl recombinant GST; lane 7, 1 µl 
recombinant GST; lane 8, 0.5 µl recombinant GST; lane 9, 0.1 µl recombinant GST. This 
SDS-PAGE gel shows the final purity and concentration of the recombinant GST used for the 
safety trial. 
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Chicken ovalbumin (Sigma) was prepared as a 1 mg/mL solution in solubilisation 
buffer and stored frozen at -20°C until required. 
The final vaccine preparations administered to cattle were prepared essentially as 
described in Chapter 5 but a mineral oil adjuvant (MOA) supplied by Vaksindo was 
utilized instead of incomplete Freund’s adjuvant (IFA). Each dose of the JDV 
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emulsified with 2 mL of mineral oil adjuvant.  The control preparation contained 1 
mL of chicken ovalbumin (1 mg/mL) and 1 mL of recombinant GST (1 mg/mL) 
emulsified with 2 mL of mineral oil adjuvant.  The vaccine was administered 
intramuscularly in a single injection site on the side of the neck.   
Vaccine trial 
Two hundred Bali cattle were made available for this study from 2 neighbouring 
regions of the Tabanan district of Bali, an area where Jembrana disease is recognized 
as endemic. The cattle were mostly female of various ages and pregnancy status and 
had not been vaccinated previously with the tissue-derived whole virus vaccine. The 
cattle were owned by local smallholder farmers who had agreed to participate in this 
study under the direction of the provincial veterinary service. At the time of 
vaccination, a multivitamin complex was also injected in a separate site as an 
incentive for farmer participation in the vaccine trial. 
The age distribution amongst the cattle utilized for the trial ranged from <23 months 
to >120 months old as shown in Table 6.1. Of the 200 cattle, 36.5% were female and 
pregnant, 58.5% were female and not pregnant, 4% were female but with an 
undefined pregnancy status, and 1% were male (Table 6.2).  
Table 6.1. The age distribution of 200 cattle used in the safety trial. The control group were 
vaccinated with 1 mg of GST + 1 mg of chicken ovalbumin and the vaccinated cattle received 
4 mg of CA/Tat-GST polyprotein.  All cattle were vaccinated twice, 28 days apart. 
 
 
Age (months) 
 
 
Control group 
 
Vaccinated group 
 
0-23 
 
13 
 
15 
24-47 22  26 
48-71 35  23 
72-95 23  15 
96-119 3  14 
≥120 4  7 
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Table 6.2. The pregnancy status of the 200 cattle before vaccination with either 1 mg of GST 
plus 1 mg chicken ovalbumin (control group) or 4 mg of CA/Tat-GST polyprotein 
(vaccinated group). 
 
 
Status 
 
 
Control group 
 
Vaccinated group 
 
Total 
Male 0  2  2 
Not pregnant  60  57  117 
Unsure 5  3  8 
1 month pregnant  4  0  4 
2 months pregnant  5  1  6 
3 months pregnant  6  9  15 
4 months pregnant  6  5  11 
5 months pregnant  0  5  5 
6 months pregnant  4  3  7 
7 months pregnant  5  4  9 
8 months pregnant  4  10  14 
9 months pregnant  1  1  2 
 
 
 
All participating farmers were questioned on the previous health status of their cattle 
and were further questioned regarding the continuing health status of the cattle on 
each occasion when samples were obtained.  None of the cattle were suspected by the 
owners to have had Jembrana disease in the immediate months preceding the trial. 
Serological response to vaccination 
Sera were collected from the 200 cattle in the 2 groups at day 0 (day of initial 
vaccination), week 4 (second vaccination), week 8, week 14, week 30 and week 52 
after the initial vaccine dose. 
  131All sera were tested for antibody to the whole virus antigen by Western immunoblot 
and an ELISA was used to quantify the CA and Tat protein-specific IgG, IgM and 
IgA as previously described in Chapter 5. The JDV Tat protein used as an antigen was 
expressed as a biotinylated protein with the PinPoint system and the histidine-tagged 
JDV CA protein was expressed with the pTrcHis system, as described in Chapter 5. 
All data was analysed using a Students 2 sample t-test to identify significant 
differences. 
Comparison of adjuvants 
As IFA was considered too expensive for large scale vaccine program in Indonesia, 
MOA was used instead of IFA in this trial. To compare the efficacy of the adjuvants 
to raise a humoral immune response to both the CA and the Tat portion of the vaccine, 
5 seronegative cattle from the trial (B15-19) were compared with 5 cattle vaccinated 
with the CA/Tat-GST (IFA) and previously reported in Chapter 5. All data were 
analysed using a Students 2 sample t-test to identify significant differences in 
antibody titre to vaccination. 
 
Results 
Serological status of cattle before vaccination 
Prior to vaccination, the prevalence of antibody to JDV CA protein in the control and 
CA/Tat-GST vaccinated group was 17% and 6%, respectively, determined by whole 
virus Western immunoblotting.  
The age distribution of the antibody-positive cattle in the 2 groups is shown in Figure 
6.3. None of the 76 cattle < 47 months of age were seropositive to JDV CA or Tat 
whilst the percentage of seropositive older cattle increased with age. There was a 
strong positive trend between age and seroprevalence (R² value=0.9901). 
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Figure 6.3. A demographic analysis of the age versus JDV antibody status of the 200 cattle 
from the Tabanan region of Bali prior to vaccination, demonstrating that no cattle < 4 years of 
age were seropositive and the proportion of seropositive animals increased with the age of the 
cattle.  
 
 
Adverse reactions to vaccination 
In the vaccinated group, abortion was reported. The first abortion occurred 20 days 
after the first vaccine dose in a 3 month pregnant heifer and the second and third 
abortion occurred within 4 days of the second vaccine dose in 5 and 8 month pregnant 
heifers. An anaphylactic-like (shock) reaction was observed in 2 of the vaccinated 
group when clinical signs of a rapid onset of dyspnea, hypersalivation and collapse 
occurred. One heifer in the vaccinated group had such a reaction about 5 min after the 
first vaccine dose and was doused with cold water and recovered.  A second heifer 
had such a reaction about 7 min after the second vaccine dose and was immediately 
injected with anti-histamine (Deladril®) and recovered.  
In the control group, 2 cattle aborted within 7 days of the second control vaccine dose. 
One heifer developed an anaphylactic-like reaction 5 min after the first vaccine dose 
and was treated with anti-histamine (Deladril®) and recovered (Table 6.3).  There 
were some local reactions including swelling and sensitivity to touch at the injection 
site observed after vaccination in the vaccinated and control groups but there was no 
recorded data on the overall numbers in the trial. 
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Table 6.3. Abortion and anaphylactic-like (shock) reactions detected in vaccinated and control 
groups after 2 vaccinations. 
 
Status 
 
 
Control group 
 
Vaccinated group 
 
Total 
Abortion Shock Abortion Shock Abortion Shock 
Male  0 0 0 0 0 0 
Not  pregnant  0 1/60 0 2/57 0  3 
Undetermined  0 0 0 0 0 0 
1  month  pregnant  0 0 0 0 0 0 
2 months 
pregnant 
0 0 0 0 0 0 
3 months 
pregnant 
0 0  1/9  0 1 0 
4 months 
pregnant 
1/6  0 0 0 1 0 
5 months 
pregnant 
0 0  1/5  0 1 0 
6 months 
pregnant 
0 0 0 0 0 0 
7 months 
pregnant 
0 0 0 0 0 0 
8 months 
pregnant 
1/4 0  1/10  0  2  0 
9 months 
pregnant 
0 0 0 0 0 0 
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Serological response to CA after vaccination 
In the vaccinated group, 6 cattle were seropositive to the CA protein prior to 
vaccination.  One month after the first vaccine dose, 98 were positive by Western 
immunoblot and ELISA and by 2 months after the initial vaccine dose all 100 had 
seroconverted and remained positive until the end of the trial (Table 6.4). The titre of 
the CA response peaked 3 months after the initial vaccine dose, declined between 6 
and 12 months after the initial vaccine dose but remained at a high level until 12 
months after the initial vaccine dose when the observations were discontinued (Figure 
6.4). 
 
Table 6.4. Number of cattle that were seropositive or became seropositiveafter vaccination to 
JDV CA antigen at 0, 1, 3, 6 and 12 months after the initial vaccination. 
  Months after initial vaccine dose 
0 1 3 6 12 
CA/Tat-GST 
vaccinated 
6/100  98/100  100/100 100/100 100/100 
Control   17/100  17/98  17/95  15/84  7/39 
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Figure 6.4. Boxplot analysis of the JDV CA antibody response showing the mean OD405 of 
the ELISA response at intervals after the initial vaccine dose. The upper and lower edges of 
the boxes correspond to the 75th and 25th percentiles, respectively, the central line represents 
the median and the vertical lines the range of values.  
 
Serological response to Tat after vaccination 
In the vaccinated group, 2 cattle were seropositive to the Tat antigen on the day 
of the initial vaccination and 98 cattle were seropositive 1 month after the initial 
vaccine doses when the second vaccine dose was administered. By 3 months 
after the initial vaccination all 100 cattle were positive to the Tat antigen and 
remained positive until 12 months after the initial vaccination (Table 6.5). The 
anti-Tat response peaked 3 months post-vaccination and markedly declined at 6 
months but was then maintained until 12 months after the initial vaccine dose 
(Figure 6.5). 
 
 
 
 
 
 
 
  136Table 6.5. The total numbers of cattle that were seropositive to the JDV Tat antigen at 1, 3, 6 
and 12 months after the initial vaccine dose. 
  Months after initial vaccine dose 
0 1 3 6 12 
CA/Tat-GST 
vaccinated 
2/100 98/100  100/100  100/100  100/100 
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Figure 6.5. Boxplot analysis of the JDV Tat antibody response showing the mean OD405 of the 
ELISA at intervals after the initial vaccination. The upper and lower edges of the boxes 
correspond to the 75th and 25th percentiles, respectively, the central line represents the 
median and the vertical lines the range of values.  
 
 
Comparison of vaccine specific titres to JDV CA and Tat antigens with 
different adjuvants  
The antibody titres obtained in this safety trial were compared to those reported 
previously in Chapter 5 in 5 cattle vaccinated twice with the same JDV CA/Tat-GST 
polyprotein but where IFA was used instead of MOA used in the field trial. The 5 
cattle inoculated with the CA/Tat-GST polyprotein emulsified in IFA developed 
significantly higher IgG titres to the CA antigen at 1 month (p=0.032) and 2 months 
after the initial vaccination (p=0.004). The cattle vaccinated with the CA/Tat-GST 
  137polyprotein vaccine emulsified in IFA also developed significantly higher IgG titres to 
the Tat antigen 1 month after the  initial vaccination and higher but not significantly 
higher (p=0.052) titres 2 months after the initial vaccination (Figure 6.6 and 6.7).  
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Figure 6.6. Graphical representation of the IgG anti-CA titres obtained with the IFA (results 
from Chapter 5) and MOA adjuvants (results from this Chapter) showing that the use of IFA 
adjuvant resulted in a much greater humoral immune response to the CA protein. 
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Figure 6.7. Graphical representation of the IgG anti-Tat reciprocal endpoint titres of 5 cattle 
vaccinated with CA/Tat-GST with the IFA and MOA adjuvants showing that the IFA 
adjuvant was associated with a greater humoral immune response to Tat. 
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The vaccine trial was conducted to assess possible adverse effects under field 
conditions of the JDV CA/Tat-GST polyprotein vaccine and the duration of the 
vaccine specific antibody responses over a 12 month period. It had been anticipated 
that there might be an outbreak of Jembrana disease during the trial which might add 
to efficacy data, but this did not eventuate. The vaccinated and control cohorts 
included a large proportion of cattle that were pregnant. It is generally recommended 
to avoid vaccinating pregnant cattle during safety trials as the altered immune and 
hormonal status may interfere with assessing the vaccine safety and efficacy (OIE 
Manual of standard for diagnostic tests and vaccines, 2000).  
All cattle were tested prior to the commencement of the trial to determine their 
infection status before vaccination. These assays detected antibody in 11.5% of the 
200 cattle which is similar to what had been found previously in an epidemiological 
study in 1994 (Putra and Sulistyana, 1995; Wiryosuhanto, 1995). However, cattle less 
than 4 years of age were JDV antibody-negative indicating that JDV was not 
circulating in the young cattle and had not been for 4 years.  It has been previously 
suggested that waning herd immunity may be an important factor in the development 
of Jembrana disease outbreaks which generally occur every 5-10 years 
(Ramachandran, 1995). It may be that once the prevalence of “immune” cattle (those 
that have been exposed to JDV previously) drop below a certain level then an 
outbreak can occur amongst the naïve cattle population (Wilcox, 1997). BIV has been 
shown to be transmitted in utero (Meas et al., 2002; Moody et al., 2002) and as JDV 
is presumed to persist in recovered cattle, the absence of seropositive young cattle in 
this study suggests that vertical transmission of JDV does not occur.  
In the control group, some cattle fluctuated between being seropositive and 
seronegative during the 12 months of the trial (data not shown) but there was no 
significant occurrence of animals developing antibody during the 12 month period of 
the trial. The results in the control animals, with no significant occurrence of animals 
developing antibody during the 12 month period of the trial, indicates that Jembrana 
disease was not circulating in the cattle during the period of the trial. The 
intermittently seropositive status of some older cattle which was detected, has been 
reported previously in some field animals in JDV-endemic areas (Putra and 
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in the field.  
Of the 100 cattle vaccinated with the fused JDV CA/Tat-GST protein in MOA, there 
were 5% that developed severe adverse reactions including anaphylactic shock and 
abortion although these adverse reactions also occurred in 3% of the control group. 
The rate of abortion in the vaccinated group (3/38, 7.9%) was not significantly higher 
than the rate in the control group (5.71%) which suggests that the abortions were not 
specific to the JDV CA/Tat-GST polyprotein vaccine.  Abortion may have been 
associated with the movement of the pregnant cattle to a centralized vaccination site 
during hot and humid conditions at the time of vaccination.  Two of the 3 abortions 
that occurred in the vaccinated group occurred in cattle with the same owner which 
suggests that the conditions under which the vaccination occurred rather than the 
actual vaccine may have been associated with the abortions. Regardless of the cause 
of the abortions, administration of the vaccine to pregnant cattle should be avoided as 
suggested by the OIE guidelines for vaccine and diagnostic reagents (Edwards, 2007).  
There were also local reactions seen in the vaccinated and control cattle at the site of 
injection which were not seen in earlier laboratory trials with 120 cattle and where 
IFA was used. The anaphylactic shock and the local reactions were possibly due to the 
change of adjuvant from IFA to the MOA. While IFA is the preferred adjuvant of 
choice for laboratory scale development of vaccines as antigen persists in the injection 
site and is also transported efficiently to the lymphatics for presentation to dendritic 
cells and it is not associated with local or hypersensitivity reactions (Gupta et al., 
1993), it is not economically viable for use in veterinary vaccinations (Gupta et al., 
1993). Mineral oil adjuvants have been shown to induce good humoral and cell-
mediated immune responses but have also been linked to local and hypersensitivity 
reactions similar to what was observed in the safety trial when used in conjunction 
with bacterial proteins (Aucouturier et al., 2001; Bowersock and Martin, 1999; Gupta 
et al., 1993). These local reactions may be avoided by the selection of alternative 
adjuvants or by the administration of less adjuvant per dose. Further studies are 
required to identify a low cost, safe and effective replacement for IFA. 
All but 2 of the 100 vaccinated cattle had become CA and Tat antibody-positive 1 
month after the initial vaccine dose and all had seroconverted to CA and Tat by 3 
months post-vaccination and remained seropositive 12 months post-vaccination, in 
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CA and Tat but the anti-Tat IgG responses were less than the anti-CA IgG responses. 
The 2 cattle that failed to elicit a CA or Tat antibody response 1 month after the first 
vaccine dose possibly did not receive the correct dose of vaccine in the initial 
vaccination as they responded well to the second vaccine dose, they developed high 
antibody titres 3 months post-vaccination but the antibody levels in these cattle 
declined faster than the remainder of the cattle and were nearly negative 12 months 
post-vaccination. The CA antibody titres obtained during this field trial were 
extremely high, much higher than has been previously reported with recombinant 
protein vaccines in humans, horses, monkeys and cattle where lower titres of between 
1,000-40,000 were detected after 2 vaccinations, (Dupont et al., 2006; Estuningsih et 
al., 1997; Hammond et al., 1999b; Naik et al., 1997; Shokri and Jafarzadeh, 2001). 
The high titres obtained in the current study may have been associated with the large 
vaccine dose of 4 mg of protein/dose used compared to lower doses ranging from 10 
µg for monkeys to 200 µg for horses (Hammond et al., 2000; Issel et al., 1992; Purcell 
et al., 2003). Further investigation of the effect of a reduced dose of the CA/Tat-GST 
polyprotein is required; this may not only be equally or even more efficacious, it 
would reduce costs of production. 
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Since the initial outbreak in 1964 of Jembrana disease in Bali, the disease has become 
endemic in the islands of Java and Sumatra and Indonesian Borneo (Kalimantan), 
with regular outbreaks every 4-6 years in the endemic regions (Hartaningsih et al., 
1993). Attempts to control the spread of the disease by restriction of the movement of 
cattle from endemic area and ring vaccination around outbreaks with a tissue-derived 
inactivated virus vaccine has slowed but not prevented the spread of the disease. 
Jembrana disease causes significant financial loss to both the individual farmers and 
the government due to the direct effects of the disease and restrictions on trade of 
cattle between endemic and disease-free areas.  
It is likely that successful control of JDV in Indonesia will only be achieved by 
development of effective immunosurveillance and a low cost alternative vaccine that 
would provide a long lived response and could be given to the majority of cattle in 
endemic and naïve areas in which the disease is detected. The current vaccine that is 
used is too expensive for widespread use and the development of an alternative 
vaccine has become a priority in Indonesia and led to the current project.  
The first major objective of the studies reported in this thesis was the development of 
an improved recombinant protein antigen for serological studies and surveillance of 
JDV infections. This was needed because of the difficulty of producing, with the 
current equipment available in Indonesia, the whole virus antigen that is purified from 
the plasma of infected cattle. This objective was successfully achieved: a CA protein 
was developed that could be used in an ELISA and replace the whole virus antigen 
immunoassay. This recombinant CA antigen was relatively simple to produce and will 
allow laboratories in Indonesia to continually monitor JDV infection in endemic 
regions and in new outbreaks on a scale that was previously not possible with the 
whole virus immunoassay. The CA ELISA assay also had the advantage of being easy 
to produce with very high yields of pure recombinant protein. It was also considerably 
cheaper to produce than the whole virus antigen. Other recombinant protein antigens 
were developed and tested but were of lesser value. For example, it was found that all 
assays which included any part of the TM protein significantly reduced the sensitivity 
of the JDV assays, which is contrary to the findings published on other lentiviral 
diagnostic assays (Abed and Archambault, 2000; Abed et al., 1999; Calzolari et al., 
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determined but it might be because of the unusual pathogenesis of Jembrana disease 
with an early acute disease process followed by apparent permanent immunity and no 
recurrence of disease.  In other lentivirus infections, the humoral response to the CA 
is detected first after the acute phase and the TM response is generally detected after 
the later clinical onset of the ensuing chronic disease (Calzolari et al., 1995).  
The second major objective of the studies reported was the development of an 
improved vaccine. Several approaches to achieving this were considered. An 
inactivated cell culture-derived whole virus vaccine, similar to that used for FIV, 
would have been an ideal replacement for the tissue-derived inactivated whole virus 
vaccine that has been used in Indonesia, but the virus has not been cultured in vitro. A 
recombinant protein vaccine was considered the next best alternative and the choice 
of expression system was driven by the expected production costs. The cost of a 
vaccine in Indonesia was an over-riding issue and as mammalian or insect cell 
expressed recombinant proteins have a poor yield and are expensive to produce, a 
bacterial expression system was chosen. The choice of which viral proteins to use 
was, however, limited by the use of the bacterial expression system chosen. 
Recombinant proteins expressed in bacteria do not undergo post-translational 
modifications and therefore JDV proteins that normally undergo significant 
posttranslational modifications such as the heavily glycosylated SU and TM would be 
different to the native proteins, which may explain why earlier attempts to use SU and 
TM proteins expressed in bacterial expression systems provided poor results 
(Ditcham, 2007).  
Much of the work described in this thesis describes the scaling up of methods for the 
production of previous reagents and development of quality control procedures for the 
manufacture of a vaccine. Therefore there is an emphasis on the development of 
different methods of production for the vaccine rather than the testing of the vaccine.  
In earlier Jembrana disease vaccine studies (Ditcham, 2007) there were poor yields 
and low purity of the individual CA-GST and the Tat-GST proteins that were used, 
possibly associated with toxicity issues in the bacterial expression system. These 
problems were overcome by fusing the individual capsid and tat1-expressed proteins 
into a single construct expressing a CA/Tat polyprotein.  This seemed to remove the 
bacterial toxicity issues and allowed extensive optimisation of the methods used for 
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recombinant protein from bacterial cells and a high level of purity. This high level of 
recombinant protein recovery reduced the actual cost of production of the proteins per 
dose from A$2.18 per for 2 vaccine doses when individual CA-GST and Tat-GST 
proteins were produced to A$0.08 per 2 vaccine doses with the fused CA/Tat-GST 
polyprotein vaccine (2008 prices). This was a significant reduction when compared to 
the cost of the tissue-derived whole virus vaccine which cost A$2.66 for 2 vaccine 
doses.  This should enable the implementation of a large scale vaccination program 
within Indonesia. The recombinant CA/Tat-GST polyprotein did not cause a 
significant increase in adverse reactions in cattle despite the very high dose of 
recombinant protein, and its use appeared to be relatively safe. Although there were 
some adverse reactions to vaccination with the CA/Tat-GST these could be reduced 
by following the recommendations (Chapter 6) that the vaccine be administered at 2 
sites during vaccination and that pregnant cattle should not be vaccinated.  In future, 
the protein per dose might be reduced without loss of efficacy and a change in the 
adjuvant could be considered to increase efficacy.  
The use of the CA/Tat-GST polyprotein vaccine reported in Chapter 5 and 6 was not 
designed to be a stand alone analysis of the safety and efficacy of the vaccine but 
rather baseline studies and an indication on the direction that further development 
should take for a commercial vaccine company in Indonesia. The development of any 
vaccine needs to consider a variety of indices such as vaccine dose, the route of 
administration of the vaccine, the time between vaccinations, the time between final 
vaccination and effective immunity detected by challenge, identification of correlates 
of protection, whether to use homologous or heterologous challenge virus, the route of 
challenge and the challenge dose; all of these may affect the outcome of any trial 
(Dunham, 2006). There were several areas of concern from the trial conducted and 
reported in Chapter 5 that were unavoidable because of time and financial constraints 
but should be mentioned.  The current studies must be considered as only part of an 
on-going process of vaccine development. 
In the current experiments, a large dose of recombinant virus protein of 4 mg was 
incorporated into each vaccine dose. This large dose was selected after a series of 
previous vaccine trials where 3 vaccinations with 2 mg each of a relatively impure 
recombinant JDV CA-GST and Tat-GST were shown to reduce viral load and 
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investigations, vaccination 2 or 3 times with 4 mg of fused CA/Tat-GST polyprotein 
of high purity provided an extremely large dose compared to that used in other 
lentiviral particulate vaccines. Horses were vaccinated with 50-200 µg/dose of 
recombinant EIAV Env protein; similar urea/DTT recombinant protein vaccines for 
sheep contained 50 µg per dose, and other recombinant protein vaccines for cattle 
have contained 50-200 µg/dose (Hammond et al., 1999a; Issel et al., 1992; Purcell et 
al., 2003; Rothel et al., 1997; Shokri and Jafarzadeh, 2001; Wu et al., 2004). The large 
dose was used in the current experiment because of the earlier success obtained with 
high doses but it is realised that these vaccines reported by Ditcham (2007) were of 
low purity and effectively contained much less than 2 mg of each protein. The  large 
dose of 4 mg was likely to be detrimental to vaccine efficacy (Fife et al., 2004) and 
the next stage of vaccine development should include a dose/response trial to 
determine the optimum dose whilst maintaining or even increasing vaccine efficacy. 
Another factor of the current experiments that must be considered in the development 
of a Jembrana disease vaccine was the short periods of only 28 days between 
vaccinations and 28 day interval from the final vaccine dose until viral challenge. This 
short interval between vaccine doses was probably not ideal for an inclusion body-
based vaccine but was selected to reduce the total holding time and cost of holding 
vaccinated cattle indoors. Short intervals between vaccinations have been effective for 
raising high titre antibody responses to vaccines but do not take into account the long-
lived nature of insoluble recombinant protein vaccines or achieving an optimal cell-
mediated response to such vaccines (Fanales-Belasio et al., 2002). Inclusion body 
vaccines generally take longer to be broken down in vivo (Hansson et al., 2000; Heath 
and Holcman, 1997; Rothel et al., 1997) and this short vaccination-challenge model 
failed to take into account cell-mediated immune responses which can take up to 8 
months post-vaccination to develop (Fanales-Belasio et al., 2002; Hosie and Flynn, 
1996). Further studies should take into account the time required for maturation of the 
humoral and cell-mediated immune responses to the viral antigens and compare 
efficacy of the different vaccine regimes especially in light of new research that the 
HIV-1 Tat protein broadens T-cell responses against the Gag and Env viral proteins 
(Gavioli et al., 2008; Gavioli et al., 2004). This would mean that responses to novel T 
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may not have had enough time to mature between vaccination and challenge.  
The challenge dose of about 1,000 ID50 of a heterologous JDVPul01 strain was probably 
too high.  It did, however, reliably induce Jembrana disease in all cattle (Ditcham, 
2007; Stewart et al., 2005) and avoided the problem seen in previous trials with the 
individual protein vaccines, where infectious doses too small to infect all cattle were 
sometimes used and resulted in failed experiments. However, a challenge dose of 
1,000 ID50 is extremely high and most groups have attempted to use lower challenge 
doses to mimic natural lentivirus infections (Finerty et al., 2000; Horton et al., 2002; 
Hosie and Flynn, 1996). A large challenge dose may considerably underestimate the 
effectiveness of the vaccine in field conditions. It is noted that when the tissue-derived 
inactivated virus vaccine was tested it was with a considerably lower challenge dose 
(400 ID50) of a less pathogenic homologous JDVTab87 strain (Hartaningsih et al., 
2001). A recommendation of this study is to utilize a similar challenge conditions for 
testing the efficacy of the recombinant protein vaccine.  
How to achieve this low challenge dose is a problem but one obvious solution is to 
utilise a standard quantified stored challenge dose of JDV. This could be achieved by 
storing virus in liquid nitrogen but a reliable source of liquid nitrogen in the 
laboratory in Bali has not been possible. This has led to infected spleen being stored at 
lower temperatures and then used to infect donor animals, with plasma from the donor 
animals on the second day of the febrile period used to infect cattle (Soeharsono et al., 
1990).  Problems of rapid quantification of the virus in the plasma from each donor 
animal made a consistent challenge dose a difficult problem. Additionally, the 
possible effect of multiple passage of the virus strains through donor animals could 
lead to variations in pathogenicity of the challenge strains. 
Despite these issues, the recombinant CA/Tat-GST polyprotein vaccine that was 
developed showed promise in reducing the clinical signs of infection and partially 
protected the cattle from a heterologous challenge with JDV. The study described in 
Chapter 5 showed that the fused CA/Tat-GST polyprotein vaccine raised a greater 
humoral immune response and provided a similar level of clinical protection as the 
individual CA-GST plus Tat-GST which were shown to be efficacious at inducing a 
protective immunity (Ditcham, 2007). 
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